

NSCI

Volume: 6, Issue: 1, June 2023
ISSN: 2619- 9645 (Print)
e-ISSN: 2667- 5722 (On-line, Pdf)



CUPMAP

Current Perspectives on Medicinal and Aromatic Plants
An International Scientific Journal
<http://dergipark.gov.tr/cupmap> - www.cupmap.org



Current Perspectives on Medicinal and Aromatic Plants

(CUPMAP)

Curr. Pers. MAPs

ISSN: 2619- 9645 (Print) e-ISSN: 2667-5722

This journal is international peer-reviewed and published two
issues per year.

Corresponding Address

Current Perspectives on Medicinal and Aromatic Plants (CUPMAP),
Nazım Şekeroğlu
Gaziantep University, Faculty of Art and Sciences, 27310, Şehitkamil, Gaziantep - Türkiye
Phone: 0 342-317 19 22
Web: <http://www.cupmap.org/>
Contact: sekeroglunazim@gmail.com / editor@cupmap.org

Volume 6

Issue 1

June, 2023

EXECUTIVE EDITORIAL BOARD

Nazım ŞEKEROĞLU

Editor-in-Chief

(Agriculture, Food, Ethnobotany)
Gaziantep University, TÜRKİYE

İlkay Erdoğan ORHAN

Editor-in-Chief
(Pharmacognosy & Phytotherapy)
Gazi University, TÜRKİYE

Anake KIJJOA

Editor-in Chief
(Marine Drugs)
University of Porto, PORTUGAL

Sevgi GEZİCİ

Editor-in-Chief
(Anticancer Phytochemicals)
Gaziantep University, TÜRKİYE

Ahmad ALI

(Biotechnology of MAPs & Secondary Metabolites)
Mumbai University, INDIA

Filiz AYANOĞLU

(Agriculture & Ethnobotany)
Hatay Mustafa Kemal University, TÜRKİYE

Hakkı ALMA

(Non-wood Forest Products)
İğdır University, TÜRKİYE

Hari Prasad DEVKOTA

(Bioactive Natural Products)
Kumamoto University, JAPAN

Ivan SALAMON

(Agriculture & Ecology)
Presov University, SLOVAKIA

Koula DOUKANI

(Antioxidants)
Ibn-i Khaldun University, ALGERIA

Kuntal DAS

(Pharmacognosy & Phytochemistry)
Mallige College of Pharmacy, INDIA

Marina SPINU

(Veterinary Herbal Medicine)
University of Agricultural Sciences, ROMANIA

Maria DAGLIA

(Food Science)
University of Pavia, ITALY

Memet İNAN

(Agriculture & Ethnobotany)
Adiyaman University, TÜRKİYE

Maryna KRYVTSOVA

(Antimicrobial & Bioactivity)
Uzhhorod National University, UKRAINE

Monica HANCIANU

(Phytochemicals)
Grigore T. Popa University, ROMANIA

Miriam De Barcellos FALKENBERG

(Marine Bioactive Metabolites)
Santa Catarina Federal University, BRAZIL

Raman DANG

(Pharmacognosy & Phytotherapy)
Al- Ameen College of Pharmacy, INDIA

Murat TUNÇTÜRK

(Agriculture & Ethnobotany)
Yüzüncü Yıl University, TÜRKİYE

Takashi WATANABE

(Functional Foods)
Kumamoto University, JAPAN

Serkan URANBEY

(Biotechnology of MAPs & Secondary Metabolites)
Ankara University, TÜRKİYE

Noureddine DJEBLI

Pharmacognosy & Api-Phytotherapy
Abdelhamid Ibn Badis University, ALGERIA

Tülay İlter BAKIREL

(Veterinary Herbal Medicine)
Istanbul University, TÜRKİYE

Ufuk KOCA ÇALIŞKAN

(Pharmacognosy & Phytotherapy)
Gazi University, TÜRKİYE

Yaowared CHULIKHIT

(Pharmaceutical Chemistry)
University of Khon Kaen, THAILAND

INTERNATIONAL ADVISORY BOARD

Prof. Dr. Ákos MÁTHÉ

University of West Hungary, HUNGARY

Prof. Dr. D. Alpaslan KAYA

Mustafa Kemal University, Agricultural Faculty,
TÜRKİYE

Prof. Dr. Belgin COŞGE ŞENKAL

Bozok University, Agricultural Faculty, **TÜRKİYE**

Prof. Dr. Biljana BAUER

University Ff SS Cyril & Methodius, MACEDONIA

Prof. Dr. Charafeddine JAMA

Université De Lille (Enscl), National, FRANCE

Prof. Dr. Emine BAYRAM

Ege University, Agricultural Faculty, **TÜRKİYE**

Prof. Dr. Fatih SEYİS

Recep Tayyip Erdoğan University, Agricultural
Faculty, **TÜRKİYE**

Prof. Dr. Hakan ÖZER

Atatürk University, Agricultural Faculty, **TÜRKİYE**

Prof. Dr. Hasan BAYDAR

Süleyman Demirel University, Agricultural Faculty,
TÜRKİYE

Prof. Dr. İbrahim TÜMEN

Bandırma 17 Eylül University, Health Science
Vocational School, **TÜRKİYE**

Prof. Dr. İsa TELCİ

Süleyman Demirel University, Agricultural Faculty,
TÜRKİYE

Prof. Dr. Janar JENIS

Al-Farabi Kazakh National University, KAZAKHSTAN

Prof. Dr. Kürşat KORKMAZ

Ordu University, Agricultural Faculty, **TÜRKİYE**

Prof. Dr. Menşure ÖZGÜVEN

Konya Food and Agriculture University, **TÜRKİYE**

Prof. Dr. Nazlı ARDA

İstanbul University, Science Faculty, **TÜRKİYE**

Prof. Dr. Olcay ARABACI

Adnan Menderes University, Agricultural Faculty,
TÜRKİYE

Prof. Dr. Alban IBRALIU

Agricultural University of Tirana, ALBANIA

Prof. Dr. Ana Paula de ALMEIDA

Diretora Científica do Instituto IDEHIA, BRAZIL

Prof. Dr. Beraat ÖZÇELİK

University of Istanbul Technical, **TÜRKİYE**

Prof. Dr. Canan SAĞLAM

Namık Kemal University, Agricultural Faculty,
TÜRKİYE

Prof. Dr. Douglas CHAVES

Universidade Federal Rural do Rio de Janeiro,
BRAZIL

Prof. Dr. Faruk ÖZKUTLU

Ordu University, Agricultural Faculty, **TÜRKİYE**

Prof. Dr. Filiz MERİÇLİ

University of Near East, Faculty of Pharmacy,
T.R.N.C.

Prof. Dr. Hamdi TEMEL

Dicle University, Pharmacy Faculty, **TÜRKİYE**

Prof. Dr. Hytham AHMED

University of Menoufia, Faculty of Pharmacy, EGYPT

Prof. Dr. Irfan Ali KHAN

Aligarh Muslim University, Department of Statistics,
INDIA

**Prof. Dr. Jackson Roberto Guedes da Silva
ALMEIDA**

Universidade Federal do Vale do São Francisco,
BRAZIL

Prof. Dr. Khaetthareeya SUTTHANUT

University of Khon Kaen, THAILAND

Prof. Dr. Madalena Maria De Magalhães PINTO

University of Porto, PORTUGAL

Prof. Dr. Murat KARTAL

Bezmialem Vakıf University, Pharmacy Faculty,
TÜRKİYE

Prof. Dr. Nuri YILMAZ

Ordu University, Agricultural Faculty, **TÜRKİYE**

Prof. Dr. Ramazan ÇAKMAKÇI

Çanakkale Onsekiz Mart University, Agricultural
Faculty, **TÜRKİYE**

Prof. Dr. Rveyde TUNÇTRK

Yznc Yıl University, Agricultural Faculty,
TRKİYE

Prof. Dr. Őengl KARAMAN

Kahramanmaraş Sti İmam University, Agricultural
Faculty, **TRKİYE**

Prof. Dr. Sezen TANSI

ukurova University, Agricultural Faculty, **TRKİYE**

Prof. Dr. Zora DAJIC STEVANOVIC

University of Belgrade, SERBIA

Assoc. Prof. Dr. F. Sezer ŐENOL DENİZ

Gazi University, Pharmacy Faculty, **TRKİYE**

Assoc. Prof. Dr. Madalina ALBU KAYA

Leather and Footwear Research Institute, ROMANIA

Assoc. Prof. Dr. Őzlem TONÇER GL

Dicle University, Agricultural Faculty, **TRKİYE**

Assist. Prof. Dr. Hakan ÇETİNKAYA

Kilis 7 Aralık University, Agricultural Faculty,
TRKİYE

Assist. Prof. Dr. Sezgin SANCAKTAROĐLU

İğdir University, Agricultural Faculty, **TRKİYE**

Prof. Dr. Saliha KIRICI

ukurova University, Agricultural Faculty, **TRKİYE**

Prof. Dr. Őevket Metin KARA

Ordu University, Agricultural Faculty, **TRKİYE**

Prof. Dr. Yksel KAN

Seluk University, Agricultural Faculty, **TRKİYE**

Assoc. Prof. Dr. Abdlhabip ŐZEL

Harran University, Agricultural Faculty, **TRKİYE**

Assoc. Prof. Dr. Glsm YALDIZ

Abant İzzet Baysal University, Agricultural Faculty,
TRKİYE

Assoc. Prof. Dr. Oya KAÇAR

Uludağ University, Agricultural Faculty, **TRKİYE**

Assist. Prof. Dr. Dođan ARSLAN

Siirt University, Agricultural Faculty, **TRKİYE**

Assist. Prof. Dr. Muhittin KULAK

İğdir University, Vocational School of Technical
Sciences, **TRKİYE**

*Alphabetically ordered



Current Perspectives on Medicinal and Aromatic Plants

Curr. Pers. MAPs

An International Peer Reviewed Journal
ISSN: 2619-9645 | e-ISSN: 2667-5722



JOURNAL INFORMATION

Journal Name	Current Perspectives on Medicinal and Aromatic Plants
Journal Abbreviation	<i>Curr. Pers. MAPs</i>
Scope & Subjects	Agriculture, Biology, Molecular Biology & Genetics, Chemistry, Biochemistry, Botany, Ethnobotany, Environmental Science, Forestry, Horticulture, Health Care & Public Health, Nutrition & Food Science, Pharmaceutical Sciences
ISSN	ISSN: 2619-9645 e-ISSN: 2667-5722
Publisher	Nazım ŞEKEROĞLU
Language	English
Frequency	Biannually (June and December)
Type of Publication	Peer Review Double-Blinded
Publication Fee	Any Submission or Processing Charges
Access type	Open Access Policy
Manuscript Submission System	CUPMAP uses the submission system of TÜBİTAK-ULAKBİM Journal Park Open Journal Systems https://dergipark.org.tr/tr/pub/cupmap
License	Journal is licensed under a Creative Commons Attributions 4.0 International License
Legal Responsibility	Authors are responsible for content of articles that published in Journal.
Indexing and Abstracting	Google Scholar, Index Copernicus International, Worldcat, Elektronische Zeitschriftenbibliothek, Sobiad, Asos Index, Paperity Open Science Aggregated, Crossref, CiteFactor, International Scientific Indexing, Semantic Scholar, Academic Journal Index, Publons
Address	Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), Nazım Şekeroğlu Gaziantep University, Faculty of Art and Sciences, 27310, Şehitkamil, Gaziantep - Türkiye
Web	http://www.cupmap.org/
Contact	Phone: 0 342-317 19 22/2960 E-mail: sekeroglunazim@gmail.com editor@cupmap.org



Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)
ISSN: 2619- 9645 (Print) e-ISSN: 2667-5722

Current Perspectives on Medicinal and Aromatic Plants (CUPMAP) is an open access, peer-reviewed and refereed international journal published by MESMAP scientific group. The main objective of the CUPMAP is to provide an intellectual outlook on the scientific researches on Medicinal and Aromatic Plants. CUPMAP have distinguished goals to promote interdisciplinary scientific studies in which results could easily be used in industrial production on MAPs. This international scientific journal publishes research papers related to Medicinal and Aromatic Plants in the fields of science and technology such as Biology, Molecular Biology and Genetics, Chemistry, Agriculture, Biochemistry, Botany, Ethnobotany, Environmental Science, Forestry, Horticulture, Health Care & Public Health, Nutrition and Food Science, Pharmaceutical Sciences, and so on. CUPMAP publishes original research papers, applied studies, and review articles in MAPs science and technology. Special Issues devoted to important topics in the MAPs science and technology could also be published.

CUPMAP Journal publishes **Biannually** (on June and December) in both **print** and **on-line versions**. The publication language of the journal is **English**. Journal of CUPMAP welcomes article submissions and **does not charge any article submission or processing charges**.

Having well known board members distinguished scientists from different disciplines with huge experiences on MAPs all over the world, CUPMAP will be indexed in many databases after first issue. The goal of the journal is to be indexed in Thomson Reuters in a short time.

CUPMAP is inviting papers for Volume 6 Issue 2, which is scheduled to be published on December, 2023. Last date of submission: December 15, 2023. However, an early submission will get preference in case of review and publication process. Please submit your manuscripts according to instructions for authors by the Journal online submission system.

Sincerely,

Prof. Dr. Nazım ŞEKEROĞLU

Editor-in-Chief

Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)

Contact: sekeroglunazim@gmail.com / editor@cupmap.org

AIM AND SCOPE

Current Perspectives on Medicinal and Aromatic Plants (CUPMAP) is an **open access**, double-blinded **peer-reviewed** and **refereed international** journal published by MESMAP scientific group. The main objective of the CUPMAP is to provide an intellectual outlook on the scientific researches on Medicinal and Aromatic Plants. CUPMAP have distinguished goals to promote interdisciplinary scientific studies in which results could easily be used in industrial production on MAPs. CUPMAP Journal publishes **Biannually** (June and December). The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others that this has been appropriately cited or quoted. All submissions are screened by **iThenticate similarity** detection software and our maximum allowed score is **24%** for the document in which the References section truncated.

This international scientific journal publishes high-quality research articles related to Medicinal and Aromatic Plants in the fields of science and technology such as Biology, Molecular Biology and Genetics, Chemistry, Agriculture, Biochemistry, Botany, Ethnobotany, Environmental Science, Forestry, Horticulture, Health Care & Public Health, Nutrition and Food Science, Pharmaceutical Sciences, and so on.

CUPMAP areas of interest include;

- Agricultural Practices of MAPs & NWFPs
- Aromatherapy & Phytotherapy & Phytochemistry
 - Biodiversity
- Biology & Biochemistry & Biotechnology
- Botany & Ethnobotany & Ethnopharmacology
- Conservation, Management and Sustainable Uses of MAPs & NWFPs
 - Essential Oils & Secondary Plant Metabolites
 - Herbal & Traditional Medicines
 - Industrial Processing Technologies of MAPs
 - Legislations on MAPs & NWFPs
 - Literature on MAPS
 - Marketing of MAPs and Products
 - Molecular Cancer Therapeutics
 - Molecular Modeling and Simulations
 - Natural Cosmetics
- Non-Governmental & Non-Profit Organizations (NGO & NPO) on MAPs
 - Pharmacognosy & Phytopharmacology & Toxicology
 - Standardization and Quality of MAP Products
 - Traditional & Modern Herbal Products

OPEN ACCESS STATEMENT

Current Perspectives on Medicinal and Aromatic Plants (CUPMAP) is a fully open access journal, which means that all articles are **freely available** on the internet without charge to the user or his/her institution.

Except for commercial purposes, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access. All the original articles and review papers published in CUPMAP journal are **free to access** immediately from the date of publication. All authors publishing with the CUPMAP accept these as the terms of publication. Copyright of the layout and design of 'Current Perspectives on Medicinal and Aromatic Plants' articles remains with the journal and cannot be used in other publications.

The articles in Current Perspectives on Medicinal and Aromatic Plants (CUPMAP) are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial No Derivatives 4.0 International (CC BY-NC-ND) license.

COPYRIGHT POLICY

Authors who publish with "Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)" agree to the following terms:

Authors transfer the copyright to Current Perspectives on Medicinal and Aromatic Plants (CUPMAP). Authors, however, upon the publication of their work, can republish it in another journal or book provided that they obtain the permission of the Journal. Moreover, they are to include the note indicating that their work has first been published in CUPMAP and the link to their work in the journal.

Authors, upon the publication of their work, can publish it in online environments and/or social networks (personal webpages, course content websites, Facebook, etc.). However, they also provide the link to the work as published in the journal.

"Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)" journal is licensed under a Creative Commons Attribution 4.0 International (CC BY-NC-ND).



PUBLICATION CHARGES

No submission, processing, page, colored figures or publication charges are received from authors or elsewhere.

All the original articles and review papers published in CUPMAP journal are **free to access** immediately as early online and on the day of publication on the journal's website. **There is no article processing charges or submission fees for any submitted or accepted articles.**

PEER REVIEW PROCESS

Peer Reviewing Instructions for the "Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)" Journal

Introductions

The primary aims of peer review are to decide whether or not an article should be published (based on quality and relevance to the journal), and to improve the article before publication. All submissions first go through an internal peer review process: an assigned editor makes an initial decision to accept or to reject the manuscript (e.g., topic is outside the scope of the Journal, important flaws in scientific validity, etc.). If the editor believes the article may be of interest, it is sent out for external peer review. The reviewers are selected by area of expertise (reviewers who grant high quality reviews within the requested time are preferred). The editorial board is frequently consulted. Once reviews are obtained, the editor makes a judgment considering the critiques and recommendations from reviewers, and other factors such as relevance to the Journal's aims and usefulness to clinicians or researchers.

Peer Reviewer Selection

Reviewers are selected according to their background and experience in some aspect of the subject. The most desirable reviewers identify the strengths and weaknesses of the submitted paper, and analyze it from different viewpoints. The peer reviewers are asked to read and analyze the assigned manuscript and provide a written opinion of its quality, novelty, relevance and suitability for publication in the "Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)" Journal. Peer reviewers also make suggestions to assist the authors in improving the article. Reviewers must not only analyze and comment on the paper, but also provide opinions about general concerns such as clarity and quality of the writing, validity of scientific approach, and whether the article provides new information.

Ethical Guidelines for Journal Peer Reviewers

When a selected individual accepts a peer reviewing assignment, the reviewer implicitly agrees to the ethical standards that are commonly accepted in biomedical publishing. Ethical guidelines for reviewers, authors, and editors are reported by the International Committee of Medical Journal Editors in the 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals' available from: www.icmje.org

Reviewers for the "Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)" Journal must agree to:

Produce as careful and objective a review as possible Respect the editor's deadline. Consider with an open mind innovations or approaches different from those of one's own.

Provide a balanced critique targeted not only to identify the strengths and weaknesses of the paper, but also to provide useful feedback to the authors to improve their manuscript, without being overly critical of minor points.

Avoid scientific misconduct such as the misappropriation of intellectual property.

Each manuscript should be treated as an extremely confidential document.

The privacy of the authors' ideas must always be guaranteed.

Direct comments about ethical concerns confidentially to the editors.

Contacting an author with questions about the manuscript is not allowed.

All critiques, including the latter, must be reported in the written critique.

Declare any conflict of interest (real or perceived) identified to the editor before the end of review. Not every potential conflict necessitates a rejection.

Reviewers are encouraged to discuss potential conflicts with the editors if they believe they can provide a fair review.

Reject an assignment if the following conflicts are present: Financial interests (e.g. paid consultancies, stock holdings), significant professional or personal relationships or rivalries, antipathy toward study question/approach, political or special interest affiliations (e.g. religious or deep convictions that conflict with the manuscript topic).

Reviewer Guidelines

Potential reviewers are contacted by e-mail, which contains the manuscript title, abstract, and assignment deadline. The selected reviewer accepts or declines the assignment within 7 days. Failure to reply within the prescribed time will be treated as an implicit rejection. It is acceptable to propose an extended deadline when the given deadline (usually 4 weeks from the task acceptance date) cannot be met. The selected reviewers usually have extensive experience as faculty members, researchers, and published authors. Sometimes reviewers from other specific areas are selected. This selection is always well thought-out, and we encourage such potential reviewers to consider the assignment if they can make a contribution to some aspect of the work. The following points must be provided by the reviewers in the written response:

General Overview

Organized Critique

Assessment of Strengths and Weaknesses: the following should be evaluated: Literature review is up-to-date; Methods align with study purpose or research questions; Methods described in sufficient and appropriate detail; Research design or study approach is adequate; Approach to data analysis is appropriate; Thoughtful consideration given to the study limitations; Manuscript provides new information that is likely to be of interest to our readers.

Possible Improvements

Commonly Overlooked Areas: Reviewers should carefully note: title, abstract, tables and figures, references.

Editor's Final Decision

After the peer review process has ended and an adequate number of reviews has been received, the assigned editor makes the final decision about the manuscript (accept, invite a revision, or reject) based on a consideration of all the reviewer comments, general critique, and other external factors (e.g. the article is consistent with the Journal purpose, similar articles recently published, number of accepted articles awaiting publication, potential impact of the article, etc.). Editors may consult with each other when making the decision. A decision summarizing the opinions of editors and reviewers will be sent to the corresponding author.

ETHIC RULES AND PLAGIARISM

Publishers Ethic Rules

“Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)” is an international journal, which publishes at the highest scientific level on original research articles dealing with Medicinal and Aromatic Plants in the fields of science and technology such as Biology, Molecular Biology and Genetics, Chemistry, Agriculture, Biochemistry, Botany, Ethnobotany, Environmental Science, Forestry, Horticulture, Health Care & Public Health, Nutrition and Food Science, Pharmaceutical Sciences, and so on. Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization. All authors submitting their works to “Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)” for publication as original articles attest that the submitted works represent their authors’ contributions and have not been copied or plagiarized in whole or in part from other works. It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editor, the peer reviewer and the publisher. “Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)” ethic statements are based on COPE’s Best Practice Guidelines for Journal Editors.

Ethic Committee Report

The studies have to be prepared according to scientific rules and ethics. The results of any research (especially biology, veterinary, aquaculture and zootechnics) to be published as a manuscript need to have the report of a committee of ethic and that report’s copy should be attached with the manuscript itself. Inclusion of the approval letter from the relevant Ethics Committee or Institution's Review Board regarding the research protocol and the rights of the subjects. The author or all the authors whose studies are to be published in the journal will own all kind of liabilities in terms of their manuscripts.

Publication Decisions

The editor is responsible for deciding which of the articles submitted to the “Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)” should be published. The editor may be guided by the policies of the CUPMAP's editorial board and constrained by

such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers in making this decision.

Fair Play

An editor at any time evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

Confidentiality

The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

Disclosure and Conflicts of Interest

Unpublished materials disclosed in a submitted manuscript must not be used in an editor's own research without the express written consent of the author.

Duties of Reviewers

Contribution to Editorial Decisions

Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper.

Promptness

Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.

Confidentiality

Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorized by the editor.

Standards of Objectivity

Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

Acknowledgement of Sources

Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

Disclosure and Conflict of Interest

Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

Duties of Authors

Reporting Standards

Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

Data Access and Retention

Authors are asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Originality and Plagiarism

The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others that this has been appropriately cited or quoted. All submissions are screened by a similarity detection software. We are using iThenticate plagiarism solution and our maximum allowed score, for the document in which the References sections truncated, is 24%. Higher scores are not allowed and the

author will be given the plagiarism report and the manuscript will be returned to the authors.

Multiple, Redundant or Concurrent Publication

An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable.

Acknowledgement of Sources

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work.

Authorship of the Paper

Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

Hazards and Human or Animal Subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

Disclosure and Conflicts of Interest

All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

Fundamental Errors in Published Works

When an author discovers a significant error or inaccuracy in his/her own published work, it is the author's obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.

CUPMAP INSTRUCTIONS FOR THE AUTHORS

- ❖ Please read all of the following manuscript preparation instructions carefully.
- ❖ Manuscript should be written in **English**.
- ❖ Maximum length for articles is **15 pages**. Articles over 15 pages in length can only be considered on an exceptional basis.
- ❖ Manuscripts can only be submitted through the CUPMAP **online** manuscript submission and evaluation system <https://dergipark.org.tr/tr/pub/cupmap>
- ❖ The journal management requires that all authors register to **ORCID** at <http://orcid.org/register> and get a free ORCID ID.
- ❖ All submissions are screened by **iThenticate** similarity detection software and our maximum allowed score is **24%** for the document in which the References section truncated.

Manuscript Types

Original Articles: This is the most important type of article since it provides new information based on original research. The manuscript should include an abstract with the following subheadings: “Introduction”, “Materials and Methods”, “Results and Discussion”, and “Conclusion”.

Short Communications: Short communication is for a concise to present scientific reports related to scope of the journal. Short communication is not intended to publish preliminary results, but if these results are of exceptional interest and are particularly topical and relevant will be considered for publication. It should include an abstract with the following subheadings: “Introduction”, “Materials and Methods”, “Results and Discussion”, and “Conclusion”.

Review Articles: Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed.

CUPMAP STRUCTURE OF THE MANUSCRIPT

Font

Word document, Cambria, 12 point, single line space. Page margins are 2.5 for all sides.

Length

Maximum length for articles is 15 pages. Articles over 15 pages in length can only be considered on an exceptional basis.

Title

A concise title of the paper, avoid Abbreviations and formulae where possible.

- Use bold 14-point Cambria font. Use title uppercase, and make title in centered.
- Name(s) and SURNAME(s) of author(s) [Use centered, bold 12-point Cambria font, Use uppercase for surnames.]
- Affiliation(s) of author(s) [Use 10-point Cambria font.]
- E-mail address of the corresponding author [Use 10-point Cambria font.]
- ORCID(s) of author(s) [Use 10-point Cambria font.]

Abstract

Each article is to be preceded by a succinct abstract, of up to 250 words, that highlights the objectives, methods, results, and conclusions of the paper. The abstract should state briefly the purpose of the research, the principal results and major conclusions. The abstract body is typed in Cambria, 10 pt.

Key Words

Provide a maximum of 6 (six) key words or phrases in order of importance, separated by commas and typed in Cambria, 10 pt.

Headings

Use bold, uppercase, 12 Cambria font for headings.

Introduction

This should define the problem and, if possible, the frame of existing knowledge. Please ensure that people not working in that particular field will be able to understand the intention. The word length of the introduction should be 150 to 300 words.

Materials and Methods

Materials and methods should be clearly presented to allow the reproduction of the experiments.

Results and Discussion

A combined Results and Discussion section is often appropriate. Results should be clear and concise and give the significance of the results of the work. Data must not be repeated in figures and tables. Implications for further studies or application may be discussed.

Conclusion

A short Conclusions section should be added if results and discussion are combined.

Tables and Figures

- Tables should have a short descriptive title.
- The unit of measurement used in a table should be stated.
- Tables should be numbered consecutively.
- Figures should be prepared in GIF, TIFF, JPEG or PowerPoint.
- Tables and Figures should be appropriately cited in the manuscript.

Acknowledgements

Acknowledgements of financial support, advice or other kind of assistance should be given at the end of the text under the heading "Acknowledgements". The names of funding organizations should be written in full.

Author Contribution

The authors should indicate the contribution of the authors.

Conflict of Interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

References

They should be grouped at the end of the paper in surname order of appearance (alphabetically ordered). Abbreviated titles of periodicals are to be used according to APA references, but names of lesser-known journals should be typed in full.

References should be styled and punctuated according to the following examples:

Original Papers

Surname, N.N., and Surname, N.N., Year. The full title of the article. Journal Full Name, volume (issue), first and last page. DOI number

Book or Proceeding

Surname, N.N., and Surname, N.N., Year. Title of the contribution. In: Title of the book or proceeding. Volume (Publisher, City), pp. first and last page

Thesis

Surname, N.N., Year. Title of the thesis, University and Faculty, City. pages.



**Current Perspectives on
Medicinal and Aromatic Plants**

Curr. Pers. MAPs

An International Peer Reviewed Journal

ISSN: 2619-9645 | e-ISSN: 2667-5722



**CURRENT PERSPECTIVES ON MEDICINAL AND AROMATIC PLANTS
(CUPMAP)**

An International Scientific Journal - ISSN: 2619- 9645 (Print)

Volume: 6, Issue: 1, June 2023

EXECUTIVE EDITORIAL BOARD	ii
JOURNAL INFORMATION	v
AIM AND SCOPE	vii
OPEN ACCESS STATEMENT	viii
COPYRIGHT POLICY	viii
PUBLICATION CHARGES	ix
PEER REVIEW PROCESS	ix
ETHIC RULES AND PLAGIARISM	xii
CUPMAP INSTRUCTIONS FOR THE AUTHORS	xvi
CUPMAP STRUCTURE OF THE MANUSCRIPT	xvii

RESEARCH ARTICLES

Anticholinesterase, Antidiabetic and Antioxidant Activities of Chloroform Extract of *Genista carinalis*

Hilmican ÇALIŞKAN, Hakime Hülya ORAK, Cansel ÇAKIR, Merve ARGON, Temine ŞABUDAK, Mehmet ÖZTÜRK, Necmettin GÜLER1

The Contribution of Protected Areas to Human Health. A Case Study from Djurdjura Biosphere Reserve (Algeria), with New Or Rarely Reported Medicinal Plants

Rachid MEDDOUR, Ouahiba SAHAR7

Impacts of Essential Oil and Extracts Obtained from *Coriander* Cultivars (*Coriandrum sativum* L.) on Important Some Pathogenic Bacteria

Esma ERSİN, Belgin COŞGE ŞENKAL27

Enzyme Inhibitory and Antioxidant Activities and HPLC Quantification of Chlorogenic Acid in *Helichrysum stoechas* (L.) Moench and *H. stoechas* Subsp. *Barrelieri* (Ten) Nyman





Nurten ABACI KAPLAN, Hasya Nazlı GÖK, Mustafa ASLAN, İlkay ERDOĞAN ORHAN38

REVIEW ARTICLES

Echinacea Genus: An Endless Natural Therapeutic Resource? An Overview

Aurel VASIU, Carmen SANDRU, Emeline CHANOVE, Diana OLAH, Eموke PALL, Ghoerghita DUCA, Marina SPİNU51

**Anticholinesterase, Antidiabetic and Antioxidant Activities of Chloroform
Extract of *Genista carinalis***

[Hilmican CALISKAN](#)¹ , [H. Hulya ORAK](#)² , [Cansel CAKIR](#)³ , [Merve ARGON](#)¹ 
[Temine SABUDAK](#)^{1*} , [Mehmet OZTURK](#)³ , [Necmettin GULER](#)⁴ 

¹ Department of Chemistry, Faculty of Science and Arts, Tekirdag Namik Kemal University, 59030, Tekirdag, Turkey, E-mail: tsabudak@nku.edu.tr, hlmcn.clskn@gmail.com, merweezer92@gmail.com,

² Department of Food Technology., Vocational School of Technical Sciences, Tekirdag Namik Kemal University, 59030, Tekirdag, Turkey, E-mail: horak@nku.edu.tr

³ Department of Chemistry, Faculty of Science, Mugla Sitki Kocman University, 48000, Mugla, Turkey, E-mail: mehmetozturk@mu.edu.tr, cansel.cakir@hotmail.com.tr

⁴ Department of Biology, Faculty of Science, Trakya University, 22030, Edirne, Turkey, E-mail: nguler@trakya.edu.tr

*Corresponding author : tsabudak@nku.edu.tr

<http://doi.org/10.38093/cupmap.1229198>

Received : 04/01/2023

Accepted : 26/03/2023

Abstract

Alzheimer's disease and diabetes have become increasingly public health issues in recent years. On the other hand, synthetic drugs are expensive, could be inadequate to treat diseases, cause irritation, and have side effects. Therefore, increasingly more research is being done on plant-derived formulas and, bioactive ingredients, which can be an alternative to synthetic drugs for treatments to solve basic health problems. In this study the antioxidant, anticholinesterase and antidiabetic activities chloroform extract of *Genista carinalis* Griseb. (Fabaceae) were determined. Based on the results, the extract was not observed inhibitory activities of α -glucosidase and α -amylase. It showed better activity for acetylcholinesterase activity than butyrylcholinesterase activity. The antioxidant potential of *G. carinalis* chloroform extract was determined with different assays. The TEAC value was determined to be 0.484 mmol TE/g, FRAP value was found to be 1023.20 μ mol Fe²⁺/g for *G. carinalis* chloroform extract. The EC₅₀ value of DPPH assays of the extract was found to be 0.101 μ g/ml.

Key Words: *Genista*, *G. carinalis*, Anticholinesterase inhibitory activity, Butyrylcholinesterase inhibitory activity, TEAC, α -Amylase inhibitory activity, α -Glucosidase inhibitory activity.

© CUPMAP. All rights reserved.

1. Introduction

Alzheimer's, one of the essential chronic diseases associated with loss of consciousness, is considered the most common type of dementia. Fifty million people are struggling with this disease and unfortunately, it is estimated to will increase to 82 million in 2030 and 152 million in 2050

(World Health Organization 2020). Acetylcholine is a neurotransmitter that inhibits first acetylcholinesterase (AChE) and then butyrylcholinesterase (BChE), which is thought to play a role in the pathology of Alzheimer's disease (Helbert et al. 1995). It is suggested that low acetylcholine level is a reasons for the progression of this disease (Talesa 2001). It is stated that AChE and

BChE inhibitors could treat Alzheimer's disease. (Orhan et al. 2004). *Diabetes mellitus* is an increasing health problem (Shaw et al. 2010). There is a need for effective anti-diabetic agents with few side effects for human health.

In this context, effective and safe plant-based inhibitors have been searching to replace synthetic inhibitors (Hasan et al. 2001). Antioxidants can prevent some inflammations that cause health problems by using mechanisms such as inhibiting reaction initiating radicals, breaking the chain reaction, and reducing localized oxygen concentrations (Dorman et al. 2003).

Genista is a genus of the Fabaceae (Legumes) family with approximately 100 species generally grown in the Mediterranean and Western Asia (Noccioli et al. 2011). It is stated that many *Genista* species show biological properties against various diseases (Rauter et al. 2009; Rainova et al. 1988; Bomtempo et al. 2013)

Expensive synthetic drugs, their inadequacy in curing diseases and their side effects, there is a tendency towards plant-derived formulas in the world (Jain et al. 2019) and confidence in traditional medicine is increasing (Craig 1999). In this study, enzyme inhibitory activities (AChE, BChE, α -amylase, α -glucosidase) and antioxidant activity of chloroform extract of *G. carinalis* were determined.

2. Material and Methods

2.1. Plant material and Extraction

Genista carinalis (2048.56 g) was collected from the Thrace region of Turkey (Location: 41°52'47.8"N 27°34'42.9"E and 41°52'29.5"N 27°34'36.4"E). The specimens (EDTU-16811) were identified by Asst. Prof. Guler at Trakya University, Faculty of Science, Department of Biology. First, the dried whole plants were cut into small pieces and extracted with methanol (Merck-

1070184000) by maceration method. After the methanol evaporation under vacuum, a small amount of water was added to the crude extract. Later, crude extract was continues to extraction with n-hexane (Merck-1043742500) (46.85 g), chloroform (Merck-1070242500) (15.50 g), ethyl acetate (Merck-1007892500) (45.66 g) and n-butanol (Merck-1019902500) (434.51 g) according to the polarity order. Solvents were evaporated in the evaporator under vacuum to obtain crude extracts and the crude extracts were obtained. (Sabudak et al. 2021).

In this study, antioxidant, anticholinesterase and antidiabetic activities were aimed at the chloroform extract.

2.2. Anticholinesterase activity

The spectrophotometric method was used to determine of acetyl- and butyrylcholinesterase inhibitory activities (Ellman et al. 1961). Electric eel AChE and horse serum BChE were used as enzymes, while acetylthiocholine iodide and butyrylthiocholine chloride were employed as substrates. Cholinesterase activity was monitored using DTNB (5,5'-dithio-bis(2-nitrobenzoic)acid). Test extract and the galantamine were dissolved in ethanol (Ozturk et al. 2011).

Acetyl- and butyrylcholinesterase inhibitory activities of extract and galantamine were given as IC₅₀. To calculate IC₅₀ value 50.0, 100.0, 200.0 and 400.0 μ g/ml extract concentrations and 3.125, 6.25, 12.5 and 25.0 μ g/ml galantamine concentrations were used. The IC₅₀ values were calculated from the curve plotted against the % inhibition versus concentration graph.

2.3. Antioxidant activity

2,2-Azino-bis-3-ethylbenzothiazoline-6-sulfonic acid radical cations (ABTS^{•+}) were used to evaluate the Trolox equivalent antioxidant capacity (TEAC) of *G. carinalis* chloroform extract. After ABTS^{•+} generation

in 2.45 mmol L-1 aqueous sodium persulfate, reaction was carried out according Re et al. (1999) procedure. The results were estimated as mmol Trolox equivalents (TE) of per g extract.

The ferric-reducing antioxidant power (FRAP) of *G. carinalis* chloroform extracts were calculated as $\mu\text{mol Fe}^{2+}$ equivalents per g of the extract by using Ferrous sulphate as standard and the absorbance values of the samples were measured at 593 nm (Benzie & Strain, 1996).

The DPPH (2,2-diphenyl-1-picrylhydrazyl) capacity of *G. carinalis* chloroform was assayed by method against DPPH radical was monitored at 517 nm as described by Amarowicz et al. (2002). The radical scavenging capacity of extract for DPPH radical was given as EC_{50} values. EC_{50} values were calculated from the graph slope of absorbance versus extract concentration (ranging from 0.4 - 2.0 mg/ml concentration) and described as the $\mu\text{g/ml}$ of extract needed to scavenge 50% of the DPPH*.

The CUPRAC assay was performed according to Apak et al. (2004). The method was based on the electron transfer to the media by the antioxidant sample. The extract was tested at four concentrations (25.0, 50.0, 100.0 and 200.0 $\mu\text{g/ml}$), while the positive antioxidant standards at six concentrations (3.125, 6.25, 12.5, 25.0, 50.0 and 100.0 $\mu\text{g/ml}$). The results were given as $A_{0.50}$ ($\mu\text{g/ml}$), which corresponds to the concentration at 0.500 absorbance value. Absorbance was recorded at 450 nm.

2.4. α -Amylase and α -Glucosidase inhibitory activities

The α -amylase / α -glucosidase inhibitory activities of the chloroform extract of *G. carinalis* were investigated spectrophotometrically (Kim et al. 2010). The extract was tested in five concentrations (50.0, 100.0, 200.0, 400.0 and 800.0 $\mu\text{g/ml}$)

to calculate the IC_{50} . Acarbose was used to compare both inhibitory activities.

3. Results and Discussion

The chloroform extract of *G. carinalis* was investigated for its bioactivities namely, antioxidant activity in four complimentary assays, anticholinesterase activity against Acetyl-butyryl-cholinesterase, and antidiabetic activity against α -amylase and α -glucosidase. Antioxidant activity, anticholinesterase activity and antidiabetic activity of chloroform extract of *G. carinalis* were studied herein for the first time.

Table 1 shows the α -glucosidase and α -amylase inhibitory activities. Based on the results, the extract inhibited α -glucosidase (IC_{50} : $117.9 \pm 14.5 \mu\text{g/ml}$) better than that of acarbose (IC_{50} : $190.9 \pm 2.16 \mu\text{g/ml}$) used as a positive standard. According to the α -amylase inhibitory activity test, the extract exhibited weak activity (IC_{50} : $418.9 \pm 14.5 \mu\text{g/ml}$) and less than that of acarbose (IC_{50} : $85.6 \pm 1.56 \mu\text{g/ml}$).

The results showed that the extract is slightly active against α -glucosidase but has less activity against α -amylase. According to the anticholinesterase activity the extract of *G. carinalis* exhibited weak activity (IC_{50} : $226.5 \pm 8.55 \mu\text{g/ml}$ and IC_{50} : $326.1 \pm 4.84 \mu\text{g/ml}$) against AChE and BChE respectively (Table 2). The extract has a very weak capability to inhibit acetylcholinesterase and butyrylcholinesterase, the chief enzymes in Alzheimer's disease.

The antioxidant potential of *G. carinalis* chloroform extract was searched with different methods. The ABTS^{•+} scavenging activity of chloroform extract as shown in Table 3, explored that *G. carinalis* has 0.484 mmol TE/g TEAC activity. FRAP capacity (Ferric-reducing antioxidant power) of plant chloroform extract was found to be 1023.20 $\mu\text{mol Fe}^{2+}/\text{g}$.

Table 1. α -Glucosidase inhibition and α -Amylase inhibition activities of the chloroform extracts of *Genista carinalis*^a.

	Antidiabetic activity	
	α -Amylase Inhibitory Activity	α -Glucosidase Inhibitory Activity
	IC ₅₀ (μ g/ml)	IC ₅₀ (μ g/ml)
<i>G. carinalis</i> Extract	418.9 \pm 14.5	117.9 \pm 4.15
Acarbose ^b	85.6 \pm 1.56	190.9 \pm 2.16

^a Values expressed herein are mean \pm SEM of three parallel measurements $p < 0.05$.

^b Reference compounds.

Table 2. Anticholinesterase activity of the chloroform extracts of *Genista carinalis*^a.

	Anticholinesterase activity	
	Acetylcholinesterase inhibitory assay	Butyrylcholinesterase inhibitory assay
	IC ₅₀ (μ g/ml)	IC ₅₀ (μ g/ml)
<i>G. carinalis</i> Extract	226.5 \pm 8.55	326.1 \pm 4.84
Galantamine ^b	5.65 \pm 0.30	12.82 \pm 0.16

^a Values expressed herein are mean \pm SEM of three parallel measurements $p < 0.05$.

^b Reference compounds.

Based on EC₅₀ value of DPPH assays, the EC₅₀ value of *G. carinalis* chloroform extract was found as 0.101 mg/mL as shown in Table 3. The CUPRAC assay is a redox potential-based method, and according to results of the CUPRAC assay, the IC₅₀ value of *G. carinalis* chloroform extract was found to be 99.81 μ g/ml (Table 3). The EC₅₀ value of DPPH of *G. carinalis* chloroform extract was found to be higher compared to previous studies,

Meriane et al. (2014) found lower values in their study with the methanolic soluble fraction of *Genista saharae* (DPPH radical scavenging activity; IC₅₀ = 8.27 μ g/mL), and Boukaabache et al. (2013) obtained lower results (IC₅₀ value of the extract against DPPH radical 61.64 μ g/mL) in their study with ethyl acetate extract of *Genista quadriflora*. The difference could be explaining the difference between *Genista* species and extract types.

Table 3. Antioxidant activity of the chloroform extracts of *Genista carinalis*.

Antioxidant activity	
<i>G. carinalis</i> Chloroform Extract	
TEAC (mmol TE/g)	0.484 \pm 0.11
FRAP (μ mol Fe ²⁺ /g)	1023.20 \pm 3.45
EC ₅₀ value of DPPH capacity (μ g/ml)	101.01 \pm 0.02
IC ₅₀ value CUPRAC (μ g/ml)	99.81 \pm 3.24

4. Conclusion

Anticholinesterase, antioxidant and anti-diabetic activities among *Genista* species are available in the literature (Batista et al. 2015; Rauter et al. 2009). In this study, this plant was chosen because there is no biological activity study on *G. carinalis* in the literature. The antioxidant, anticholinesterase and antidiabetic activities of *G. carinalis*

chloroform extract were studied in this report. Briefly, the extract exhibited weak anticholinesterase activity which is related with Alzheimer's disease. However, it inhibits α -glucosidase better than acarbose used as antidiabetic drug. Moreover, it has also low inhibitory activity against α -amylase which is also a chief enzyme for diabetic activity. What's more, the extract can be considered as powerful antioxidant activity. The TEAC

value was determined to be 0.484 mmol TE/g, ferric-reducing antioxidant power was found to be 1023.20 $\mu\text{mol Fe}^{2+}/\text{g}$ for *G. carinalis* chloroform extract. The EC_{50} value of DPPH assays for extract was found to be 0.101 $\mu\text{g}/\text{ml}$.

This is the first report on the various bioactivities of *G. carinalis* chloroform extract. The results triggered us as a future study to isolate and elucidate the antioxidant compounds which may also have α -glucosidase inhibitory capacity.

Acknowledgements

One of us (C.C.) thanks the Higher Education Commission of Turkey (YOK) for the YOK 100/2000 thematic scholarship.

Author Contribution

TS, HHO and MO conceptualized the experimental procedures. NG identified the plant. HC, HHO, CC, MA, TS and MO conducted the experiments. HC, HHO, CC, MA and MO performed the data analysis. HC prepared the first draft of the manuscript. HC, HHO, CC, MA, TS and MO edited and revised the final draft of the manuscript. All authors approved the final version for submission

Conflicts of Interest

This study was funded by Scientific Research Projects Coordination Unit of Tekirdag Namik Kemal University. Project number: NKUBAP.01.DR.22.352

References

1. Amarowicz, R., Karamać, M., Weidner, S., Abe, S., Shahidi, F. (2002). Antioxidant activity of wheat caryopses and embryos extracts. *Journal of Food Lipids*, 9, 201-210. <https://doi.org/10.1111/j.1745-4522.2002.tb00219.x>
2. Apak, R., Güçlü, K., Özyürek, M., Karademir, S.E. (2004). Novel total antioxidant capacity index for dietary polyphenols and vitamin C and E, using their cupric ion reducing capability in the presence of neocuproine: CUPRAC Method. *Journal of Agricultural and Food Chemistry*, 52, 7970-7981. <https://doi.org/10.1021/jf048741x>
3. Batista, D., Fale, P. L., Serralheiro, M. L., Araujo, M. E., Madeira, P. J. A., Borges, C., Torgal, I., Goulart, M., Justino, J., Martins, A., Rauter, A. P. (2015). New in vitro studies on the bioprofile of *Genista tenera* antihyperglycemic extract. *Natural Products and Bioprospecting*, 5, 277-285. <https://doi.org/10.1007/s13659-015-0077-z>
4. Boukaabache, R., Boubekri, N., Boumaza, O., Mekkiou, R., Seghiri, R., Sarri, D., Zama, D., Benayache, F. and Benayache S. (2013). Phytochemical study of ethyl acetate extract and antioxidant activity of *Genista quadriflora* Munby (Fabaceae). *Der Pharmacia Lettre*, 5, 56-59.
5. Benzie, I.F.F., Strain, J.J. (1996) The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power, the FRAP assay. *Analytical Biochemistry*, 239, 70-76. <https://doi.org/10.1006/abio.1996.0292>
6. Bontempo, P., Rigano, D., Doto, A., Formisano, C., Conte, M., Nebbioso, A., Carafa, V., Caserta, G., Sica, V., Molinari, A.M., Altucci, L. (2013). *Genista sessilifolia* DC. extracts induce apoptosis across a range of cancer cell lines. *Cell Proliferation*, 46, 183-192. <https://doi.org/10.1111/cpr.12022>
7. Craig, W.J. (1999). Health-promoting properties of common herbs. *American Journal of Clinical Nutrition*, 70, 491-499. <https://doi.org/10.1093/ajcn/70.3.491s>
8. Dorman, H.J.D., Peltoketo, A., Hiltunen, R., Tikkanen, M.J. (2003). Characterisation of the antioxidant properties of deodourised aqueous extracts from selected Lamiaceae herbs. *Food Chemistry*, 83, 255-262. [https://doi.org/10.1016/S0308-8146\(03\)00088-8](https://doi.org/10.1016/S0308-8146(03)00088-8)
9. Ellman, G.L., Courtney, K.D., Andres, V., Featherston, R.M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochemical Pharmacology*, 7, 88-95. [https://doi.org/10.1016/0006-2952\(61\)90145-9](https://doi.org/10.1016/0006-2952(61)90145-9)
10. Hasan, M.M., Ahmed, Q.U., Soad, S.Z.M., Tunna, T.S. (2001). Animal models and natural products to investigate in vivo and in vitro antidiabetic activity. *Biomedicine & Pharmacotherapy*, 101, 833-841. <https://doi.org/10.1016/j.biopha.2018.02.137>
11. Herbert, L.E., Scherr, P.A., Beckeff, L.A. (1995) Age-specific incidence of Alzheimer's Disease in a community population. *JAMA*, 273, 1354-1359. <https://doi.org/10.1001/jama.1995.03520410048025>
12. Jain, C., Khatana, S., Vijayvergia, R. (2019). Bioactivity of secondary metabolites of various plants: A review. *International Journal of Pharmaceutical Sciences and Research*, 10, 494-504. [https://doi.org/10.13040/IJPSR.0975-8232.10\(2\).494-04](https://doi.org/10.13040/IJPSR.0975-8232.10(2).494-04)

13. Kim, J.S., Kwon, C.S., Son, K.H. (2010). Inhibition of α -glucosidase and amylase by luteolin, a flavonoid. *Bioscience, Biotechnology and Biochemistry*, 64, 2458-2461. <https://doi.org/10.1271/bbb.64.2458>
14. Noccioli, C., Meini, L., Loi, C.M., Potenza, D., Pistelli, L. (2011). A new alpinumisoflavone derivative from *Genista pichisermolliana*. *Phytochemistry Letters*, 4, 342-344. <https://doi.org/10.1016/j.phytol.2011.07.005>
15. Meriane, D., Genta-Jouve, G., Kaabeche, M., Michel, S., Boutefnouchet, S. (2014). Rapid identification of antioxidant compounds of *Genista saharae* Coss. & Dur. By combination of DPPH scavenging assay and HPTLC-MS. *Molecules*, 19, 4369-4379. <https://doi.org/10.3390/molecules19044369>
16. Orhan, I., Sener, B., Choudhary, M.I., Khalid, A. (2004). Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. *Journal of Ethnopharmacology*, 91, 57-60. <https://doi.org/10.1016/j.jep.2003.11.016>
17. Ozturk, M., Kolak, U., Topçu, G., Oksüz, S., Choudhary, M.I. (2011). Antioxidant and anticholinesterase active constituents from *Micromeria cilicica* by radical-scavenging activity-guided fractionation. *Food Chemistry*, 126, 31-38. <https://doi.org/10.1016/j.foodchem.2010.10.050>
18. Rainova, L., Nakov, N. (1988). Ulceroprotective activity of the flavonoids of *Genista rumelica* Vel. *Phytotherapy Research*, 2, 137-139. <https://doi.org/10.1002/ptr.2650020307>
19. Rauter, A.P., Martins, A., Lopes, R., Ferreira, J., Serralheiro, L.M., Araújo, M., Borges, C., Justinob, J., Silvab, F.V., Goulartb, M., Thomas-Oatesc, J., Rodriguess, J.A., Edwardsc, E., Noronhad, J.P., Pintoe, R., Mota-Filipe, H. (2009). Bioactivity studies and chemical profile of the antidiabetic plant *Genista tenera*. *Journal of Ethnopharmacology*, 122, 384-393. <https://doi.org/10.1016/j.jep.2008.10.011>
20. Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C. (1999). Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radical Biology and Medicine*, 26, 1231-1237. [https://doi.org/10.1016/S0891-5849\(98\)00315-3](https://doi.org/10.1016/S0891-5849(98)00315-3)
21. Sabudak, T., Caliskan, H., Orak, H.H., Ozer, M. (2021). Biological activity of new flavonoids and phenolic compounds from *Cirsium italicum* (Savi) DC. *Natural Product Research*, 35(10), 1613-1619. <https://doi.org/10.1080/14786419.2019.1630121>
22. Shaw, J.E., Sicree, R.A., Zimmet, P.Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Research and Clinical Practice*, 7, 4-14. <https://doi.org/10.1016/j.diabres.2009.10.007>
23. Talesa, V.N. (2001). Acetylcholinesterase in Alzheimer's disease. *Mechanisms of Ageing and Development*, 122, 1961-1969. [https://doi.org/10.1016/s0047-6374\(01\)00309-8](https://doi.org/10.1016/s0047-6374(01)00309-8)
24. World Health Organization (WHO) (2020). Dementia. <https://www.who.int/news-room/fact-sheets/detail/deme>



The Contribution of Protected Areas to Human Health. A Case Study from Djurdjura Biosphere Reserve (Algeria), with New or Rarely Reported Medicinal Plants

[Rachid MEDDOUR](#)^{*} , [Ouahiba SAHAR](#) 

Department of Agronomy, Faculty of Biological Sciences and Agronomic Sciences, Mouloud Mammeri University of Tizi Ouzou, BP 17 RP, 15000, Tizi Ouzou, Algeria.

*Corresponding author : rachid_meddour@yahoo.fr

<http://doi.org/10.38093/cupmap.1243327>

Received : 29/01/2023

Accepted : 30/03/2023

Abstract

In the protected areas of the Mediterranean Basin, inventories on the ethnomedicinal uses of plants have been carried out both on its northern and southern shores. An outstanding wealth of ancestral knowledge on traditional medicine still exists in the mountainous area of the Djurdjura Biosphere Reserve. An ethnomedicinal survey was performed in the field with 64 informants from the villages of three municipalities, through a semi-structured questionnaire and direct interviews. It is especially illiterate women without activity, over 45 years old, who hold the best knowledge about this traditional medicinal practice. Overall, 121 plant species have been identified, with 42 plant species newly recorded. They belong to 108 genera and 56 families. The Lamiaceae are the most mentioned family with 13 species. The majority of these medicinal plants are growing in the wild (79.3%). They are used to treat a wide range of 83 diseases and symptoms. Digestive disorders are the disease group the most treated in the study region, with 63 species. Indigestion and diarrhea are the most commonly treated ailments by the local population, which mainly use the fresh leaves (48.51%) as infusion or decoction, the most common preparations. From the perspective of conservation and improvement of this ethnobotanical knowledge, the medicinal plants recorded, particularly the 12 endemic and/or rare species (e.g. *Origanum vulgare* L. subsp. *glandulosum* (Desf.) Ietswaart, which cures the highest number of diseases), deserve the greatest conservative attention for their patrimonial and therapeutic values.

Key Words: Ethnoflora, Ethnomedicinal Uses, Traditional Knowledge, Biodiversity, Protected Area, Djurdjura.

© CUPMAP. All rights reserved.

1. Introduction

Protected areas provide a variety of ecosystem services, including the direct use of plants, of which medicinal plants play a major role (Zank and Hanazaki 2011). The protected areas are particularly interesting from an ethnomedicinal point of view because they show not only the wide range of

medicinal plants but also a huge knowledge on their uses by local populations (da Silva et al. 2019). In the protected areas of the Mediterranean Basin, inventories on the ethnomedicinal uses of plants have been carried out both on its northern shore (di Sanzo et al. 2013; Belda et al. 2013; Leto et al. 2013; Vitalini et al. 2015; Menale et al. 2016; Vinagre et al. 2019) than on its southern

shore (Boumar et al. 2013; Rhafouri et al. 2015; Rhattas et al. 2016; Boughrara and Belgacem 2016; Benaissa et al. 2018; Souilah et al. 2018; Chohra and Ferchichi 2019; Lazli et al. 2019; Hadjadj et al. 2019; Zatout et al. 2021). These inventories of medicinal plants and their uses in protected areas concerned some Algerian protected areas, such as those of El Kala, Taza, Belezma, Tlemcen and Djebel Aissa. On the other hand, to our knowledge, the Djurdjura Biosphere Reserve (DBR) has been the subject of only one published ethnobotanical study (Meddour et al. 2020). Without such ethnobotanical studies, information would not be recorded and, as the knowledge base evolves, it could eventually be lost. Moreover, the study of local knowledge on medicinal plants is becoming increasingly important in defining strategies for the conservation and sustainable use of plant resources (da Silva et al. 2019).

In this global framework, the major objective of this ethnobotanical study is to identify and document the indigenous knowledge on traditional uses of plant species used by the local populations for human health. The results will bring to limelight the plant species of high ethnobotanical value. This knowledge is also necessary to assist managers and decision makers in incorporating actual and potential valuable species into economic future planning, policy, and investment.

2. Material and Methods

2.1. Study area

The Djurdjura Biosphere Reserve (and National Park) is located 30 km south-east of Tizi Ouzou and 50 km from the Mediterranean Sea (Figure 1A), on the high slopes of the Djurdjura mountain range, between 800 and 2300 m a.s.l. It covers an area of 18550 ha, between latitudes 36°25'42" and 36°32'02" North and longitudes 3°57'23" and 4°19'43" East. This biosphere reserve, a Mediterranean

mountainous site, very diversified in terms of flora and landscape (UICN 2015), was set up as a biosphere reserve in 1997. This study is carried out at the level of 14 villages surrounding or enclosed in the territory of the DBR. These villages depend on the municipalities of Iboudrarene (4 villages), Akbil (4), and Saharidj (6) (Figure 1B). The rural population of these three municipalities was estimated in 2008 at 22817 inhabitants in total, with a high human occupation density of 167 to 235 inhabitants per km² on northern slope and only 92 inhabitants per km² on southern slope (UICN 2015). In this wooded region of the biosphere reserve, with its mountainous and isolated relief (deep valley), traditional practices are preserved, in particular the use of herbal medicine by rural populations.

2.2. Data collection

To collect ethnomedicinal data, we carried out an inventory of current popular uses of medicinal plants as daily primary health care. We followed standard ethnobotanical data collection procedures (Bellakhdar 2008; Albuquerque et al. 2014). The choice of the sample was focused on the research of informants considered the most knowledgeable, with expertise regarding local medicinal plants. At the villages concerned by the survey, we applied the snowball technique (Martin 2004), to select the informants. The field survey was therefore performed with our key informants, who are native to the villages studied, via direct interviews in Kabyle (the Berber language of Northern Algeria) with a semi-structured questionnaire prepared in French. This implies an in-depth knowledge of the local culture.

During our survey in March-July 2019, we interviewed 64 informants from the villages. The code of ethics of the International Society of Ethnobiology (ISE 2006) was strictly followed. Prior informant consent (PIC) was obtained orally from all informants before beginning any of the interviews. They were

assured anonymity to participate in the survey and freely share their ethnobotanical knowledge (Vitalini et al. 2015). Direct face-

to-face interviews alternated with botanical field trips, where the informant directly told us about the plant and its uses.




Figure 1. Location of the Djurdjura National Park in northern Algeria (A) (<https://fr-ch.topographic-map.com/maps/4c2a/>), and the study municipalities (B): Iboudrarene and Akbil are located on the northern slope of the DBR, and Saharidj on its southern

The systematic identification of plants, labelled with their vernacular names, was performed using the “Flora of Algeria” (Quézel and Santa 1962-1963). The nomenclature was updated according to the synonymic index of Dobignard and Chatelain

(2010-2013). The specimens of plants collected were deposited at the Herbarium of the Faculty of Biological and Agronomic Sciences (Mouloud Mammeri University of Tizi Ouzou, Algeria).

2.3. Data analysis

The ethnobotanical data was entered into a table of raw data and processed using the Microsoft Excel® 2016 spreadsheet. We have standardized the information relating to the following aspects, frequency of use of medicinal plants, local medicinal uses and other uses of each plant, plant parts used, pharmaceutical preparation methods, administration modes (internal or external use), diseases and symptoms treated. To perform a simple statistical analysis of the collected data, we calculated the relative frequency of citation (RFC) at which each species of plant was used for its medicinal properties (Belda et al. 2013). This index, proposed by Tardío and Pardo-de-Santayana (2008), reflects the local therapeutic importance of each species and it results from the frequency of citation (FC), i.e. the number of informants who mentioned a given species, divided by the total number of informants (N); $RFC = FC/N$ ($0 < RFC < 1$). The diseases and symptoms have been clustered into 10 major disease groups following the classification adopted in the Mediterranean region by Gonzalez-Tejero et al. (2008).

3. Results and Discussion

3.1. Informants' profile

We conducted our survey with 64 informants, whose characteristics are summarized in Table 1. Women have a numerical advantage over men (65.96% against 34.04%). Most of the surveyed population that has ethnobotanical knowledge is that of age groups over 45 years (45-60, 60-75, 75-90 years), a total of 65.96%. Age groups under 45 years (15-30, 30-45 years) are only represented by 34.04% (15-30 years old account for much less, i.e. 17.02%).

The holders of ethnomedicinal knowledge are thus people over 45 years of age and more often women, who are traditionally

the legatees of ethnomedicinal information (Aqaron 2006). They are better informed about local medicinal practices compared to men, due to their social relationships, where they exchange more information related to family health care (Hoang et al. 2008; Sousa et al. 2012). These findings on the gender and age of the informants were likewise reported by other authors in Algeria (Boutabia et al. 2011), in Morocco (Mehdioui and Kahouadji 2007; Benkhniqne et al. 2011), and as well in Vietnam (Hoang et al. 2008). In addition, the younger generations compared to the elderly, know much less about the uses of plant species, as knowledge and experience are accumulated with age (Susanti and Zuhud 2019).

The people surveyed are housewives (27.66%), unemployed (10.64%), or retirees, with 8.51%. This shows that the majority (46.81% in all) of people surveyed are unwaged in this isolated mountainous region. Besides, farmer-herders are represented with 38.3%. Ethnobotanical information can be acquired from different sources. However, the main source of informants comes from family knowledge held by the elderly (65.45%). The other sources are represented by 12.73% for other persons (neighbors, friends), 16.36% for books (written sources), and 5.45% for the media and internet.

The majority of informants are illiterate, with a high percentage of 48.94%. It is obvious that there is a significant risk of loss due to illiteracy and especially to the non-transcription of local knowledge (Baydoun et al. 2017). The main source of ethnobotanical information for the holders of this ancestral knowledge is family knowledge transmitted by old people. This attests to the originality of ethnomedicinal knowledge, transmitted primarily orally within the family, between individuals, and from one generation to another in the Djurdjura Mountains, without resorting to the literature, as in other areas of Algeria

(Hamel et al. 2018). Mattalia et al. (2020) confirm likewise the vertical transmission of traditional medicinal knowledge from

one generation to the next through family members (especially from mothers to daughters).

Table 1. Socio-demographic characteristics of the informants

Characteristics	Categories	Percentage of informants (%) (N = 64)
Gender	Men	34,04
	Women	65,96
Age group	15-30	17,02
	30-45	17,02
	45-60	25,53
	60-75	29,79
	75-90	10,64
Education level	Illiterate	48,94
	Primary	14,89
	Secondary	19,15
	High school	12,77
	University	4,26
Profession	Housewives	27,66
	Unemployed	10,64
	Retirees	8,51
	Students	4,26
	Farmers-herders	38,30
	Workers	10,64
Residence	Akbil	26,56
	Iboudraren	37,50
	Saharidj	35,93
Source of knowledge	Family members	65,45
	Other persons	12,73
	Books	16,36
	Media, Internet	5,45

3.2. Analysis of the medicinal flora recorded in the study region

In the DBR, informants from the villages reported 121 plant species that have medicinal uses for humans, belonging to 108 genera and 56 families. All these recorded medicinal plants are presented in Table 2, in alphabetical order of species and subspecies. The number of 121 plant species, although far from being complete, reflects a greater diversity of medicinal flora

in Djurdjura Biosphere Reserve, compared to the first contribution (cf. Meddour et al. 2020), and with 42 plants newly recorded. On the other hand, it reveals also a bigger diversity compared to those recorded in similar ethnobotanical studies in other protected areas in Algeria. Indeed, the number of medicinal plants inventoried varies from 23 to 59, according to data from Bounar et al. (2013), Boughrara and Belgacem (2016), Benaissa et al. (2018), Chohra and Ferchichi (2019), Hadjadj et al.

(2019) and Lazli et al. (2019). However, Zatout et al. (2021) and Souilah et al. (2018) report 109 and 111 medicinal plant species in Tlemcen and El Kala National Parks, respectively.

Among the 56 families, the Lamiaceae are the most represented with 13 species (10.7% of all species recorded), followed by Asteraceae (9.1%), Apiaceae (7.4%), Rosaceae (6.6%), Poaceae, Amaryllidaceae, and Fabaceae (3.3% each), Fagaceae and Oleaceae (2.5% each). The remaining 47 families are represented by one or two species. The preponderance of families, such as Lamiaceae and Asteraceae, in medicinal flora is a well-established fact through the Mediterranean Region (Gonzalez-Tejero et al. 2008), particularly in Algeria (Hadjadj et al. 2019), in Morocco (Ennabili et al. 2000; Mehdioui and Kahouadji 2007), and in Spain (Belda et al. 2013). It has also been observed elsewhere in protected areas (e.g., Zank and Hanazaki 2011).

Allium (4 species), *Mentha* and *Prunus* (3 species each) are the most represented genera, followed by *Acer*, *Daphne*, *Malva* and *Quercus*, with two species each. The species most frequently cited by the informants with the highest RFC value (= 0.43) is *Origanum vulgare* subsp. *glandulosum* (Desf.) Ietswaart. It is followed by another *Lamiaceae*, *Marrubium vulgare* L., with a RFC value = 0.34. According to Rhattas et al. (2016), *Marrubium vulgare* L. is also one of the species most cited by informants in a protected area of Rif (Morocco). These aromatic plants are of very wide therapeutic use, given their efficacy, their status in the local pharmacopoeia, and are easily available in the DBR. Then, twenty-five species (20.7% of all recorded plants) are mentioned with a RFC value > 0.15, of which 12 have a RFC value > 0.21. However, a great number of species (70 or 58%) are cited with the lower RFC value (< 0.06).

On the other hand, the spontaneous plants growing in the wild participate with a high rate (79.3%) in the traditional pharmacopoeia of the DBR. Fully cultivated

species are represented with only 20.7% (n = 25). Thus, local populations most often resort to wild flora, given the importance of spontaneous plant resources in this forested region. Belda et al. (2013) also found that medicinal plants are mostly collected from scrubland or forests. Globally, at least 60% of medicinal plants are gathered from the wild (Bonet and Vallès 2007). This demonstrates the strong connection of local populations with their immediate natural environment (Zank and Hanazaki 2011).

Most of the medicinal plants listed in the DBR are common species. However, the local population has recourse to some rare and/or endemic plants (10.8% of all plants), collected within this protected area, for medicinal and other uses. These rare and endemic plants species are *Cedrus atlantica* (Endl.) Manetti ex Carrière, *Thymus numidicus* Poir., *Origanum vulgare* subsp. *glandulosum*, *Isatis djurdjurae* Coss. & Durieu, and rare non-endemic plants are *Artemisia absinthium* L., *Daphne laureola* L., *Lonicera etrusca* Santi, *Acer monspessulanum* L., *Acer obtusatum* Waldst. & Kit. ex Willd., *Ilex aquifolium* L., *Taxus baccata* L., and *Tussilago farfara* L. (montane plants). This part of the ethnoflora deserves the greatest conservatory attention for its heritage value. In particular, the Djurdjura pastel (*Isatis djurdjurae*), endemic to Algeria and Morocco, is used for skin diseases (boils and abscesses). Otherwise, the traditional exploitation of these species must be done in a reasonable way in order to preserve them and ensure their sustainability in this protected area. Local people should be informed on sustainable methods of harvesting plants to treat diseases today without compromising their availability for future use (Adaeze et al. 2018).

Table 2. Medicinal plants reported by the informants in the Djurdjura Biosphere Reserve with their ethnomedicinal uses. For each species, we mention the scientific name, the family, the Kabyle vernacular names, its relative frequency of citation (RFC), whether spontaneous (S) or cultivated (C) type. Data such as therapeutic uses or treated diseases, plant parts used, mode of preparation, administration route, are likewise provided. * Newly recorded plant species compared to Meddour et al. (2020).

Plant species	Families	Vernacular names	Parts used	Preparation methods	Administration modes	Treated diseases/Therapeutic uses	Type	RFC
* <i>Acer monspessulanum</i> L.	Sapindaceae	Adharchi	leaves	decoction	bath	hair loss	S	0,06
* <i>Acer obtusatum</i> Waldst. & Kit. ex Willd.	Sapindaceae	Lqikev	leaves	decoction	bath	hair loss	S	0,04
<i>Ajuga iva</i> (L.) Schreb.	Lamiaceae	Chkentoura	leaves leaves	infusion maceration	oral ingestion local application	diabetes, stomach pain, circulatory disorders scars	S	0,15
<i>Allium ampeloprasum</i> L.	Amaryllidaceae	Tharnast	leaves, bulbs	cooking	oral ingestion	physical weakness, indigestion, dry cough	C	0,19
<i>Allium cepa</i> L.	Amaryllidaceae	Leysel	bulbs bulbs bulbs	raw raw juice	compresses poultices local application	headache furuncles, abscesses warts	C	0,09
<i>Allium sativum</i> L.	Amaryllidaceae	Thicherth	bulbs bulbs	raw raw	oral ingestion local application	cough, diabetes bee stings	C	0,04
<i>Allium triquetrum</i> L.	Amaryllidaceae	Vivras	aerial part	raw	oral ingestion	indigestion, general fatigue	S	0,06
* <i>Aloysia citriodora</i> Paláu	Verbenaceae	Tizane, Zatage	leaves	infusion	oral ingestion	insomnia, headache, stomach pain	C	0,02
* <i>Ampelodesmos mauritanicus</i> (Poir.) T. Durand & Schinz	Poaceae	Adless	leaves	decoction	gargle	oral conditions, canker sores	S	0,06
<i>Apium graveolens</i> L.	Apiaceae	Kravez	leaves	decoction	rinses	frostbites	C	0,02
<i>Arbutus unedo</i> L.	Ericaceae	Issisnou	leaves	decoction	oral ingestion	diarrhea	S	0,04
<i>Artemisia absinthium</i> L.	Asteraceae	Jaret meriem	leaves, flowers leaves leaves leaves	infusion powder maceration juice, maceration	oral ingestion oral ingestion oral ingestion oral ingestion, local application	diabetes, diarrhea anorexia, nausea fever, stomach pain diarrhea, vomiting (babies)	S	0,23
<i>Arum italicum</i> Mill.	Araceae	Aveqouq	leaves	decoction	oral ingestion	influenza, indigestion	S	0,09
* <i>Arundo donax</i> L.	Poaceae	Aghanim	leaves rhizomes	juice decoction	oral ingestion oral ingestion	tonsillitis tonsillitis	S, C	0,06
* <i>Asphodelus ramosus</i> L.	Asphodelaceae	Abarwaq	tubers	heating	instillation	otitis	S	0,02
<i>Asplenium ceterach</i> L.	Aspleniaceae	Thiwjirrhin	leaves	infusion	oral ingestion	kidney stones	S	0,21
<i>Beta vulgaris</i> L.	Amaranthaceae	Thividhest	leaves	raw	oral ingestion	anemia, indigestion	S, C	0,04
<i>Blackstonia grandiflora</i> (Viv.) Maire	Gentianaceae	Qlilu	aerial part	infusion	oral ingestion	anemia, diabetes, lack of appetite, nausea, indigestion	S	0,04
<i>Borago officinalis</i> L.	Boraginaceae	Ahledjedh, Chikh levqoul	leaves, flowers flowers	juice infusion	oral ingestion oral ingestion	indigestion bronchitis, cold, joint pain	S	0,04
<i>Calicotome spinosa</i> (L.) Link	Fabaceae	Uzzu	aerial part seeds	lotion powder	local application mask	sores and injuries, hemorrhage headache	S	0,13

<i>Chamaeleon gummifer</i> Cass.	Asteraceae	Addadh	flowers flowers	crushed crushed	oral ingestion bath	headache, cough hemorrhoids	S	0,04
* <i>Castanea sativa</i> Mill.	Fagaceae	Abeludh urumi	fruits	raw	oral ingestion	diarrhea	S, C	0,02
<i>Cedrus atlantica</i> (Endl.) G.Manetti ex Carrière	Pinaceae	Avawel	leaves, bark	decoction	oral ingestion	bloating, cold	S	0,11
* <i>Celtis australis</i> L.	Cannabaceae	Ivikes	bark, roots flowers	tar (qedhran) infusion	oral ingestion oral ingestion	cough, general fatigue hypertension, nervousness	S	0,06
* <i>Centaurium erythraea</i> Rafn	Gentianaceae	Qlilu	flowers	infusion	oral ingestion	anemia, diabetes, lack of appetite, nausea, indigestion	S	0,09
* <i>Ceratonia siliqua</i> L.	Fabaceae	Akharouv	leaves leaves leaves	infusion juice juice	oral ingestion inhalation oral ingestion	diarrhea, nausea, stomach pain, fever, insomnia nasal congestion vomiting	S	0,04
<i>Citrus limon</i> (L.) Osbeck	Rutaceae	Lkares	fruits leaves	juice infusion	oral ingestion oral ingestion	tonsillitis, cold, general fatigue influenza, cold, anxiety	C	0,09
* <i>Coriandrum sativum</i> L.	Apiaceae	Leksvar	seeds seeds	infusion crushed	oral ingestion massage	bloating joint pain, rheumatism	S, C	0,06
<i>Crataegus monogyna</i> Jacq.	Rosaceae	Idhmim	fruits	infusion	oral ingestion	insomnia, hypertension	S	0,06
* <i>Cupressus sempervirens</i> L.	Cupressaceae	Thaydha	resin leaves bark	raw decoction powder	local application oral ingestion oral ingestion	scars influenza, cold stomach ulcer	C	0,09
<i>Cydonia oblonga</i> Mill.	Rosaceae	Thakthounia	leaves fruits	infusion cooking	oral ingestion oral ingestion	colon pain indigestion	C	0,04
<i>Cynara cardunculus</i> L.	Asteraceae	Thaga	leaves	raw	oral ingestion	indigestion	S, C	0,06
<i>Cynodon dactylon</i> (L.) Pers.	Poaceae	Affar	leaves leaves	infusion decoction	oral ingestion oral ingestion	colon pain kidney stones	S	0,04
<i>Daphne gnidium</i> L.	Thymelaeaceae	Alezaz	leaves	decoction	oral ingestion	constipation	S	0,04
<i>Daphne laureola</i> L.	Thymelaeaceae	Telt drar	leaves	powder	oral ingestion	constipation	S	0,02
* <i>Daucus carota</i> L.	Apiaceae	Thazdelt	seeds	crushed	poultices	burns, furuncles	S	0,04
* <i>Daucus carota</i> subsp. <i>sativus</i> (Hoffm.) Arcang.	Apiaceae	Zrodia	roots roots	raw paste	oral ingestion mask	vomiting, heartburn, diarrhea rough skin	C	0,04
<i>Dittrichia viscosa</i> (L.) Greuter	Asteraceae	Amagraman	leaves leaves aerial part leaves	decoction juice infusion paste	poultices local application oral ingestion local application	rheumatism, muscle aches scars, hemorrhages colon pain cracks in the feet	S	0,28
<i>Ecballium elaterium</i> (L.) A.Rich.	Cucurbitaceae	Afequs lehmir	leaves	infusion	oral ingestion	hemorrhoids, jaundice	S	0,04
<i>Erica arborea</i> L.	Ericaceae	Akhlenj	flowers	decoction	oral ingestion	indigestion, nervousness	S	0,04
* <i>Eriobotrya japonica</i> (Thunb.) Lindl.	Rosaceae	Thouvrest	leaves	decoction	oral ingestion	menstrual pains, indigestion	C	0,11
<i>Eucalyptus globulus</i> Labill.	Myrtaceae	Kalytous	leaves, flowers bark	infusion decoction	inhalation mouthwash	bronchial evacuation, cold, cough dental pain	C	0,04
<i>Ferula communis</i> L.	Apiaceae	Awli, Afougel	stem	splints	local application	fracture	S	0,06

<i>Ficus carica</i> L.	Moraceae	Thiqlets	fruits	raw	oral ingestion	general fatigue, constipation	S, C	0,15
<i>Foeniculum vulgare</i> (Mill.) Gaertn.	Apiaceae	Besvas	leaves, seeds	infusion	oral ingestion	bloating, lack of appetite, intestinal worms	S, C	0,06
<i>Fraxinus angustifolia</i> Vahl	Oleaceae	Aslen	roots	decoction	oral ingestion	diarrhea, menstrual pains	S, C	0,17
<i>*Fumaria officinalis</i> L.	Papaveraceae	Thijujar n yesghi	leaves	crushed	local application	fever	S	0,04
<i>Glebionis segetum</i> Fourr.	Asteraceae	Wamlal	bark	decoction	oral ingestion	stomach ulcer	S	0,04
<i>Globularia alypum</i> L.	Plantaginaceae	Thasselgha	seeds	powder	poultices	scars, joint pain	S	0,06
<i>*Hyoscyamus albus</i> L.	Solanaceae	Bounarjouf	leaves	raw	oral ingestion	rheumatism	S	0,04
<i>Hyoseris radiata</i> L.	Asteraceae	Tughmas n temgharin	aerial part	juice	local application	indigestion	S	0,04
<i>*Ilex aquifolium</i> L.	Aquifoliaceae	Iskerchi	leaves	infusion, decoction	oral ingestion	rough skin, varicose veins	S	0,06
<i>Isatis djurdjurae</i> Coss. & Durieu	Brassicaceae	Messlama	leaves	cooking	oral ingestion	asthma	S	0,02
<i>Juglans regia</i> L.	Juglandaceae	Thajujets	leaves	powder	mask	infertility	S	0,02
<i>Juniperus oxycedrus</i> L.	Cupressaceae	Taqqa	leaves	salad	oral ingestion	acne and pimples	S	0,16
<i>Laurus nobilis</i> L.	Lauraceae	Arihan, arend	leaves	decoction	oral ingestion	colon crisis, digestive disorders, bloating	S	0,04
<i>Lavandula stoechas</i> L.	Lamiaceae	Amezir beghyul	leaves	decoction	oral ingestion	?	S	0,04
<i>Lawsonia inermis</i> L.	Lythraceae	L'Henni n yifer	leaves	decoction	poultices	furuncles, abscesses	S	0,04
<i>Lonicera etrusca</i> Santi	Caprifoliaceae	Anaref	leaves, flowers	infusion, decoction	oral ingestion	oral conditions, gum infection	C	0,06
<i>Malva multiflora</i> (Cav.) Soldano, Banfi & Galasso	Malvaceae	Mejjir	roots (bark)	maceration	gargle, mouthwash	dull hair, bad foot odor	S	0,02
<i>*Malva sylvestris</i> L.	Malvaceae	Mejir	leaves	decoction	oral ingestion	insomnia	S, C	0,13
<i>Marrubium vulgare</i> L.	Lamiaceae	Marnuyeth	leaves	infusion	oral ingestion	indigestion, insomnia	S	0,11
<i>Melissa officinalis</i> L.	Lamiaceae	Ifer tzizwith	leaves	decoction	bath	intestinal pain	S	0,03
<i>Mentha pulegium</i> L.	Lamiaceae	Flegu	leaves	infusion, decoction	oral ingestion	heartburn	S	0,06
<i>Mentha spicata</i> L.	Lamiaceae	Naanaa	leaves, flowers	infusion	oral ingestion	scabies	S	0,23
<i>Mentha suaveolens</i> Ehrh.	Lamiaceae	Thimeja	aerial part	infusion	inhalation	eczema, hair loss	C	0,03
			leaves	decoction	oral ingestion	angina, cough	S	0,06
			leaves, roots	crushed	poultices	boils, mumps	S	0,23
			leaves, roots	decoction	instillation	sinusitis	S	0,06
			leaves	infusion	oral ingestion	bronchitis, cough	S	0,06
			leaves	decoction	oral ingestion	diarrhea, intestinal worms, fever	S	0,34
			leaves	decoction	instillation	weakness of children (thagdhit)	S	0,19
			leaves	infusion	oral ingestion	otitis	S	0,19
			leaves	decoction	inhalation	bloating, insomnia	S	0,19
			leaves	decoction	inhalation	influenza	S	0,28
			aerial part	maceration	oral ingestion	cold, insomnia	S	0,28
			leaves, flowers	infusion	oral ingestion	indigestion, anemia, lack of appetite	C	0,13
			leaves	infusion	oral ingestion	general fatigue	C	0,13
			aerial part	infusion	oral ingestion	insomnia, influenza, cough, menstrual evacuation, vomiting	C	0,13
			leaves	decoction	compresses	fever, dizziness	S	0,23
			leaves	decoction	compresses	diarrhea	S	0,23

			leaves	decoction	rinses	hair loss		
<i>*Myrtus communis</i> L.	Myrtaceae	Chilmoun	leaves	infusion, decoction	oral ingestion	cold, bronchitis, hemorrhoids	S	0,04
<i>Nerium oleander</i> L.	Apocynaceae	Ilili	leaves	infusion	mouthwash	oral infection	S	0,11
			leaves	latex	local application	scabies, pimples, warts		
<i>Nigella damascena</i> L.	Ranunculaceae	Sanoudj	seeds	maceration	oral ingestion	lack of appetite	S	0,06
			seeds	infusion	gargle	dental pain		
<i>Ocimum basilicum</i> L.	Lamiaceae	Lahvek	leaves	infusion	oral ingestion	galactogenic	S, C	0,06
<i>Olea europaea</i> L. subsp. <i>europaea</i> var. <i>europaea</i>	Oleaceae	Azemour	fruits	oil	oral ingestion	food poisoning, sore throat	C	0,26
			fruits	oil	massage	lumbago, furuncles		
			leaves, fruits	decoction	oral ingestion	hypertension		
<i>Olea europaea</i> L. subsp. <i>europaea</i> var. <i>sylvestris</i> (Mill.) Lehr	Oleaceae	Ahechadh, Azeboudj	leaves	decoction	local application	heavy legs, varicose veins	S	0,13
			bark	decoction	oral ingestion	indigestion		
<i>*Ophrys apifera</i> Huds.	Orchidaceae	Thiheythin thimeythin	bulbs	cooking, powder	oral ingestion	sexual impotence	S	0,06
<i>*Opuntia ficus-indica</i> (L.) Mill.	Cactaceae	Akarmous	flowers	infusion	oral ingestion	diarrhea	C	0,06
			fruits	raw	oral ingestion	diarrhea, general fatigue		
			cladodes	raw	poultices	sciatica		
<i>Origanum vulgare</i> subsp. <i>glandulosum</i> (Desf.) Ietswaart	Lamiaceae	Zaatar	aerial part	infusion	oral ingestion	diabetes, general fatigue, fever, influenza, cold, cough, angina, indigestion, lack of appetite, stomach pain, nausea, vomiting	S	0,43
				crushed decoction	poultices, friction, mask inhalation	joint pain insomnia, nervousness, headache, migraine, dizziness		
<i>Papaver rhoeas</i> L.	Papaveraceae	Wahrir, Djihbut	flowers	infusion	oral ingestion	cough, insomnia	S	0,09
<i>Paronychia argentea</i> Lam.	Caryophyllaceae	Latay n'lakhla	flowers	infusion	oral ingestion	intestinal problems	S	0,06
<i>*Peganum harmala</i> L.	Nitrariaceae	Elharmel	aerial part	maceration	rinses	rheumatism	S	0,04
<i>Petroselinum crispum</i> (Mill.) Fuss	Apiaceae	Maadnous	aerial part	decoction	oral ingestion	cardiotonic, hypertension	S, C	0,11
			aerial part	raw	local application	dental pain		
			leaves	juice	instillation	otitis		
<i>*Pimpinella anisum</i> L.	Apiaceae	Hebet hlawa	seeds	decoction	oral ingestion	cough, bronchitis	C	0,02
<i>*Pinus halepensis</i> Mill.	Pinaceae	Azoumbi	seeds, bark	decoction	mouthwash	canker sores, oral infection	S	0,04
<i>Pistacia lentiscus</i> L.	Anacardiaceae	Thidhekth	leaves	infusion	oral ingestion	hypertension, bronchial evacuation	S	0,17
			leaves	decoction	oral ingestion	colon pain, stomach pain, diarrhea, dizziness		
			leaves	powder	oral ingestion	hemorrhoids		
<i>Plantago lanceolata</i> L.	Plantaginaceae	Thahchicht n'hmed	leaves	powder	local application	eczema, skin fungus	S	0,30
			leaves	raw	poultices	abscesses, foot nails		
			leaves	juice	local application	hemorrhages, scars		
<i>*Prunus armeniaca</i> L.	Rosaceae	Elkhokh	leaves	juice	poultices	?	C	0,04
<i>*Prunus avium</i> (L.) L.	Rosaceae	Ardherim	fruits (peduncles)	infusion	oral ingestion	urine retention, diarrhea	S	0,06

<i>Prunus cerasus</i> L.	Rosaceae	Lesriz, Heb lemlouk	fruits (peduncles)	infusion	oral ingestion	urine retention, kidney stones, diarrhea, stomach pain	C	0,15
* <i>Pteridium aquilinum</i> (L.) Kuhn	Dennstaedtiaceae	Ifelkou	rhizomes rhizomes	decoction oil	oral ingestion massage	intestinal worms joint pain	S	0,02
<i>Punica granatum</i> L.	Lythraceae	Reman	fruits fruits bark	juice maceration powder	oral ingestion gargle oral ingestion	cold, fever, diarrhea, hemorrhoids, lack of appetite canker sores, oral infection indigestion, vomiting	C	0,23
<i>Quercus rotundifolia</i> Lam.	Fagaceae	Abeludh	bark fruits	decoction infusion	oral ingestion bath	stomach ulcer urinary tract infection	S	0,13
* <i>Quercus suber</i> L.	Fagaceae	Akarouch	leaves bark	decoction decoction	oral ingestion bath	indigestion heavy legs	S	0,04
<i>Rhamnus alaternus</i> L.	Rhamnaceae	Imliles	roots	decoction	friction, mask	jaundice	S	0,02
* <i>Nasturtium officinale</i> R.Br.	Brassicaceae	Garninouch	aerial part aerial part	paste raw	mask oral ingestion	acne and pimples heartburn	S	0,04
<i>Rosa canina</i> L.	Rosaceae	Iaâfar	seeds fruits	powder raw	oral ingestion oral ingestion	urine retention, diarrhea	S	0,15
<i>Rosmarinus officinalis</i> L.	Lamiaceae	Amezir, Thiklilt	leaves leaves	infusion powder	oral ingestion oral ingestion	menstrual pains menstrual pains	S, C	0,11
<i>Rubus ulmifolius</i> Schott	Rosaceae	Inigel	leaves, roots leaves leaves leaves fruits leaves	decoction infusion maceration juice raw	oral ingestion oral ingestion oral ingestion oral ingestion local application	diabetes hypertension tonsillitis, tooth decay goiter wounds, burns, hemorrhages	S	0,30
<i>Rumex conglomeratus</i> Murray	Polygonaceae	Tassemumt n yezgaren	leaves	raw	poultices	boils, sores, indigestion, diarrhea	S	0,13
* <i>Ruscus aculeatus</i> L.	Asparagaceae	Icher n'yizem	leaves roots	infusion decoction	oral ingestion oral ingestion	fever, inflammation urinaire improves blood circulation	S	0,02
<i>Ruta angustifolia</i> Pers.	Rutaceae	Awermi	flowers roots	infusion raw	oral ingestion poultices	anemia, anorexia, stomach pain burns, scars	S	0,19
* <i>Salix alba</i> L.	Salicaceae	Issemlel	bark	decoction	oral ingestion	colon pain, rheumatism, sciatica	S	0,06
* <i>Salvia officinalis</i> L.	Lamiaceae	Marissem	leaves	infusion	oral ingestion	indigestion, diabetes	C	0,06
<i>Sambucus nigra</i> L.	Viburnaceae	Arwuri	leaves	raw	poultices	back pain	S	0,06
<i>Scolymus hispanicus</i> L.	Asteraceae	Thilitsen, Taghedith	leaves (ribs)	sauce	oral ingestion	physical weakness, indigestion	S, C	0,26
<i>Scrophularia canina</i> L.	Scrophulariaceae	Harm larvi	aerial part	raw	poultices	back pain, joint pain, rheumatism	S	0,16
<i>Silene vulgaris</i> (Moench) Garcke	Caryophyllaceae	Thaghighachth	roots aerial part	crushed raw	compresses oral ingestion	infertility general fatigue	S	0,09
* <i>Solanum tuberosum</i> L.	Solanaceae	Batata	tubers	raw	local application	migraine, headache	C	0,09
<i>Sonchus oleraceus</i> L.	Asteraceae	Thifaf	leaves leaves, stems	juice raw	local application oral ingestion	scars, burns kidney stones	S	0,09
<i>Tamarix gallica</i> L.	Tamaricaceae	Amemmay	leaves	decoction	oral ingestion	asthma, cough	S	0,03

<i>*Taraxacum erythrospermum</i> Andrz. ex Besser	Asteraceae	Thughmes temgharth	leaves aerial part	raw juice	oral ingestion friction	indigestion jaundice	S	0,04
<i>*Taxus baccata</i> L.	Taxaceae	Thifuzalet	leaves	decoction?	?	urinary disorders, rheumatism	S	0,02
<i>Teucrium polium</i> L.	Lamiaceae	Jaada	leaves leaves	decoction powder	oral ingestion oral ingestion	menstrual evacuation infertility	S	0,02
<i>Thapsia garganica</i> L.	Apiaceae	Adviv	roots leaves	decoction crushed	oral ingestion poultices	general fatigue, indigestion joint pain	S	0,13
<i>Thymus numidicus</i> Poir.	Lamiaceae	Thimezirth	aerial part aerial part	infusion rinses	oral ingestion rinses	bloating, cholesterol, cough wounds, rough skin	S	0,19
<i>*Tragopogon porrifolius</i> L.	Asteraceae	Thawelment	leaves	infusion	oral ingestion	urine retention	S	0,11
<i>*Trigonella foenum-graecum</i> L.	Fabaceae	Thifidhas	seeds seeds seeds	infusion powder powder	oral ingestion maceration mask	anemia, nausea, nervousness asthma hair loss	C	0,26
<i>*Tussilago farfara</i> L.	Asteraceae	Ifer budhi	leaves leaves	decoction rinses	oral ingestion rinses	cough, indigestion rough skin	S	0,02
<i>*Ulmus minor</i> Mill.	Ulmaceae	Oulmou	roots leaves	infusion raw	bath poultices	hair loss, scars joint pain	S	0,06
<i>Umbilicus rupestris</i> (Salisb.) Dandy	Crassulaceae	Thichoufthin	leaves	heating	poultices	furuncles, pimples	S	0,02
<i>Urtica dioica</i> L.	Urticaceae	Azegdouf	aerial part leaves, roots	infusion infusion	oral ingestion bath	anemia hair loss, pellicules, rheumatism	S	0,19
<i>*Vicia faba</i> L.	Fabaceae	Ivawen	flowers fruits (pods)	raw raw	inhalation friction	food poisoning skin fungus (thifiri)	C	0,04
<i>Vitis vinifera</i> L.	Vitaceae	Thara thaezgeghth	leaves leaves	infusion juice	oral ingestion bath	anxiety, nervousness circulatory disorders	S, C	0,09
<i>*Zea mays</i> L.	Poaceae	Akvel	seeds flowers (beard)	cooking infusion	oral ingestion oral ingestion	diarrhea urine retention, rough skin	C	0,06

3.3. Plants parts used, preparation and administration mode

The local population of the DBR uses plants mainly in their fresh form (68.46% of citations). This is linked to the direct relationship between local populations and nature and the daily harvest of fresh plants, which may eventually be also used for food. Conversely, the local population has little recourse to dried plants (12.61%). In addition, 18.91% of plants are used fresh or dried. Leaves are the most frequently used part in traditional medicine recipes, accounting for 48.51% of all citations by informants (Figure 3). This wide use of leaves has been largely reported in other similar ethnobotanical studies conducted in the Maghreb countries (Benkhnigue et al. 2011; Boutabia et al. 2011) or elsewhere (Leto et al. 2013). This can be explained by the availability and ease of collecting the leaves (Nasution et al. 2018), and as the leaves are the main organs of photosynthesis (Susanti and Zuhud 2019), which have chemicals that could be responsible for medicinal effects (Balick and Cox 1997). Otherwise, leaf collection, when moderate, does not damage or compromise the development of the plants (Brito et al. 2017). The underground vegetative organs (roots, bulbs, rhizomes, and tubers) come second with 12.87%. Aerial parts and fruits in third place (8.41% each), seeds (6.93%) and flowers (6.43%) follow them. The other organs (barks, stems) are mentioned less (5.94% and 2.47% respectively).

Infusion and decoction are the most common preparations among local populations of DBR, accounting for 26.53% of all citations each, followed by raw consumption with 13.78%. This reflects the ease of preparing the infusion and decoction with water. This is likewise the case in other studies (Estrada et al. 2007), where these preparations play a very important role in local traditional medicines, both for oral and

topical routes (Vinagre et al. 2019). On the other hand, it is often enough for local populations of the DBR to consume wild plants uncooked (as salads), to cure the common diseases from which they suffer. Lastly, the other methods of preparation (juice, maceration powder, cooked, crushed and others) are cited with amounts of less than 10% each.

Oral ingestion is the predominant mode accounting for 58% of all citations. This high rate is related to the large number of internal diseases (digestive, circulatory and respiratory disorders) encountered during our study. The other modes of internal administration (inhalation, instillation, gargles and mouthwashes) are represented with 8.5% in all. In consent with Vinagre et al. (2019), internal administration, essentially the oral route, represents the most recommended mode. Local applications come in second, with 9.5% of citations, followed by other modes used externally, such as baths and rinses (9%), poultices (8.5%), masks, and friction (6.5%). They are mainly linked to skin ailments, but also musculoskeletal problems.

3.4. Traditional medicinal uses of recorded plant species

A wide range of 83 diseases and symptoms, reported by the local population of DBR during our investigation, were assembled into 10 disease groups, based on the body system (Table 3). The number of diseases in each group varies between 3 and 17. Three groups (circulatory, digestive, and skin disorders) include 10, 14 and 17 treated diseases, respectively. They are followed by mental-nervous, genitourinary group (8 each), respiratory group (7), skeletomuscular group (6), oral-dental and other diseases groups (5 each), and endocrine-metabolic-nutritional group (3).

Table 3. Major disease categories, diseases treated, and number of plant species used in the study area

Disease categories	Number of diseases treated	Number of species used per group	Diseases (number of species used per disease)
Digestive diseases	14	63	indigestion (23), diarrhea (16) , stomach pain (10), bloating (7), colon pain (7), lack of appetite (7), nausea (6), constipation (3), heartburn (3), intestinal worms (3), stomach ulcer (3), vomiting (3), food poisoning (1), hepatic-biliary insufficiency (1)
Skin diseases	17	35	scars (11) , rough skin (8), hair loss (6), furuncles (4), abscesses (3), scabies (2), acne and pimples (2), wart (2), skin fungus (2), eczema (1), dandruff (1), burns (1), wound (1), bites (1), cracked feet (1), dull hair (1), bad foot odor (1)
Cardiovascular and circulatory diseases	10	27	anemia (7), hypertension (6), hemorrhages (4), hemorrhoid (4), jaundice (3), heavy legs (2), varicose veins (2), circulatory disorders (2), heart weakness (1), frostbite (1)
Respiratory diseases	7	23	cough (11) , cold (9), influenza (5), bronchitis (3), angina (3), asthma (2), discharge of mucus (2)
Mental-nervous diseases	8	21	insomnia (9), headache (5), nervousness (4), sciatica (2), anxiety (2), dizziness (2), migraine (2), anorexia (2)
Other diseases	5	18	general fatigue (9), fever (8), otitis (4), tiredness (2), weakness of children (1)
Genitourinary and reproductive diseases	8	17	urine retention (7), kidney stones (4), infertility (3), menstrual pains (2), menstruation evacuation (2), genital impotence (1), galactogenic (1), urinary tract infection (1)
Skeletomusclar diseases	6	13	rheumatism (7), joint pain (5), muscle aches (2), lumbago (1), fracture (1), back pain (1)
Oral-dental diseases	5	12	oral infection (5), dental pain (5), tonsillitis (3), canker sores (2), gum infection (1)
Endocrine, metabolic and nutritional diseases	3	9	diabetes (6), cholesterol (1), goiter (1)

The disease group that is treated by the largest number of plants (63 in total) is those of digestive disorders (indigestion, diarrhea, stomach pain). This disease group is the most treated in several Mediterranean countries (Gonzalez-Tejero et al. 2008), thus confirming our observations and giving a broad character to this fact. The group of skin conditions takes second place, with 35 plants used to cure them; third place goes to the group of cardiovascular-circulatory

disorders (27), fourth to respiratory problems (23). Nervous-mental group (21), other diseases (18), genitourinary group (17), skeletomuscular group (13), oral-dental group (12), and endocrine-metabolic-nutritional group (9) follow them. The predominance of digestive, skin and respiratory disorders treated by local populations is similarly observed in several Mediterranean countries (Scherrer et al. 2005; Gonzalez-Tejero et al. 2008; di Sanzo et

al. 2013; Menale et al. 2016). This is also the case in non-Mediterranean areas (Sousa et al. 2012; Safeer et al. 2017). Out of the 83 diseases identified in our survey, 31 of them are commonly treated with a large number of plants, at least four (Figure 2). Indigestion and diarrhoea are the most treated ailments by the local population, with 21 and 16 species respectively, followed by cough and scars, with 11 species each, and stomach

pains, with 10 species. In addition, nine species can treat insomnia, cold or general fatigue. According to Belda et al. (2013), most of the reported species were likewise used to treat indigestion and diarrhea. In other studies, medicinal plants are mentioned mainly for the same therapeutic uses, indigestion (Sousa et al. 2012) or diarrhea (Qureshi 2012). Finally, the 41 remaining diseases are treated with one or two species.




Figure 2. The most treated diseases and the number of species used in each case (≥ 4)

The DBR villagers use 22 medicinal plants to treat a minimum of five diseases per plant (Table 4). Oregano (*Origanum vulgare* L. subsp. *glandulosum*) treats the maximum number of diseases (18), such as diabetes, insomnia, headache, digestive disorders (indigestion, stomach pain, nausea ...) and respiratory problems (cough, cold, influenza, and angina). Then, *Rubus ulmifolius* Schott is used in eight therapeutic usages (diabetes, wounds, burns, hypertension, tonsillitis, haemorrhage, toothache, goitre). To treat seven diseases (angina, lumbago, back pain, hypertension, sore throat, food poisoning, furuncles), local people use the olive tree (*Olea europaea* L. subsp. *europaea* var.

europaea); its oil is considered a panacea in local pharmacopoeia. These plants are followed by *Artemisia absinthium*, used to remedy seven diseases, such as anorexia, diabetes, fever, and digestive disorders (diarrhoea, stomach pain, nausea, vomiting), *Punica granatum* L. (diarrhea, indigestion, cold, haemorrhoids, canker sores...), and *Pistacia lentiscus* L. (colon pain, stomach pain, diarrhoea, hypertension, dizziness, etc.). The greater figures of therapeutic uses of these species can be explained by their abundance in the study area and by their reputation in the local pharmacopoeia. Lastly, the majority of the plants (82%) are used to treat one to four ailments each.

Table 4. Classification of the most used plants treating more than five diseases

Medicinal plants treated	Relative Frequency of citation (RFC)	Number of diseases
<i>Origanum vulgare</i> subsp. <i>glandulosum</i> (Desf.) Ietswaart	0,43	18
<i>Rubus ulmifolius</i> Schott	0,3	8
<i>Olea europaea</i> L. subsp. <i>europaea</i> var. <i>europaea</i>	0,26	7
<i>Artemisia absinthium</i> L.	0,23	7
<i>Punica granatum</i> L.	0,23	7
<i>Pistacia lentiscus</i> L.	0,17	7
<i>Plantago lanceolata</i> L.	0,3	6
<i>Mentha pulegium</i> L.	0,28	6
<i>Thymus numidicus</i> Poir.	0,19	6
<i>Urtica dioica</i> L.	0,19	6
<i>Petroselinum crispum</i> (Mill.) Fuss	0,11	6
<i>Ceratonia siliqua</i> L.	0,04	6
<i>Marrubium vulgare</i> L.	0,34	5
<i>Dittrichia viscosa</i> (L.) Greuter	0,28	5
<i>Trigonella foenum-graecum</i> L.	0,26	5
<i>Asplenium ceterach</i> L.	0,21	5
<i>Ruta angustifolia</i> Pers.	0,19	5
<i>Fraxinus angustifolia</i> Vahl	0,17	5
<i>Mentha spicata</i> L.	0,13	5
<i>Centaurium erythraea</i> Rafn	0,09	5
<i>Citrus limon</i> (L.) Osbeck	0,09	5
<i>Blackstonia grandiflora</i> (Viv.) Maire	0,04	5

3.5. New or rarely reported medicinal plants and their uses

To evaluate the degree of originality of the ethnoflora reported in this study, we have compared our list of medicinal plants with: i) those reported in other regions of Kabylia (Ait Youssef 2006; Meddour and Meddour-Sahar 2015), ii) a large corpus of recently published articles (about 50) on Algerian ethnobotany (e.g. Gonzalez-Tejero et al. 2008; Boutabia et al. 2011; Bounar et al. 2013; Benarba et al. 2015; Boughrara and Belgacem 2016; Ouelbani et al. 2016; Benaissa et al. 2018; Souilah et al. 2018; Hamel et al. 2018; Hadjadj et al. 2019; Chohra and Ferchichi 2019; Lazli et al. 2019;

Baziz et al. 2020, Zatout et al. 2021, etc.), and iii) the information available for Algeria in the Prelude database (2022).

From this comparison, it appears that eight species did not appear in this recent bibliography on medicinal plant uses in Algeria. Those are *Acer monspessulanum* and *Acer obtusatum* (both fights hair loss). *Blackstonia grandiflora* (Viv.) Maire (anaemia, diabetes, lack of appetite, nausea, indigestion), *Celtis australis* L. (hypertension, nervousness), *Daphne laureola* L. (constipation), *Isatis djurdjurae* (furuncles, abscesses), *Ophrys apifera* Huds. (sexual impotence) and *Tragopogon porrifolius* L. (diuretic). These plants are cited for the first time in Algeria as

medicinal, and their traditional therapeutic uses are therefore to be considered new and previously undocumented for the Algerian pharmacopoeia. Some other plants are rarely reported in Algerian ethnobotanical studies. They are confined in forest ecosystems of mountainous humid area. We will review them underneath.

Ilex aquifolium, used as a diuretic by local population of Djurdjura, is likewise diuretic and treats rheumatism in the Northeastern part of Algeria (Hamel et al. 2018). *Lonicera etrusca*, used to treat respiratory problems (angina, cough) in Djurdjura, is known as suitable for skin problems in Belezma National Park (East of Algeria) (Chohra and Ferchichi 2019). *Ruscus aculeatus* L., which improves blood circulation, and treats fever and urinary inflammation in the DBR, is mentioned for the treatment of several diseases (cardiovascular diseases, digestive disorders, spasms, sinusitis, and psoriasis) in the regions of Constantine and Mila (Ouelbani et al. 2016). *Taxus baccata* is used to manage urinary disorders and rheumatism according to local population of Djurdjura. Elsewhere in Algeria, it is known to treat reproductive problems in Mitidja, Algiers region (Gonzalez-Tejero et al. 2008), anaemia and nervousness in Eastern Algeria (Ouelbani et al. 2016). *Tussilago farfara*, which has several local uses (cough, indigestion, rough skin) in Djurdjura, is similarly used to treat cough in Northwest of Algeria (Benarba et al. 2015). Finally, *Umbilicus rupestris* (Salisb.) Dandy, whose leaves treat skin disorders (furuncles, pimples) in Djurdjura, is used precisely to treat skin diseases (inflammation, rough skin (as softener), wound healing) in Aures mountains at eastern Algeria (Baziz et al. 2020), and also in Italy (Gonzalez-Tejero et al. 2008). In the northern Mediterranean rim, the leaves of this plant are used against inflammation of the skin, wounds, burns, and as an ophthalmic disinfectant (Benhouda et al. 2014). There is therefore a high consensus

on the therapeutic indications of this plant in the Mediterranean basin.

4. Conclusion and outlooks

This ethnobotanical survey in the Djurdjura Biosphere Reserve, among rural populations isolated in a mountainous area, permitted the faithful transcription of noteworthy medicinal knowledge. The ethnobotanical data acquired are evidencing a diversity of medicinal flora and traditional therapeutic uses of plants and a vital role of the protected area in preserving the human health of local populations. The long-lasting interest of local populations in the therapeutic virtues of plants was clearly reflected in the important number of medicinal plant species (more than a hundred) used to manage primary human health care. Indeed, the local populations have succeeded in preserving the ancestral therapeutic practice of plants until today, by a use of plants deeply rooted in the local tradition that can make a significant contribution to sustainable development.

Finally, if management and decision-making are conducted through a participatory approach, local populations can play a crucial role in the *in situ* conservation of plant resources, by incorporating their traditional ecological knowledge (TEK) into a strategy for the sustainable management of this protected area, of national and international importance.

Acknowledgements

The authors are very grateful to all the informants and villagers of the DBR for their hospitality, kindness, and for sharing willingly their time and information.

Author Contribution

RM and SO settled the research and data collection protocol, and wrote the manuscript. RM did the fieldwork. SO performed the data analysis and processing.

Conflicts of Interest

The authors reported no conflict of interest.

References

1. Aadaeze, J.E., Abubakar, A. and Jatau, D.F., 2018. Ethnobotany among the Gashaka inhabitants of Gashaka Gumti National Park, Taraba state, Nigeria. *Journal of Research in Forestry Wildlife and Environment*, 10(4), 17-24.
2. Ait Youssef, M., 2006. *Plantes médicinales de Kabylie*. Ibis Press, Paris, 349 pp.
3. Albuquerque, U.P., Lucena, R.F.P., Cunha, L.V.F.C. and Alve, R.R.N., 2014. *Methods and techniques in ethnobiology and ethnoecology*. Springer Protocols Handbooks, Humana Press, New York, 480 pp. <https://doi.org/10.1007/978-1-4614-8636-7>
4. Aquaron, M., 2006. Relations entre les hommes et les plantes médicinales. *Des pratiques empiriques aux pratiques scientifiques*. *Bipedia*, 24, 1-10.
5. Balick, M.J. and Cox, P.A., 1997. Ethnobotanical research and traditional health care in developing countries. In: Bodeker, G.C., Bhat, K.K.S., Burley, J. and Vantomme, P. (Eds), *Medicinal plants for forest conservation and health care*. FAO, Rome, pp. 12-23.
6. Baydoun, S.A., Kanj, D., Raafat, K., Aboul Ela, M., Chalak, L. and Arnold-Apostolides, N., 2017. Ethnobotanical and Economic Importance of Wild Plant Species of Jabal Moussa Bioserve, Lebanon. *Journal of Ecosystem and Ecography*, 7(3), 1-8.
7. Baziz, K., Maougal, R.T. and Amroune, A., 2020. An ethnobotanical survey of spontaneous plants used in traditional medicine in the region of Aures, Algeria. *European Journal of Ecology*, 6(2), 49-69.
8. Belda, A., Zaragoza, B., Belda, I., Martinez, J.E. and Seva, E., 2013. Traditional knowledge of medicinal plants in the Serra de Mariola natural park, southeastern Spain. *African Journal of Traditional Complementary and Alternative Medicines*, 10(2), 299-309.
9. Bellakhdar, J., 2008. Hommes et plantes au Maghreb. *Éléments pour une méthode en ethnobotanique*. *Plurimondes*, Metz, 386 pp.
10. Benaissa, M., El Haitoum, A. and Hadjadj, K., 2018. Floristic diversity and medical interest of Djebel Aissa national park (Ksour Mountains, Algeria). *Malaysian journal of fundamental and applied sciences*, 14(2), 303-306.
11. Benarba, B., Belabid, L., Righi, K., Bekkar, A., Elouissi, M., Khaldi, A. and Hamimed, A., 2015. Ethnobotanical study of medicinal plants used by traditional healers in Mascara (North West of Algeria). *Journal of Ethnopharmacology*, 175, 626-637.
12. Benhouda, A., Yahia, M., Benhouda, D., Bousnane, N.E., Benbia, S., Hannachi, N.E. and Ghecham, A., 2014. Antimicrobial and antioxidant activities of various extracts of *Hyoscyamus albus* L. and *Umblicus rupestris* L. leaves. *Algerian journal of natural products*, 2(1), 4-17.
13. Benkhniq, O., Zidane, L., Fadli, M., Elyacoubi, H., Rochdi, A. and Douira, A., 2011. Étude ethnobotanique des plantes médicinales dans la région de Mechraâ Bel Ksiri (Région du Gharb du Maroc). *Acta botánica barcinonensia*, 53, 191-216.
14. Bonet, M.A. and Vallès, J., 2007. Ethnobotany of Montseny biosphere reserve (Catalonia, Iberian Peninsula), Plants used in veterinary medicine. *Journal of ethnopharmacology*, 110(1), 130-147.
15. Boughrara, B. and Belgacem, L., 2016. Ethnobotanical study close to the population of the extreme north east of Algeria, the municipalities of El Kala National Park (EKNP). *Industrial crops and products*, 88, 2-7.
16. Bounar, R., Rebbas, K., Gharzouli, R., Djellouli, Y. and Abbad, A., 2013. Ecological and medicinal interest of Taza national park (Jijel, Algeria). *Global Journal of Research on Medicinal Plants and Indigenous Medicine*, 2(2), 89-101.
17. Boutabia, L., Telailia, S., Cheloufi, R. and Chefrour, A., 2011. La flore médicinale du massif forestier d'Oum Ali (Zitouna, wilaya d'El Tarf, Algérie), inventaire et étude ethnobotanique. *Annales de l'INRGREF*, 15, 201-213.
18. Brito, M.F.M., Marin, E.A. and da Cruz, D.D., 2017. Medicinal plants in rural settlements of a protected area in the littoral of Northeast Brazil. *Ambiente and Sociedade*, São Paulo, 20(1), 83-104.
19. Chohra, D. and Ferchichi, L., 2019. Ethnobotanical study of Belezma national park (BNP) in Batna, East of Algeria. *Acta scientifica Naturalis*, 6(2), 40-54.
20. da Silva, N.F., Hazanaki, N., Albuquerque, U.P., Almeida Campos, J.L., Feitosa, I.S. and de Lima Araujo, E., 2019. Local knowledge and conservation priorities of medicinal plants near a protected area in Brazil. *Evidence-based complementary and alternative medicine*, Article ID 8275084. <https://doi.org/10.1155/2019/8275084>
21. di Sanzo, P., De Martino, L., Mancini, E. and De Feo, V., 2013. Medicinal and useful plants in the tradition of Rotonda, Pollino National Park, Southern Italy. *Journal of ethnobiology and ethnomedicine*, 9, 19-33.
22. Dobignard, A. and Chatelain, C., 2010-2013. *Index synonymique et bibliographique de la flore d'Afrique du Nord*. Éditions des Conservatoire et Jardin Botaniques, Genève. Vol. 1-5.
23. Ennabili, A., Gharnit, N. and El Hamdouni, E.M., 2000. Inventory and social interest of medicinal aromatic and honey plants from Mokrisset region (NW of Morocco). *Studia Botanica*, 19, 57-74.
24. Estrada, E., Villareal, J.A., Cantu, C., Cabral, I., Scott, L. and Yen, C., 2007. Ethnobotany in the Cumbres de Monterrey National Park, Nuevo León, México.

- Journal of ethnobiology and ethnomedicine, 3(8), 1-8.
25. Gonzalez-Tejero, M.R., Casares-Porcel, M., Sanchez-Rojas, C.P., Ramiro-Gutierrez, J.M., Molero-Mesa, J., Pieroni, A., Giusti, M.E., Corsorii, E., De Pasquale, C., Della, A., Paraskeva-Hadijchambi, D., Hadjichambis, A., Houmani, Z., El-Demerdash, M., El-Zayat, M., Hmamouchi, M. and Eljohrig, S., 2008. Medicinal plants in the Mediterranean area, synthesis of the results of the project Rubia. *Journal of ethnopharmacology*, 116, 341-357.
 26. Hadjadi, K., Benaissa, M., Mahammedi, M., Ouragh, A. and Rahmou, A., 2019. Importance des plantes médicinales pour la population rurale du Parc National de Djebel Aissa (Sud-Ouest algérien). *Lejeunia, revue de Botanique, N.S.*, 199, 1-12.
 27. Hamel, T., Zaafour, M. and Boumendjel, M., 2018. Ethnomedical knowledge and traditional uses of aromatic and medicinal plants of the wetlands complex of the Guerbes-Sanhadja plain (wilaya of Skikda in Northeastern Algeria). *Herbal medicine*, 4(1-3), 1-9.
 28. Hoang, V.S., Baas, P. and Kebler, P.J.A., 2008. Traditional medicinal plants in Ben En National Park, Vietnam. *Blumea*, 53, 569-601.
 29. ISE (International Society of Ethnobiology), 2006. ISE Code of Ethics (with 2008 additions). <http://ethnobiology.net/code-of-ethics/>
 30. Lazli, A., Beldi, M., Ghouri, L. and Nouri, N.E.H., 2019. Étude ethnobotanique et inventaire des plantes médicinales dans la région de Bougous (Parc National d'El Kala, Nord-est algérien). *Bulletin de la Société Royale des Sciences de Liège*, 88, 22-43.
 31. Leto, C., Tuttolomondo, T., La Bella, S. and Licata, M., 2013. Ethnobotanical study in the Madonie Regional Park (Central Sicily, Italy). Medicinal use of wild shrub and herbaceous plant species. *Journal of ethnopharmacology*, 146, 90-112.
 32. Martin, G.J., 2004. *Ethnobotany. A methods manual (People and plant conservation)*. Rotledge, New York, 292 pp.
 33. Mattalia, G., Stryamets, N., Pieroni, A. and Soukand, R., 2020. Knowledge transmission patterns at the border; ethnobotany of Hutsuls living in the Carpathian Mountains of Bukovina (SW Ukraine and NE Romania). *Journal of ethnobiology and ethnomedicine*, 16, Article number 41. <https://doi.org/10.1186/s13002-020-00391-33>
 34. Meddour, R. and Meddour-Sahar, O., 2015. Medicinal plants and their traditional uses in Kabylia (Tizi Ouzou, Algeria). *Arabian Journal of Medicinal and Aromatic Plants*, 1(2), 137-151.
 35. Meddour, R., Meddour-Sahar, O. and Ouyessad, M., 2020. Enquête ethnobotanique des plantes médicinales dans le Parc National du Djurdjura et sa zone d'influence, Algérie. *Ethnobotany Research and Applications*, 20, 1-25. <http://dx.doi.org/10.32859/era.20.46.1-25>
 36. Mehdioui, R. and Kahouadji, A., 2007. Etude ethnobotanique auprès de la population riveraine de la forêt d'Amsittène, cas de la commune d'Imi n'Tlit (province d'Essaouira). *Bulletin de l'Institut Scientifique, section Sciences de la vie*, 29, 11-20.
 37. Menale, B., De Castro, O., Cascone, C. and Muoio, R., 2016. Ethnobotanical investigation on medicinal plants in the Vesuvio National Park (Campania, Southern Italy). *Journal of ethnopharmacology*, 192, 320-349. <https://doi.org/10.1016/j.jep.2016.07.049>
 38. Nasution, A., Chikmawati, T., Walujo, E.B. and Zuhud, E.A.M., 2018. Ethnobotany of Mandailing tribe in Batang Gadis National Park. *Journal of tropical life science*, 8(1), 48-54.
 39. Ouelbani, R., Bensari, S., Mouas, T.N. and Khelifi, D., 2016. Ethnobotanical investigations on plants used in folk medicine in the regions of Constantine and Mila (Northeast of Algeria). *Journal of ethnopharmacology*, 194, 196-218.
 40. Prelude database, 2022. Prelude medicinal plants database. Royal museum for Central Africa. (http://www.africamuseum.be/collections/external/prelude/view_country?cc=DZ)
 41. Quézel, P. and Santa, S., 1962-1963. Nouvelle flore de l'Algérie et des régions désertiques méridionales. Vol. 1-2. CNRS, Paris, 1170 pp.
 42. Qureshi, R., 2012. Medicinal flora of Hingol National Park, Baluchistan, Pakistan. *Pak. J. Bot.*, 44(2), 725-732.
 43. Rhafouri, R., Aafi, A., Zair, T., Strani, B., El Omari, M., Ghanmi, M. and Bentayeb, A., 2015. Ethnobotanical study of medicinal plants in Ifran's National Park (Morocco). *Journal of Materials and Environmental Sciences*, 6(3), 619-630.
 44. Rhattas, M., Douira, A. and Zidane, L., 2016. Étude ethnobotanique des plantes médicinales dans le Parc National de Talassemtane (Rif occidental du Maroc). *Journal of Applied Biosciences*, 97, 9187-9211.
 45. Safeer, S., Qureshi, R., Hassan, U., Khalid, S. and Anware, F., 2017. Ethnobotanical study on useful indigenous plants in Mahasheer National Park, AJK. *Journal of coastal life medicine*, 5(3), 109-115.
 46. Scherrer, A.M., Motti, R. and Weckerle, C.S., 2005. Traditional plant use in the areas of Monte Vesole and Ascea, Cilento National Park (Campania, Southern Italy). *Journal of ethnopharmacology*, 97, 129-143.
 47. Souilah, N., Zekri, J., Gira, A., Akkal, S. and Medjeroubi, K., 2018. Ethnobotanical study of medicinal and aromatic plants used by the population of National Park of El Kala (northeastern Algeria). *International Journal of Biosciences*, 12(4), 55-77.

48. Sousa, R.D.S., Hanazaki, N., Batista Lopes, J. and Barros, R.F.M., 2012. Are gender and age important in understanding the distribution of local botanical knowledge in fishing communities of the Parnaíba delta environmental protection area? *Ethnobotany Research and Applications*, 10, 551-559.
49. Susanti, R. and Zuhud, E.A.M., 2019. Traditional ecological knowledge and biodiversity conservation, the medicinal plants of the Dayak Kraya people in Kayan Mentarang National Park, Indonesia. *Biodiversitas*, 20(9), 2764-2779.
50. Tardío, J. and Pardo-de-Santayana, M., 2008. Cultural importance indices, a comparative analysis based on the useful wild plants of southern Cantabria (Northern Spain). *Economic Botany*, 62(1), 24-39.
51. UICN, 2015. Renforcement des connaissances et du partenariat sur les zones clés pour la biodiversité en Algérie, cas du Parc National du Djurdjura. Rapport technique. Centre de la coopération pour la Méditerranée de l'UICN, Malaga, 163 pp.
52. Vinagre, C., Vinagre, S. and Carrilho, E., 2019. The use of medicinal plants by the population from Protected Landscape of « Serra de Montejunto », Portugal. *Journal of ethnobiology and ethnomedicine*, 15, Article number 30. <https://doi.org/10.1186/s13002-019-0309-0>
53. Vitalini, S., Puricelli, C., Mikerezi, I. and Iriti, M., 2015. Plants, people and traditions, ethnobotanical survey in the Lombard Stelvio national park and neighbouring areas (central Alps, Italy). *Journal of ethnopharmacology*, 173, 435-458.
54. Zank, S. and Hanazaki, N., 2011. Exploring the links between ethnobotany, local therapeutic practices, and protected areas in Santa Catarina coastline, Brazil. *Evidence-Based Complementary and Alternative Medicine*, Article ID 563570. <https://doi.org/10.1155/2012/563570>
55. Zatout, F., Benarba, B., Bouazza, A., Babali, B., Nacer Bey, N. and Morsli, A., 2021. Ethnobotanical investigation on medicinal plants used by local populations in Tlemcen National Park (extreme North West Algeria). *Mediterranean Botany*, 42, e69396. <https://dx.doi.org/10.5209/mbot.69396>

Impacts of Essential Oil and Extracts Obtained from Coriander Cultivars (*Coriandrum sativum* L.) on Important Some Pathogenic Bacteria

[Esma ERSİN^{1*}](#) , [Belgin COŞGE ŞENKAL^{2*}](#) 

¹Department of Field Crops, Faculty of Agriculture, University Yozgat Bozok, 66900, Yozgat, Türkiye

²Department of Field Crops, Faculty of Agriculture, University Yozgat Bozok, 66900, Yozgat, Türkiye

*Corresponding author : belgin.senkal@yobu.edu.tr

<http://doi.org/10.38093/cupmap.1281520>

Received : 12/04/2023

Accepted : 24/05/2023

Abstract

In this study, the antibacterial activity of the essential oil obtained from the seeds of two coriander (*Coriandrum sativum* L.) cultivars (Gürbüz and Arslan) and extracts obtained from the seeds, leaves and stems with methanol and ethanol against seven Gram-negative (*Escherichia coli* ATCC@25922, *Pseudomonas aeruginosa* ATCC@9027, *Salmonella typhimurium* ATCC@14028, *Serratia marcescens* ATCC@13880, *Proteus vulgaris* ATCC@6380, *Enterobacter cloacae* ATCC@13047, and *Klebsiella pneumoniae* ATCC@4352), and one Gram-positive bacteria (*Staphylococcus aureus* ATCC@6538) were evaluated. Summer sowing was carried out for the supply of herbal materials and the plants were grown in Yozgat / TURKEY climatic conditions. Linalool (average 74%) has been noted as the main component in essential oils, and γ -terpinene, geraniol and camphor have been identified as other important components. It has been determined that essential oils exhibit varying levels of activity against *S. aureus*, *E. coli*, *S. typhimurium*, *S. marcescens*, *P. vulgaris*, and *E. cloacae* bacteria in this study. Especially, the essential oil obtained from Arslan cultivar exhibited strong activity against *P.aeruginosa* and *S.aureus* bacteria.

Key Words: Clevenger, Fruit, GC/MS, Kirby-Bauer Method, Linalool, Methanol

© CUPMAP. All rights reserved.

1. Introduction

Coriander (*Coriandrum sativum* L.) is an economically important spice and essential oil plant from the Apiaceae (Umbelliferae) family. It is an annual herbaceous structure. Light or dark green leaves are segmented and usually 3-lobed. The flowers are white or light pink in the form of umbrellas at the ends of the branches and bloom in June-July. The fruits are light yellow-brown, spherical schizocarp with a diameter of 2-4 mm. 1000 fruit weight varies between 5-18 g (Diederichsen and Hammer, 2003; Yeung and

Bowra, 2011). The leaves, stem, flowers and fruits of the plant contain high levels of essential oil. The amount and chemical composition of the essential oil differ according to the organs of the plant (Mandal and Mandal, 2015).

The predominant component in the essential oil obtained from coriander fruits is linalool. In some essential oils, the linalool content can reach up to 80%. The essential oil contains α -pinene, γ -terpinene, camphor, geraniol acetate, geraniol, borneol, citronellol, thymol,

β -caryophyllene and caryophyllene oxide”, although at lower concentrations than this component (Zekovića et al., 2011; Vasconcelos Dos Santos et al., 2019; Satyal and Setzer, 2020; Al-Khayri et al. 2023).

Coriander has essential oil that exhibits broad biological activity (antifungal, antibacterial, antioxidant, antibacterial, antidiabetic, antidepressant etc.) (Gkogka et al., 2013; Al-Khayri et al. 2023). Studies have shown that coriander essential oil has determined the inhibitory efficacy against *Bacillus subtilis*, *Candida albicans*, *Enterococcus faecalis*, *Enterococcus faecium*, *Klebsiella pneumoniae*, *Listeria innocua*, *Pseudomonas aeruginosa*, *Salmonella enteritidis*, *Salmonella infantis*, and *Salmonella kentucky*. (Serban et al., 2011; Niamah and Alali 2016; Ozkinali et al., 2017; Rizk et al., 2022; Al-Khayri et al., 2023). In this study, it was aimed to determine to what extent essential oils and extracts of coriander

cultivars grown in cultural conditions inhibit the growth of important pathogenic bacteria.

2. Material and Methods

2.1. Plant Material

Two coriander cultivars (cv. Arslan-large fruited and cv. Gürbüz- small fruited) registered by Ankara University/TURKEY were used as plant material.

2.2. Production area

Production of plant material to be used in analysis was carried out in Yozgat Bozok University, Research and Application Area (Yozgat/TURKIYE; Locality: 39° 45' 08" N, 34° 48' 11" E, Altitude:1267 m). The precipitation, temperature and humidity values of the vegetation period of the production area, and soil properties are given in Figure 1 and Table 1, respectively.

Table 1. The soil analysis results of the production area (Yakupoglu, 2018)

Clay	Silt	Sand	pH	Salt	CaCO ₃	Organic matter	Total N
(g kg ⁻¹)			(%)				
476	138	386	7.09 ¹	0.178 ²	7.15 ³	2.49 ⁴	0.15 ⁵
P	K	Ca	Mg	Fe	Cu	Zn	Mn
(µg g ⁻¹)							
78 ⁶	728 ⁶	7060 ⁶	5604 ⁷	8.08 ⁶	2.84 ⁵	0.62 ⁸	4.07 ⁸

1 Neutral, 2 Slightly salty, 3 Medium calcareous, 4 Medium, 5 Enough, 6 Much, 7 Excessive, 8 Little

The semi-arid continental climate of the Central Anatolia Region is dominant in the Yozgat Province. Summers are hot and dry, as it is closed to sea influence; winters are cold and rainy. Temperature differences between day and night, and summer and winter are high. The total precipitation, the average temperature and the average relative humidity were 177 mm, 18.74 C, and 45.24%, respectively in the production area during the vegetation (Figure 1). The production area with medium level of organic matter has a heavy structured soil (Table 1).




Figure 1. Climate data recorded during vegetation

2.3. Production practices

The seeds of the coriander cultivars were 30 cm between rows and 3 m in row length, 1 g of seeds were planted in rows. Sowing was made on April 21, 2017, with 30 rows of each variety. Weed control has been done when necessary. Any irrigation and fertilization have not been done. Plants were harvested in two different periods.

Period 1: Fresh plant harvesting: All above ground parts of plants were collected when the plants were in full flowering stage. (5 July 2017, 12:00)

Period 2: Dried plant harvesting: During the seed ripening period, all plant parts were harvested (12 August 2017, 11:00). The harvested fresh plants (Period 1) were dried in the shade. Plants in Period 1 were divided into three parts as flower, stem and leaf; Plants in Period 2 were divided into two parts as seed and stem (Figure 2).



Figure 2. Development stages of coriander and its fruits

2.4. Preparation of extracts

The dried plant parts (flower, green stem, green leaf, seed and dry stem) were ground separately with a laboratory type blender. The dry matter of 1 g from the flowers, 2 g from the green stem and leaf, and 4 g from the dry stem was used. Two different

solvents (methanol and ethanol, 1/10 w / v) were used in the study. The samples mixed with the solvent were first incubated in the oven (Elekto-mag M 5040p) at 40 ° C for 24 hours. Then, the solvents were removed from the extracts filtered through Whatman No 1 filter paper with the help of a rotary evaporator, and then it was left in the oven for another 24 hours to ensure complete drying. The dried extracts were dissolved in 2 ml of methanol and stored at +4 ° C until analyzed (Zakaria et al., 2019).

2.5. Essential oil extraction

100 g of the ground seeds of the coriander varieties were weighed and after they were placed in 2 L balloon flasks, 750 mL of water was added to them. It was subjected to water distillation in Clevenger device for 3 hours. Essential oil values (% , v/w) were calculated as volume on dry matter. The essential oils obtained as a result of distillation were kept at +4 C in dark glass bottles until analyzed (Baj et al., 2015).

2.6. Determination of the chemical composition of essential oil

Chemical component determination of essential oils obtained as a result of the research was made by Shimadzu, QP2010 ULTRA Gas Chromatography-Mass Spectrometer (GC / MS) at Yozgat Bozok University, Science and Technology Application and Research Center. Separation of the components was made on an Rxi-5ms capillary column with a length of 30 m, an inner diameter of 0.25 mm, and a film thickness of 0.25 µm. The split rate was set to 10, the flow rate was set to 1.10 mL/min. In the analysis, a temperature program that ends at 70°C for 1 minute, with an increase of 20°C/min to 180°C, 1 minute at 180°C, and 280°C with an increase of 10°C/min was applied. Helium was used as the carrier gas, and the injector temperature was kept at 250°C. Substances exiting the column were screened in the mass range of

50-550 (m/z) (70eV). The transfer temperature was set to 250°C and the ion source temperature to 200°C. Identification of components was done using FFNSC 1.2 library search software and literature data (Babushak et al., 2011).

2.7. Antibacterial activity test

In the study, three different medium was prepared, as below:

1:Tryptic Soy Agar (TSA, a general purpose growth medium for a wide variety of microorganisms),

2:Tryptic Soy Broth (TSB, a high nutrient-containing bacteria and fungus growth medium,) and

3:Muller-Hinton Agar (MHA, having international validity in antimicrobial susceptibility tests). The contents of the medium are given in Table 2. While preparing the medium, 40 g TSA, 30 g TSB and 38 g MHA were weighed on a precision scale and mixed with 1L distilled water, then autoclaved at 121 °C for 15 minutes to sterilize the media. Medium were stored at + 4C until analysis.

Disk diffusion technique (Kirby-Bauer method) was used to evaluate the antimicrobial activity (Prescott et al., 1990). In the tests, 7 Gram-negative (*Escherichia coli* ATCC®25922, *Pseudomonas aeruginosa* ATCC®9027, *Salmonella typhimurium* ATCC®14028, *Serratia marcescens* ATCC®13880, *Proteus vulgaris* ATCC®6380, *Enterobacter cloacae*, ATCC®13047, and *Klebsiella pneumoniae* ATCC®4352), and 1 Gram-positive bacteria (*Staphylococcus aureus* ATCC®6538) were used. These pathogenic organisms were selected for the study considering their clinical and pharmaceutical importance (Table 3). Bacteria were transferred to test tubes containing 2 ml TSB and incubated in an oven at 37 ° C for 3 hours, and at the end of 3 hours, each microorganism was spread on TSA containing medium and inoculated.

Table 2. TSA, TSB and MHA contents

Tryptic Soy Agar (TSA)	
Typical Formula	gL⁻¹
Pancreatic Digest of Casein	15.0
Piapiac Digest of Soybean Meal	5.0
Sodium chloride	5.0
Agar (gelatin)	15.0
pH =7.3 ± 0.2	
Tryptic Soy Broth (TSB)	
Typical Formula	gL⁻¹
Pancreatic Digest of Casein	17.0
Soybean Meal Piapiac Digest	3.0
Sodium chloride	5.0
Dipotassium Phosphate	2.5
Glucose	2.5
pH =7.3 ± 0.2	
Mueller-Hinton Agar (MHA)	
Typical Formula	gL⁻¹
Beef, dried infusion	300.0
Casein hydrolysate	17.5
Starch	1.5
Agar	17.0
pH=7.3 ± 0.1	

It was left in the oven at 37 ° C for another 2 days. At the end of the two days, 4-5 loops bacteria were taken from pure cultures, transferred to medium containing 20 ml TSB and incubated at 37 ° C until the morning. 0.5Mc Farland (McF) unit bacteria were put into tubes containing 2 ml TSB with the help of a densitometer. Then, 100 µl of the obtained suspension was taken and spread in Petri dishes containing MHA and the medium were prepared for antibacterial test. 5 separate antibiotic discs "Erythromycin (15µg), Ampicillin (10 µg), Carpenicillin (100µg), Tetracycline (30µg), Chloramphenicol (30µg)" were used for controls. All stages were carried out in a laminar flow sterile cabin. Filter papers to be used in the study were cut in 0.22 µm shape and autoclaved for 15 minutes at 121 ° C and sterilized. With the help of a densitometer, 0.5Mc Farland (McF) unit was set from the bacteria, 100 µl was drawn with a pipette, transferred to the medium containing MHA and spread on the media with an iron loop and waited for 30 minutes. Sterile discs were dipped in extracts (5 mL) and essential oils (2 mL), and the excess water was removed on sterile blotting paper and placed in petri dishes. The trial was set

up in 2 replications. Petri dishes were kept in the oven at 37 ° C for 24 hours, and then, the diameters of the inhibition zones around the discs were measured in mm with the help of a digital caliper. (Figure 3).

Table 3. The effects of bacteria used in the research on human health (WHO, 2001; Hogg 2005)

Pathogen	Diseases
<i>Escherichia coli</i>	Urinary tract infection, Chronic renal failure, Stomachache, Diarrhea, Vomiting, Dysentery, Meningitis, Liver abscess
<i>Pseudomonas aeruginosa</i>	Eye disease, External and middle ear infection, Burn and wound infections, Meningitis, Bronchitis, Cramp, Nausea, Epidemic diarrhea, Death in infants
<i>Salmonella typhimurium</i>	Fever, Nausea, Headache, Diarrhea, Tuberculosis, Meningitis
<i>Serratia marcescens</i>	Urinary tract, upper respiratory tract and wound infections, Meningitis
<i>Proteus vulgaris</i>	Urinary tract and wound infections, Meningitis
<i>Enterobacter cloacae</i>	Diarrhea, Sepsis (organ failure) Urinary tract infection, Fever, Shortness of breath, Cough
<i>Klebsiella pneumoniae</i>	Sudden fever, Wound infections, Shortness of breath, Bronchitis, Heart disease
<i>Staphylococcus aureus</i>	Meningitis, Vomiting, Fatigue, Inflamed wounds, Sweating, Skin and Organ infections

All tests and analyzes performed in the study were carried out with 3 repetitions, and the mean of the values was given with the standard deviation (mean \pm SD). Antibacterial activity results were evaluated according to the criteria reported by Davis and Stout (1971) (Table 4).

Table 4. The criteria for evaluating antibacterial activity

Inhibition zone diameter (mm)	Evaluation
<5	Weak
5-10	Moderate
10-19	Strong
>20	Very strong

3. Results and Discussion

3.1. Extract yield

Flowers, leaves and stems were harvested during the flowering period, and seeds and stem were harvested at full maturity. The values obtained from the extracts prepared by using ethanol (E) and methanol (M) of these plant samples are given in Table 5.

Table 5. Extract amount and yield of plant samples

Fresh Plant Organs				
Cv.	Plant Organ	Solvent ¹	Extract Amount (g)	Extract Yield (%)
Arslan	Flower	E	0.027 \pm 0.0022	2.54 \pm 0.20
		M	0.080 \pm 0.0046	7.63 \pm 0.18
	Leaf	E	0.037 \pm 0.0035	1.77 \pm 0.15
		M	0.083 \pm 0.0075	5.67 \pm 0.38
	Stem	E	0.017 \pm 0.0012	0.80 \pm 0.06
		M	0.045 \pm 0.0009	2.23 \pm 0.07
Gürbüz	Flower	E	0.021 \pm 0.0004	2.02 \pm 0.07
		M	0.077 \pm 0.0030	7.37 \pm 0.31
	Leaf	E	0.021 \pm 0.0010	1.05 \pm 0.05
		M	0.088 \pm 0.0092	4.31 \pm 0.46
	Stem	E	0.018 \pm 0.0014	0.86 \pm 0.07
		M	0.053 \pm 0.0040	2.60 \pm 0.23
Dry Plant Organs				
Cv.	Plant Organ	Solvent	Extract Amount (g)	Extract Yield (%)
Arslan	Seed	E	0.029 \pm 0.0029	1.42 \pm 0.13
		M	0.038 \pm 0.0031	1.87 \pm 0.19
	Stem	E	0.026 \pm 0.0052	0.32 \pm 0.26
		M	0.017 \pm 0.0049	0.82 \pm 0.25
Gürbüz	Seed	E	0.061 \pm 0.0264	2.99 \pm 1.29
		M	0.042 \pm 0.0046	2.03 \pm 0.25
	Stem	E	0.038 \pm 0.0030	0.19 \pm 0.14
		M	0.011 \pm 0.0022	0.52 \pm 0.97

The extract yields of the fresh plant parts obtained from the flowering period were higher than the seed and stem obtained from the full maturity period. In general, it was observed that the yields of extracts prepared using methanol were higher than those prepared with ethanol. Palmieri et al.

(2020) reported that the yields of extracts prepared using different traditional and non-traditional methods in coriander fruits varied between 0.57-2.36% (w / w). Jangra et al. (2018), who prepared extracts from coriander leaves using acetone, ethanol and water, obtained extract yields (g 100 g⁻¹) of 2.22-2.45, 2.59-3.35, and 1.99-2.4, respectively, and they had emphasized that higher yields were obtained from extracts prepared with ethanol. It is stated that in general, extraction yield is lower in seeds and higher in stems and leaves (Palmieri et al. 2020). According to the literature findings, we can say that the yields of herbal extracts vary according to the organ of the plant, the solvent and method used.

3.2. The chemical compositions and content of essential oil

Mean values belong to the ratio and chemical composition of light yellow-colored essential oils obtained from coriander varieties are presented in Table 6. The fruit essential oil ratio of cv. Arslan (large-fruited) and cv. Gürbüz (small-fruited) were recorded as 0.31% (v/w) and 0.42% (v/w), respectively. Beyzi et al. (2017) worked with the same cultivars, essential oil contents of cultivars detected 0.30% in cv. Arslan and 0.33% in cv. Gürbüz. Generally, the essential oil content of small-fruited varieties (0.8-1.8%, v/w) is higher than the varieties with large-fruited (0.1-0.35%, v/w) (Burdock and Carabin, 2009). Similar results were obtained in our study, but the essential oil content of the small-fruited cultivar was found to be lower than the values stated in the literature. In a study conducted in Bangladesh, fruit essential oil was found to be 0.42% (Bhuiyan et al., 2009). In other studies, the essential oil content of coriander fruits was reported as 0.39% by Ravi et al (2006), 0.35% by Msaada et al. (2007), and 0.23% by Mansori et al. (2018). Although coriander fruits contain 0.2-1.5% essential oil, in some genotypes this rate is up to 2.6% (Ebrahimi

et al., 2010). However, it is also possible to come across genotypes containing essential oil higher than 2.6%. For example, the essential oil yields obtained by hydro distillation method from fruits belonging to coriander genotypes originating from different countries have taken values in the range of 0.1-5.2 % (Orav et al., 2011). It is observed that there are differences in the essential oil content of coriander fruits grown in different geographies.

Table 6. Chemical composition and content of fruit essential oils of coriander cultivars (%)

Compound	RT ¹	cv. Arslan	cv. Gürbüz	EPS ²
<i>α</i> -pinene	3.760	1.03	1.67	3-7
Camphene	3.909	0.11	0.15	
Sabinene	4.093	0.13	0.13	
<i>β</i> -Pinene	4.152	0.23	0.31	
<i>β</i> -Myrcene	4.182	0.21	0.26	
Ortho-Cymene	4.537	0.73	0.67	
Limonene	4.578	1.43	1.45	1.5-5
p-cymene				0.5-4
<i>γ</i> -Terpinene	4.831	8.11	6.94	1.5-8
Trans-sabinenehydrate	4.930	0.01	0.02	
Linalool	5.203	73.52	74.38	65-78
Citronellal	5.615	-	0.02	
Camphor	5.667	3.67	4.22	3-6
1-Borneol	5.836	0.14	0.22	
Terpinen-4-ol	5.911	0.19	0.18	
<i>α</i> -Terpineol	6.013	0.21	0.25	0.1-1.5
Myrtenol	6.074	0.27	0.29	
Geraniol	6.444	6.11	8.45	0.5-3
Cis-myrtanol	6.615	-	0.01	
Caryophyllene	8.109	0.21	0.31	
Bicyclogermacrene	8.833	-	0.06	
Geranyl acetate	-	-	-	0.5-4
TOTAL		96.31	99.99	
Essential oil content (%)		0.31 ±0.02 5	0.42 ±0.03	min. 0.3

¹RT: Retention Time; ²EPS: European Pharmacopoeia Standards (Gebarowska et al., 2019).

In the cv. Arslan, 17 components representing 96.31% of the oil and in the cv. Gürbüz, 20 components representing 99.99% of the oil were detected. It was observed that the main component is linalool in both essential oils. Also, *γ*-terpinene, geraniol and camphor were determined as other important components in essential oils (Table 5). Considering the literature data and our study results, linalool was determined as the component

with the highest value in the essential oil obtained from coriander fruits. Overall, it was reported that the linalool content in the essential oils obtained from coriander fruits ranged from 37.3% to 87.5% (de Figueiredo et al. 2004; Msaada et al., 2007; Bhuiyan et al., 2009; Ebrahimi et al., 2010). γ -terpinene, α -pinene, p-cymene, camphor, and geranyl acetate were determined as the other characteristic components of the essential oil (Orav et al., 2011; Zekovića et al., 2011; Vasconcelos Dos Santos et al. 2019; Satyal and Setzer, 2020; Al-Khayri et al. 2023). Micića et al. (2019) stated that they detected α -pinene (7.31%), geranyl acetate (5.76%), γ -terpinene (5.59%), camphor (4.245), p-cymene (3.83%), and limonene (1.60%) in addition to linalool (64.04%) in the essential oil of coriander fruits. When we compare the data obtained from our study with EP standards; α -pinene and limonene values are low, geraniol and γ -terpinene values are very high, and essential oil content, linalool and camphor values are among the limit values. On the other hand, geranyl acetate and p-cymene were not detected in the essential oil samples we studied (Table 6).

Although some of the findings we obtained from our study are compatible with the literature data, there are differences. In this context, cultural conditions are an important factor (Mandal and Mandal, 2015). Within the scope of the study, coriander varieties were grown in arid conditions and no additional irrigation was done. The literature data indicate that the essential oil content and composition may differ depending on the climatic conditions of the region, the growing conditions of the plant, cultural practices (sowing time, harvest time etc.) and the genotype of the plant (Gebarowska et al., 2019; Delibaltova 2020).

3.3. Antibacterial activity

Inhibition zone diameters (mm), which are the indicators of the activity of the research

materials against one Gram-positive and seven Gram-negative bacteria, are given in Table 7. The antibacterial activity of essential oils obtained from Arslan and Gürbüz cultivars was similar. While none of the antibiotic discs in the study showed any effect against *S. aureus*, the only Gram-positive bacteria included in the study, essential oils were effective. When evaluated the antibacterial activity according to the criteria reported by Davis and Stout (1971), EO (essential oil) Arslan was strong and EO-Gürbüz was medium. The CB-100 antibiotic used as a control showed the highest activity against *E. coli* bacteria. A moderate activity recorded in essential oils was similar to that of the C-30 and TE-30 antibiotics. The essential oil of both varieties showed no activity against *P. aeruginosa* bacteria. In most studies examining the effect of essential oils against pathogens, it is revealed that the effect of essential oils against Gram-positive bacteria is more than Gram-negative bacteria. The cell wall of Gram-negative bacteria is surrounded by lipopolysaccharides, which prevents the antibacterial effect. The outer membrane surface of Gram-negative bacteria such as *P. aeruginosa* is rich in hydrophilic and lipopolysaccharide molecules. Therefore, they show a very different internal resistance to essential oils (Dorman and Deans, 2000; Esen et al., 2007; Turker and Usta, 2008).

The highest activity against *S. tyhimurium* bacteria was observed with antibiotic discs. However, the activity exhibited by essential oils was close to E-15. M-10 and E-15 control antibiotics were ineffective against *S. marcescens* bacteria. C-30 and CB-100 antibiotics exhibited the highest activity against this bacterium. It was noted that the activity (moderate) exhibited by essential oils was close to the TE-30 control disc. TE-30, C-30 and CB-100 control discs, respectively, exhibited the highest activity against *P. vulgaris* bacteria.

Table 7. Antibacterial activity of essential oils and extracts from coriander varieties against tested bacteria

Mean inhibition zone diameters (mm±SD)				
Material	1 ¹	2	3	4
EO-A	11.34±0.29(S)	9.99±0.34 (M)	-	8.36±0.23 (M)
EO-G	10.23±0.72 (M)	9.56±0.55 (M)	-	7.30±0.06 (M)
Fruit (Ethanol-G)	-	7.08±0.94 (M)	-	-
C (30 µg)	-	10.73±0.00 (M)	23.92±2.03 (VS)	22.80±2.26 (VS)
TE-(30 µg)	-	8.64±1.02 (M)	22.14±0.43 (VS)	20.09±1.02 (VS)
AM-(10 µg)	-	-	13.46±0.00 (S)	17.13±4.18 (S)
CB-(100 µg)	-	22.16±0.00 (VS)	21.38±0.02 (VS)	10.44±1.68 (M)
E-(15 µg)	-	-	8.97±0.05 (M)	9.29±0.20 (M)
	5	6	7	8
EO-A	9.17±0.21 (M)	9.24±0.36 (M)	11.43±0.07 (S)	-
EO-G	10.79±0.22 (M)	9.48±0.68 (M)	10.52±0.00 (M)	-
Fruit (Ethanol-G)	-	-	-	-
C (30 µg)	23.41±0.40 (VS)	22.25±0.69 (VS)	24.67±0.71 (VS)	29.65±1.37 (VS)
TE-(30 µg)	11.58±0.00 (S)	22.26±1.19 (VS)	16.53±0.00 (S)	22.52±4.09 (VS)
AM-(10 µg)	-	-	21.32±0.04 (VS)	-
CB-(100 µg)	25.51±1.42 (S)	19.64±0.57 (S)	31.93±0.21 (VS)	-
E-(15 µg)	-	-	-	18.43±0.06 (S)

¹¹: *S. aureus*, 2: *E. coli*, 3: *P. aeruginosa*, 4: *S. tyhimurium*, 5: *S. marcescens*, 6: *P. vulgaris*, 7: *E.cloacae*, 8: *K. pneumoniae*

EO: Essential oil, A: cv. Arslan, G: cv. Gürbüz, C: Chloramphenicol, TE:Tetracycline, AM:Ampicillin, CB:Carbencillin, E:Erythromycin, M: Moderate, S: Strong, VS: Very Strong

AM-10 and E-15 antibiotics were ineffective against the bacterium in question. The inhibition zone diameter recorded for these bacteria, in the essential oils was lower than that of in the controls, with an average of 9.36 mm. CB-100 showed the highest activity against *E. cloacae* bacteria with an inhibition zone diameter of 31.93. C-30 (24.67 mm, VS), AM-10 (21.32 mm, VS) and TE-30 (16.53 mm, VS) followed respectively. E-15 had no activity against this bacterium. EO-Arslan and EO-Gürbüz showed strong and moderate activity, respectively, against this bacterium. Essential oils and AM-10 and CB-100 antibiotics were ineffective against *K. pneumoniae* bacteria. C-30 exhibited the highest activity, followed by TE-30 and E-15, respectively (Table 7).

It is known that essential oils obtained from different organs of coriander (such as fruits and leaves) inhibit microorganisms in a wide spectrum (Bhuiyan et al., 2009; Begnami et al., 2010; Mandal and Mandal,

2015; Beyzi et al., 2017; Al-Khayri et al., 2023). Coriander essential oil has been observed to be effective against both Gram-positive and Gram-negative bacteria (*E. coli*, *Salmonella* spp., *S. aureus*, *S. typhimurium*, *K. pneumoniae*, *P. aeruginosa*, *E. cloacae*) (Delaquis et al., 2002; Asgarpanah and Kazemivash, 2012; Dima et al., 2015; Mandal and Mandal, 2015; Rezaei et al., 2016). In our study, essential oils were ineffective against *K. pneumoniae* and *P. aeruginosa* bacteria.

In the study we carried out, only the extract prepared with ethanol from the fruits of the cv. Gürbüz showed moderate activity against *E. coli* bacteria. However, this activity was lower than both essential oils and control antibiotics (Table 7). None of the other extracts exhibited antibacterial activity against tested microorganisms. In the studies conducted also, it has been stated that the coriander aqueous extract had no antimicrobial activity (Sahib et al., 2013).

It has been reported that the antimicrobial activity of coriander essential oil is due to active ingredients such as linalool, α -pinene, β -pinene, p-cymene and γ -terpinene (Dorman and Deans, 2000; Koutsoudaki et al., 2005; Xianfei et al., 2007). In addition, it was determined that the antimicrobial activity of coriander essential oil is not only related to the linalool amount of the essential oil, but also the interaction of other components in the essential oil is important on the antimicrobial activity (Begnami et al., 2010).

Although the amount of linalool (63% and 66%) in coriander fruit essential oils obtained by two different methods is similar, it was determined that the essential oil with higher γ -terpinene, α -pinene and p-cymene contents exhibited a stronger activity against *S. aureus* bacteria (Sourmaghi et al., 2015). In our study, since the essential oil composition of the cultivars was similar, their activity against the tested bacteria was also found similar (Table 5 and Table 7).




Figure 3. Procedures in this research

4. Conclusion

In this study, the antimicrobial activities of essential oils obtained from the seeds of two coriander varieties grown under semi-arid culture conditions and extracts obtained from different parts against pathogenic bacteria that threaten human health were evaluated (Figure 3). All but one of the extracts (Fruit /Ethanol-Gürbüz) showed no activity against test microorganisms. It has been determined that essential oils exhibit varying levels of activity against *S. aureus*, *E. coli*, *S. tyhimurium*, *S. marcescens*, *P. vulgaris*, and *E. cloacae* bacteria. In line with the findings, these essential oils may inhibit the growth of different bacteria. Therefore, more research with different bacteria is needed to better explain the healthcare use of these essential oil samples.

Acknowledgements

We would like to thank Research Assistant Dr. Tansu USKUTOĞLU for his contribution in the realization of laboratory studies.

Author Contribution

This article was produced from a graduate test.

Conflicts of Interest

The authors declare that they have no conflict of interest.





References

1. Al-Khayri, J.M., Banadka, A., Nandhini, M., Nagella, P., Al-Mssallem, M.Q., Alessa, F.M.(2023). Essential oil from *Coriandrum sativum*: A review on its phytochemistry and biological activity. *Molecules*, 28, 696.

2. Asgarpanah, J., Kazemivash, N. (2012). Phytochemistry, pharmacology and medicinal properties of *Coriandrum sativum* L. African Journal of Pharmacy and Pharmacology, 6, 2340-2345.
3. Babushok, V.I., Linstrom, P.J., Zenkevich, I.G. (2011). Retention indices for frequently reported compounds of plant essential oils. Journal of Physical and Chemical Reference Data, 40, 1-47.
4. Baj, T., Sieniawska, E., Kowalski, R., Wesolowski, M., Ulewicz-Magulska, B. (2015). Effectiveness of the drying and cleverger-type apparatus in isolation of various types of components of essential oil from the Mutelina purpurea Thell. flowers. Acta Poloniae Pharmaceutica, 72, 507-515.
5. Begnami, A.F., Duarte, M.C.T., Furletti, V., Rehder, V.L.G. (2010). Antimicrobial potential of *Coriandrum sativum* L. against different Candida species in vitro. Food Chemistry, 118,74-77.
6. Beyzi, E., Karaman, K., Gunes, A., Buyukkilic, B.S. (2017). Change in some biochemical and bioactive properties and essential oil composition of coriander seed (*Coriandrum sativum* L.) varieties from Turkey. Industrial Crops and Products, 109,74-78.
7. Bhuiyan, M.N.I., Bagum, J., Sultana, M. (2009). Chemical composition of leaf and seed essential oil of *Coriandrum sativum* L. from Bangladesh. Bangladesh Journal of Pharmacology, 4,150-153.
8. Burdock, G.A., Carabin, I.G. (2009). Safety assessment of coriander (*Coriandrum sativum* L.) essential oil as a food ingredient. Food and Chemical Toxicology, 47, 22-34.
9. Davis, W.W., Stout, T.R. (1971). Disc plate method of microbiological antibiotic assay. I. Factors influencing variability and error. Applied Microbiology, 22,659-665.
10. de Figueiredo, R.O., Marques, M.O.M., Nakagawa, J., Ming, L.C. (2004). Composition of coriander essential oil from Brazil. Acta Horticulturae, 2004, 135-138.
11. Delaquis, P.J., Stanich, K., Girard, B., Mazza, G. (2002). Antimicrobial activity of individual and mixed fractions of dill, cilantro, coriander and eucalyptus essential oils. International Journal of Food Microbiology, 74,101-109.
12. Diederichsen, A., Hammer, K. (2003). The infraspecific taxa of coriander (*Coriandrum sativum* L.). Genetic Resources and Crop Evolution, 50, 33-63.
13. Dima, C., Ifrim, G.A., Coman, G., Alexe, P., Dima, Ş. (2015). Supercritical CO₂ extraction and characterization of *Coriandrum sativum* L. essential oil. Journal of Food Process Engineering, 39,204-211.
14. Dorman, H.J.D., Deans, S.G. (2000). Antimicrobial agents from plants: antibacterial activity of plant volatile oils. Journal of Applied Microbiology, 88,308-316.
15. Ebrahimi, S.N., Hadian, J., Ranjbar, H. (2010). Essential oil compositions of different accessions of *Coriandrum sativum* L. from Iran. Natural Product Research, 24,1287-1294.
16. Esen, G., Azaz, A.D., Kurkcuoglu, B., Baser, K.H.C., Tinmaz, A. (2007). Essential oil and antimicrobial activity of wild and cultivated *Origanum vulgare* L. subsp. *hirtum* (Link) letsvaart from the Marmara region, Turkey. Flavour and Fragrance Journal, 22, 371-376.
17. Gebarowska, E., Pytlarz-Kozicka, M., Nöfer, J., Łyczko, J., Adamski, M., Szumny, A. (2019). The Effect of Trichoderma spp. on the composition of volatile secondary metabolites and biometric parameters of coriander (*Coriandrum sativum* L.). Journal of Food Quality, 5687032.
18. Gkogka, E., Hazeleger, W.C., Posthumus, M.A., Beumer, R.R. (2013). The antimicrobial activity of the essential oil of *Pistacia lentiscus* var. *chia*. Journal of Essential Oil Bearing Plants, 16, 714-729.
19. Hogg, S. (2005). Essential Microbiology. (John Wiley&Sons, Ltd., England), pp.157-422.
20. Jangra, S.S., Madan, V.K., Singh, I. (2018). Comparative analysis of phytochemical profile and antioxidant activity of coriander (*Coriandrum sativum* L.). Asian Journal of Chemistry, 30:508-512.
21. Koutsoudaki, C., Krsek, M., Rodger, A. (2005). Chemical composition and antibacterial activity of the essential oil and the gum of *Pistacia lentiscus* var. *chia*. Journal of Agricultural and Food Chemistry, 53, 7681-7685.
22. Mandal, S. Mandal, M. (2015). Coriander (*Coriandrum sativum* L.) essential oil: Chemistry and biological activity. Asian Pacific Journal of Tropical Biomedicine, 5, 421-428.
23. Mansori, N., Aoun, L., Dalichaouche, N., Hadri, D. (2018). Yields chemical composition and antimicrobial activity of two Algerian essential oils against 40 avian multi drug-resistant *Escherichia coli* strains. Veterinary World, 11, 1539-1550.
24. Micića, D., Ostojića, S., Pezoa, L., Blagojevića, S., Pavličb, B., Zekovićb, Z., Đurovića, S. (2019). Essential oils of coriander and sage: investigation of chemical profile, thermal properties and QSRR analysis. Industrial Crops and Products, 138,111438.
25. Msaada, K., Hosni, K., Taarit, M. B., Chahed, T., Khouk, M., Marzouk, E. (2007). Changes on essential oil composition of coriander (*Coriandrum sativum* L.) fruits during three stages of maturity. Food Chemistry, 102, 1131-1134.
26. Niamah, A.K., Alali, H.A. (2016). Antibacterial and antioxidant activities of essential oils extracted from Iraqi coriander (*Coriandrum sativum* L.)

- seeds. International Journal of Scientific & Engineering Research, 7, 1511-1515.
27. Orav, A., Arak, E., Raal, A. (2011). Essential oil composition of *Coriandrum sativum* L. fruits from different countries. Journal of Essential Oil Bearing Plants, 14, 118-123.
 28. Ozkinali, S., Sener, N., Gur, M., Guney, K., Olgun, C. (2017). Antimicrobial activity and chemical composition of coriander & galangal essential oil. Indian Journal of Pharmaceutical Education and Research, 51, 221-224.
 29. Palmieri, S., Pellegrini, M., Ricci, A., Compagnone, D., Lo Sterzo, C. (2020). Chemical composition and antioxidant activity of thyme, hemp and coriander extracts: A comparison study of maceration, soxhlet, UAE and RSLDE techniques. Foods, 9, 1221.
 30. Prescott, M.L., Harley, J., Donald, P. and Klein, A. (1999) Antimicrobial Chemotherapy. In: Microbiology, 2nd Edition (C. Brown Publishers, USA), pp.325.
 31. Ravi, R., Prakash, M., Bhat, K. K. (2006). Aroma characterization of coriander (*Coriandrum sativum* L.) oil samples. European Food Research and Technology, 225, 367-374.
 32. Rezaei, M., Karimi, F., Shariatifar, N., Mohammadpourfard, I., Shiri Malekabad, E. (2016). Antimicrobial activity of the essential oil from the leaves and seeds of *Coriandrum sativum* toward food-borne pathogens. West Indian Medical Journal, 65,8.
 33. Rizk, A.E., Othman, D.B., Helmy, S.A. (2022). Biological evaluation and application of coriander fruits and its essential oil. Carpathian Journal of Food Science and Technology, 14, 99-121.
 34. Sahib, N.G., Anwar, F., Gilani, A.H., Hamid, A.A., Saari, N., Alkharfy, K.M. (2013). Coriander (*Coriandrum sativum* L.): A potential source of high-value components for functional foods and nutraceuticals-A review. Phytotherapy Research, 27,1439-1456.
 35. Satyal, P., Setzer, W.N. (2020). Chemical compositions of commercial essential oils from *Coriandrum sativum* fruits and aerial parts. Natural Product Communications, 15, 1-12.
 36. Sourmaghi, M.H.S., Kiaee, G., Golfakhrabadi, F., Jamalifar, H., Khanavi, M. (2015). Comparison of essential oil composition and antimicrobial activity of *Coriandrum sativum* L. extracted by hydrodistillation and microwave-assisted hydrodistillation. Journal of Food Science and Technology, 52, 2452-2457.
 37. Serban E. S., Ionescu M., Matinca D., Maier C. S., Bojiță M. T. (2011). Screening of the antibacterial and antifungal activity of eight volatile essential oils. Farmacia, 59, 440-446.
 38. Turker, A.U., Usta, C. (2008). Biological screening of some Turkish medicinal plant extracts for antimicrobial and toxicity activities. Natural Product Research, 22, 136-146.
 39. Vasconcelos Dos Santos M.D., De Carvalho Neto M.F., Goncalves Reis De Melo A.C., Takahashi J.A., Ferraz V.P., Chagas E.A., Chagas Cardoso P., De Melo Filho A.A. (2019). Chemical composition of essential oil of coriander seeds (*Coriandrum sativum*) cultivated in the Amazon Savannah, Brazil. Chemical Engineering Transactions, 75, 409-414.
 40. World Health Organization WHO, (2001). Infections and infectious diseases. <https://apps.who.int/iris/handle/10665/107489> (accessed 22 January 2021).
 41. Xianfei, X., Xiaoqiang, C., Shunying, Z., Guolin, Z. (2007). Chemical composition and antimicrobial activity of essential oils of *Chaenomeles speciosa* from China. Food Chemistry, 100,1312-1315.
 42. Yakupoglu, T. (2018). Bozok Yöresinde Araştırma Amaçlı Kullanılan Tarım Arazilerinin Bazı Toprak Özellikleri ve Bölgesel Kalkınmaya Katkı Sağlayacak Araştırmalar Açısından Çeşitli Öneriler, III. Uluslararası Bozok Sempozyumu, Yozgat, Bildiri Kitabı, pp. 1338-1343.
 43. Yeung, E.C., Bowra, S. (2011). Embryo and endosperm development in coriander (*Coriandrum sativum*). Botany, 89, 263-273.
 44. Zakaria, N.A., Ibrahim, D., Sulaiman, S.F., Supardy, N.A. (2011). Assessment of antioxidant activity, total phenolic content and in vitro toxicity of Malaysian red seaweed, *Acanthophora spicifera*. Journal of Chemical and Pharmaceutical Research, 3,182-191.
 45. Zekovića, Z., Adamović, D., Četković, G., Radojković, M., Vidović, S. (2011). Essential oil and extract of coriander (*Coriandrum sativum* L.). Acta Periodica Technologica, 42, 281-288.

Enzyme inhibitory and antioxidant activities and HPLC quantification of chlorogenic acid in *Helichrysum stoechas* (L.) Moench and *H. stoechas* subsp. *barrelieri* (Ten) Nyman

[Nurten ABACI KAPLAN](#)¹ , [Hasya Nazlı GÖK](#)¹ , [Mustafa ASLAN](#)^{1,2} ,
[Ilkay Erdogan ORHAN](#)^{1,3*} 

¹Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330 Ankara, Türkiye

²Department of Pharmacognosy, Faculty of Pharmacy, Cyprus International University, Lefkoşa, KKTC

³Principal Member, Turkish Academy of Sciences (TÜBA), Vedat Dalokay Cad., No. 122, 06670 Ankara, Türkiye

*Correspondence: iorhan@gazi.edu.tr

Received : 15/06/2023

Accepted : 29/06/2023

<http://doi.org/10.38093/cupmap.1314950>

Abstract

The inhibitory effects of ethanol (80%) and aqueous extracts of *Helichrysum stoechas* (L.) Moench and *H. stoechas* subsp. *barrelieri* (Ten) Nyman on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), two sister enzymes associated with the pathogenesis of Alzheimer's disease (AD), as well as on elastase and collagenase, linked to inflammation and skin aging, were investigated. Simultaneously, the antioxidant activity of the extracts was assessed through DPPH radical scavenging activity, ferric reducing antioxidant power (FRAP), and metal-chelating activity assays since oxidative damage plays a critical role in AD pathophysiology and skin aging. Total phenol and flavonoid contents in the extracts were spectrophotometrically determined. The highest AChE inhibitory activity ($44.60 \pm 4.4\%$ at $2000 \mu\text{g/mL}$) was found in the ethanol extract of *H. stoechas* subsp. *barrelieri* collected from Hatay, and the uppermost BChE inhibitory activity at same concentration was found in the aqueous extract of *H. stoechas* subsp. *barrelieri* collected from Izmir ($80.24 \pm 2.63\%$, IC_{50} : $38.52 \pm 1.41 \mu\text{g/mL}$). Both of them inhibited AChE and BChE in a concentration-dependent manner. Nevertheless, none of the extracts from the two plants inhibited elastase and collagenase. Although both ethanolic and aqueous extracts had significant antioxidant activity in DPPH radical scavenging and FRAP assays, they demonstrated inadequate antioxidant activity in the metal-chelating assay. Chlorogenic acid was quantified in the extracts using HPLC. The mentioned two extracts with strong cholinesterase (ChE) inhibition also had the highest chlorogenic acid content. The ethanol extract of *H. stoechas* (Hatay sample) and the aqueous extract of *H. stoechas* (Izmir sample) seem to contain promising ChE inhibitors, which deserve further investigation.

Key words: *Helichrysum stoechas*, enzyme inhibition, Alzheimer's disease, antioxidant activity, chlorogenic acid.

© CUPMAP. All rights reserved.

1. Introduction

Helichrysum stoechas (L.) Moench, a member of Asteraceae family, is a perennial medicinal plant that grows naturally in the Western and Eastern regions of Türkiye. Aside from Türkiye, it grows naturally in Italy, the Balkans, Cyprus, and Lebanon, where it is

cultivated in many parts of the world due to its medicinal importance. This plant is called by many different names such as “altın çiçeği, guddeme çiçeği, kudama, ölmez çiçek, altın otu” in diverse parts of Anatolia. *Helichrysum stoechas* subsp. *barrelieri* (Ten) is a sub-taxon of *H. stoechas* that grows in the southern

Marmara, Aegean, and Mediterranean regions of Türkiye as well as Albania, Cyprus, Egypt, Greece, and Italy (Aksoy et al., 2011; Aslan, 1994; Eroğlu, 2018). The ethnopharmacological records of *H. stoechas* indicate that the plant's capitulum is used for its diuretic, emmenagogue, anticoagulant, kidney stone-lowering, appetite-raising, and anthelmintic properties along with its utilization in the treatment of dermatological illnesses such as dermatitis, burn-wound treatment, and body crack healing (Gras et al., 2017; Memariani et al., 2018; Tsioutsiou et al., 2022).

Alzheimer's disease (AD) is an incurable and progressive neurological disease that deprives people of their memory and cognitive abilities, primarily affecting the elderly population. The specific cause of the illness is unknown, while there is no proven therapy yet, to seize the disease. According to the cholinergic theory, levels of two neurotransmitters, *i.e.* acetylcholine and butyrylcholine, have been low in the brains of AD patients, which break down by two sister enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Inhibition of cholinesterases (ChE) is critical for the treatment and thus, ChE inhibitors are currently used to treat AD symptoms. Relevantly, current FDA-approved pharmacotherapy for AD includes ChE inhibitors, *e.g.* rivastigmine, galantamine, tacrine, and donepezil, along with *N*-methyl *D*-aspartate (NMDA) receptor antagonists (*e.g.* memantine) (Terry & Buccafusco, 2003). In a study, which inspired us to carry out the present work, inhibition by the extract prepared from *H. stoechas* capitula on AChE (IC₅₀ value of 260.7 µg/mL) shown by *in vitro* and *in silico* molecular docking methods was determined, where chlorogenic acid, cynarin, and arzanol were reported to be responsible for the inhibitory activity of the extract (Silva et al., 2017). On the other hand, skin aging ranks as one of the most widespread dermatologic concerns; it is a multifaceted and unavoidable process of human existence.

Elastin and collagen, two key proteins that make up connective tissue, are responsible for the skin's resilience and suppleness. With the skin's natural aging process, their breakdown by elastase and collagenase, which free oxygen radicals would activate, promotes wrinkle development. Many researchers working on skin aging have turned their attention to plant extracts after discovering that cosmetic products containing synthetic agents, including such sodium lauryl sulphate and triethanolamine as active ingredients cause side effects such as allergic or irritant contact dermatitis, phototoxicity, and photoallergic responses. Natural skin care goods are acknowledged to be also effortlessly received through into the epidermal layer and to be typically hypoallergenic. Although so called "natural beauty products" appear to be remarkably popular amongst consumers throughout the globe, yet, the overwhelming of them lack scientific evidence to back up their putative aesthetic effects (Mukherjee et al., 2011).

It should be mentioned that free radicals and reactive oxygen species (ROS) have been identified as playing a crucial part in both skin and brain aging, *i.e.* AD. The capitula of *H. stoechas* were previously revealed to possess high antioxidant activity (Haddouchi et al., 2014). Furthermore, a single research examining antiaging action of *H. petiolare* has described its ability to prevent skin aging, which should be explored further (Sagbo & Otang-Mbeng, 2020). Based on the aforementioned little data, we were inspired to do research on the skin and brain aging potential of *H. stoechas*. For this purpose, *H. stoechas* and *H. stoechas* subsp. *barrelieri* were subjected to enzyme inhibition assays towards AChE, BChE, collagenase, and elastase, as well as antioxidant assays using 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging, ferric-reducing antioxidant power (FRAP), and metal-chelating activity as well as HPLC analysis, which will constitute the first study of its kind on this species and sub-taxon.

2. Materials and methods

2.1. Plant materials

The cultivated samples of *H. stoechas* obtained from a farm in Izmir (Türkiye) and naturally growing samples *H. stoechas* subsp. *barrelieri* collected from two provinces of Türkiye (e.g. Izmir and Hatay) were used as the plant materials in this study. Firstly, the capitula of these species were manually separated and utilized for extraction and bioassays performed herein. The species were identified by one of us (M.A.) and their herbarium species are preserved at Faculty of Pharmacy, Gazi University (Ankara, Türkiye).

2.2. Preparation of the extracts

The separated capitula of the plant samples were dried in circulating air. The dried plant

materials were homogeneously pulverized using a mechanical grinder and each sample was weighed accurately (4.5 g) on a digital scale (Shimadzu, Japan). Each plant material was extracted with ethanol (EtOH, 80%, 150 mL) and hot water (150 mL), sequentially, through maceration for 24 hours with periodic handshaking. The EtOH phases were evaporated under reduced pressure by a rotary evaporator (Büchi, Switzerland) to obtain the crude extracts. A lyophilizer (Telstar Lyo Quest, Japan) was used to freeze-dry the aqueous extracts. A total of six extracts was obtained from three plant samples. The crude extracts were kept in the refrigerator at +4°C until bioassays were performed. Table 1 displays the yields of the extracts obtained from each plant.

Table 1. Yields of the extracts (w/w)

Extracts	Yields (% w/w)
EtOH extract (80%) cultivated in Izmir (CE)	10.89
Aqueous extract cultivated in Izmir (CW)	14.91
EtOH extract (80%) grown naturally in Izmir (NIE)	9.65
Aqueous extract grown naturally in Izmir (NIW)	13.55
EtOH extract (80%) grown naturally in Hatay (NHE)	7.88
Aqueous extract grown naturally in Hatay (NHW)	14.29

2.3. Determination of total phenol and flavonoid content in the extracts

Total phenolic contents of EtOH (80%) and aqueous extracts were determined using the Folin-Ciocalteu colorimetric technique with some slight modifications (Singleton & Rossi, 1965). To construct the calibration curve, gallic acid (GA) solutions (used as standard) at various concentrations (1, 0.5, 0.25, 0.125, 0.125, 0.0625, and 0.03125 mg/mL) were prepared to calculate total phenol content. The aqueous and EtOH (80%) extracts were dissolved in EtOH (96%). Both samples and varying concentrations of GA were treated with 30 µL of Folin-Ciocalteu reagent (diluted twice, Sigma, USA) and 150 µL of sodium carbonate (3.5%). After half an hour at 40°C incubation, absorbance at 760 nm was measured with an ELISA microplate

reader (Molecular Devices, Spectramax i3 microplate reader, USA). The experiment was performed in triplicate. GA equivalents (mg/g extract) were used to express the results. With some slight changes, total flavonoid content of the extracts was determined in the extracts using aluminum chloride colorimetric technique (Woisky & Salatino, 1998). Numerous concentrations of quercetin (1, 0.5, 0.25, 0.125, 0.125, 0.125, 0.0625, and 0.03125 mg/mL) employed as standard were prepared to create the calibration curve. In a 96-well microplate, each sample and quercetin solutions at the given concentrations were mingled with 75 µL of EtOH (96%), 5 µL of AlCl₃ (10%), 5 µL of 1 M sodium acetate, and 100 µL of distilled water, respectively. The samples and standard solutions were then incubated for

30 minutes in the dark at room temperature. Absorbance of each sample was measured at 415 nm using an ELISA microplate reader (Molecular Devices, Spectramax i3 Microplate Reader, USA). The experiment

was conducted on three parallel assays. The results were represented in milligrams of quercetin equivalent (mg/g extract). Table 2 demonstrates total phenol and flavonoid contents of the extracts.

Table 2. Total phenolic and flavonoid content of the extracts

Extracts	Total phenol content ^a ± S.D ^b	Total flavonoid content ^c ± S.D ^b
CE	118.77 ± 4.88	91.87 ± 0.81
CW	71.50 ± 9.27	47.21 ± 1.92
NIE	113.60 ± 5.37	79.86 ± 1.44
NIW	94.62 ± 1.95	48.09 ± 3.74
NHE	141.55 ± 2.93	75.45 ± 2.05
NHW	108.76 ± 1.46	65.20 ± 2.02

^aData expressed in mg equivalent of gallic acid to 1 g of extract, ^bStandard deviation (n: 3), ^cData expressed in mg equivalent of quercetin to 1 g of extract.

2.4. Antioxidant activity assays

2.4.1. DPPH radical scavenging activity assay

The bleaching characteristic of a violet-colored methanol solution of DPPH (Sigma, USA) was used to determine the antioxidant capacity of the extracts prepared in 80% ethanol and water. Stable DPPH radical scavenging activity was tested utilizing (Hatano et al., 1988) method with mild

modifications (Barros et al., 2007). Samples/references (10 µL for each) dissolved in EtOH (96%) were transferred to 96-well plates. After then, using a calibrated multichannel pipette (Eppendorf Research, Germany), 90 µL of DPPH solution (1.5×10^{-4} M) prepared in EtOH was poured *per* each well. Table 3 illustrates DPPH radical scavenging capabilities of the extracts.

Table 3. Antioxidant activities of the extracts

Extracts	Metal-chelating capacity (Capacity % ± S.D. ^a)	Ferric-reducing antioxidant power ^b (FRAP) (Absorbance at 700 nm ± S.D.)	DPPH radical scavenging activity (Inhibition % ± S.D.)
CE	NA ^c	0.98 ± 0.01	83.58 ± 1.43
CW	6.58 ± 0.74	0.72 ± 0.02	64.97 ± 1.81
NIE	4.96 ± 0.74	1.23 ± 0.04	83.58 ± 1.72
NIW	22.7 ± 2.35	0.89 ± 0.01	70.68 ± 1.45
NHE	NA [*]	1.49 ± 0.0	87.39 ± 0.17
NHW	6.29 ± 0.82	0.83 ± 0.09	69.98 ± 0.6
References	94.75 ± 0.13 ^d	1.34 ± 0.02 ^e	85.51 ± 0.17 ^f

^aStandard deviation (n: 3), ^bHigher absorbance indicates higher antioxidant activity in FRAP, ^cNo activity, ^dEDTA (2 mg/mL), ^eQuercetin (1 mg/mL)

2.4.2. FRAP assay

Ferric-reducing potential of the EtOH (80%) and aqueous extracts as well as quercetin (reference) was investigated using Oyaizu's method (Oyaizu, 1986) with minor modifications. The test is based on the

diminishing power of the transformation of ferric ion (Fe^{3+}) into ferrous ion (Fe^{2+}), which leads to the creation of a blue complex ($Fe^{2+}/TPTZ$) that enhances absorbance at 700 nm. In summary, 10 µL of samples and reference in EtOH (96%) were transferred to

a 96-well microplate and pre-incubated at 50°C for 20 minutes with 25 µL phosphate buffer (pH: 6.6) and 25 µL [K₃Fe(CN)₆] (1%, w/v, Sigma, USA). FRAP values of the extracts are tabulated in Table 3.

2.4.3. Metal-chelating assay

For evaluating metal-chelating activity, Carter's modified approach was utilized with ethylenediaminetetraacetic acid (EDTA, Sigma, USA) provided as reference (Carter, 1971). In sum, 20 µL of each extract and reference were incubated for 10 minutes at ambient temperatures with EtOH (96%), 2 mM FeCl₂ (Sigma, USA), and 5 mM ferrozine (Sigma, USA). Through the use of an ELISA microplate reader (Molecular Devices, Spectramax i3 microplate reader, USA), absorbance of the formed ferrozine-Fe²⁺ complex was measured at 562 nm. Metal-chelating activity of the extracts is presented in Table 3.

2.4.4. Data analysis for antioxidant activity assays

The subsequent DPPH radical scavenging and metal-chelating results of the extracts and references were determined and expressed in percent inhibition (I%) in accordance to the formula below:

$$\%I = \frac{A_{blank} - A_{sample}}{A_{blank}} \times 100$$

A_{blank} indicates absorbance of the control reaction (all reagents except the test sample) and A_{sample} represents absorbance of the extracts/references. The bioassays were carried out three times, and the results were expressed as means with standard deviations (S.D.).

2.5. Enzyme inhibition assays

2.5.1. ChE Inhibition assays

Inhibitory capacity of the extracts against AChE and BChE was assessed using a slightly altered version of Ellman's procedure (Ellman et al., 1961). Electric eel AChE (Type-VI-S, EC 3.1.1.7, Sigma) and equine serum

BChE (EC 3.1.1.8, Sigma) were employed as enzyme sources, whilst also acetylthiocholine iodide and butyrylthiocholine chloride were employed as the reaction substrates (Sigma, St. Louis, MO, USA). The activity of ChEs was determined using 5,5'-dithio-bis(2-nitrobenzoic)acid (DTNB, Sigma, St. Louis, MO, USA). Sodium phosphate buffer (0.1 mM, pH 8.0, 140 µL) was added to the 96-well microplate using a multichannel automated pipette (Eppendorf Research, Germany), followed by 20 µL of the samples/EtOH (negative control) at dilutions ranging from 25-200 µg/mL. After that, 0.2 M AChE/BChE solution (20 µL) was incorporated using a multichannel automated pipette (Gilson Pipetman, France). Having followed that, it was incubated for a total of ten minutes at room temperature. As substrates, 0.2 M acetylthiocholine iodide/butyrylthiocholine chloride (10 µL) were supplied to the 96-well microplate to initiate the reaction. Thiocholine is produced by hydrolyzing thiol esters employing AChE or BChE. The yellow byproduct of thiocholine-DTNB reaction is 2-nitro-5-thiobenzoate (TNB). The rate of production and color intensity of the product created as a result of the reaction were analyzed with an ELISA microplate reader (Molecular Devices, Spectramax i3x microplate reader, USA) at 412 nm. Galantamine hydrobromide (Sigma, USA) was utilized as a reference in both investigations. Table 4 displays AChE and BChE inhibition by the extracts.

2.5.2. Elastase inhibition assay

The spectrophotometric approach of Kraunsoe et al. (as modified by Lee et al.) was used to investigate elastase inhibition (Kraunsoe et al., 1996; Lee et al., 2009). The enzyme source was porcine pancreatic elastase (Type IV, Sigma, EC 3.4.21.36), while the substrate was *N*-Suc-(Ala)₃-*p*-nitroanilide (Sigma, USA). The reaction is based on determining the quantity of nitroaniline emitted from the substrate at 410 nm. The substrate (1.015 mM) was

prepared in 0.1 M Tris-Cl (pH 8.0) buffer and blended with 10 µL for each extract dissolved in DMSO in a 96-well microplate. After pre-incubating the microplate for 5 minutes at 25°C, 15 µL 0.5 units/mL of the enzyme solution was added. After adding the enzyme, the microplate was incubated at 25°C for 30 minutes, and the quantity of *p*-nitroaniline released from the substrate was measured using an ELISA microplate reader at 410 nm. The reference and control were oleanolic acid (Sigma, USA) and DMSO, respectively. Elastase inhibition percentage of the extracts was estimated using the formula below. The assay was performed in triplicate, and the data are shown as the mean standard deviation of % inhibitions from experimental trials.

$$\text{Inhibition\%} = 100 - [(A_1 / A_2) \times 100]$$

In this formula, A_1 represents the absorbance of the sample solutions at 410 nm, and A_2 represents the average absorbance of the control solutions at 410 nm. Table 5 displays the elastase inhibition findings of the extracts tested.

2.5.3. Collagenase inhibition assay

The slightly modified spectrophotometric approach established by Wart and Steinbrink was used to evaluate collagenase inhibition

(Barrantes & Guinea, 2003; Van Wart & Steinbrink, 1981). The enzyme source was *Clostridium histolyticum* (Sigma, EC 3.4.23.3), and the substrate was *N*-(3-[2-furyl]acryloyl)-Leu-Gly-Pro Ala (FALGPA) (Sigma, USA). The enzyme was dissolved in a tricine buffer with a pH of 7.5. FALGPA was dissolved in the same buffer at a concentration of 2 mM. Each well in a 96-well microplate was filled with 25 µL of buffer, 25 µL of DMSO or extract, and 25 µL of the enzyme. After 15 minutes of pre-incubation, FALGPA (50 µL) was added. Absorbance was measured at 340 nm in an ELISA microplate reader. The reference was (-)-epigallocatechin gallate (Sigma, USA), while the control was DMSO. Percentage collagenase inhibition of the extracts was estimated using the formula below. Each assay was performed in triplicate and the data is displayed as the mean standard deviation of % inhibitions.

$$\text{Inhibition \%} = 100 - [(A_1 / A_2) \times 100]$$

In the formula given above, A_1 represents the absorbance of the sample solutions at 340 nm and A_2 represents the average absorbance of the control solutions at 340 nm. Table 5 displays the collagenase inhibition findings of the samples tested.

Table 4. Cholinesterase inhibitory activities of the extracts and their IC₅₀ values

Extracts	(Inhibition % ± S.D. ^a) at 200 µg/mL ^b	
	AChE	BChE
CE	7.36 ± 4.87	16.08 ± 4.98
CW	31.33 ± 4.79	12.36 ± 0.65
NIE	13.18 ± 6.07	25.67 ± 1.76
NIW	23.12 ± 5.86	80.24 ± 2.63 (IC ₅₀ : 38.52 ± 1.41 µg/mL)
NHE	44.60 ± 4.41	67.24 ± 3.74 (IC ₅₀ = 157.3 ± 6.93 µg/mL)
NHW	30.14 ± 3.01	32.39 ± 2.17
Reference ^c	97.57 ± 2.59 (IC ₅₀ = 0.67 ± 0.02 µg/mL)	89.56 ± 0.8 (IC ₅₀ = 92.34 ± 5.05 µg/mL)

^aStandard deviation (n: 4), ^bFinal concentration, ^cGalantamine hydrobromide (200 µg/mL)

Table 5. Elastase and collagenase inhibitory activities of the extracts

Sample	Collagenase Inhibition (Inhibition % \pm S.D. ^a) 133 μ g/mL ^b	Elastase Inhibition (Inhibition % \pm S.D. ^a) 133 μ g/mL
CE	NA*	6.47 \pm 4.4
CW	NA*	2.44 \pm 2.1
NIE	NA*	1.79 \pm 3.49
NIW	NA*	2.4 \pm 1.5
NHE	NA*	8.3 \pm 3.11
NHW	28.8 \pm 1.48	NA*
Reference	80.83 \pm 11.53 ^c	99.65 \pm 0.08 ^d

^aStandard deviation (n: 4), ^b Final concentration, *No activity, ^c Epigallocatechin gallate (1 mM), ^dOleonic acid (1 mM)

2.6. RP-HPLC analysis of chlorogenic acid in crude extracts

Chlorogenic acid is utilized to standardize *Helichrysum* crude extracts according to Turkish Pharmacopoeia as an approved standard. Chlorogenic acid analysis was carried out in crude extracts prepared with 80% EtOH and water using the technique defined for RP-HPLC (Gök et al., 2022). Each extract solution was prepared with 25% (v/v) acetonitrile at a concentration of 1 mg/mL and transferred to vials through membrane filters. Chlorogenic acid (Sigma, USA) was prepared at various concentrations using 25% aqueous acetonitrile, including 100, 50, 20, 5, and 1 ppm. An HP Agilent 1260 series LC System and an ACE₅ C18 (5 m, 150 mm x 4.6 mm) column with a diode array detector (DAD) was employed for the analysis. Temperature inside the column was adjusted to 25°C. Solvent A (acetonitrile:H₂O:formic acid/80:20:0.1) and solvent B (H₂O:formic acid/100:0.5) were used as the mobile phase. A gradient method has been used to separate the peaks appropriately. The flow chart was adjusted as follows; from 0-minute 5% A, to 10 minutes 15% A, to 17 minutes 15% A, to 22 minutes 20% A, to 32 minutes 30% A, to 50 minutes 100% A, to 53 minutes 100% A. Duration of the analysis was set at 53 minutes. Injection volume was 20 μ L, and the flow rate was 0.8 mL/min. The calibration equation and correlation coefficient for chlorogenic acid were determined as $y = 124.09x - 9.988$ and $r^2 = 0.9999$, respectively.

Table 6 and Figure 1 demonstrate chlorogenic acid quantities in each extract.

Table 6. Amount (% w/w) of chlorogenic acid in the extracts

Extracts	Amount (% w/w)
CE	1.14 \pm 0.000
CW	0.15 \pm 0.000
NIE	0.81 \pm 0.000
NIW	1.36 \pm 0.000
NHE	1.95 \pm 0.000
NHW	1.22 \pm 0.000

3. Results and discussion

3.1. Enzyme inhibition findings

AChE and BChE inhibitory activities of aqueous and EtOH extracts prepared from *H. stoechas* subsp. *barrelieri* (Izmir and Hatay samples) and *H. stoechas* (Izmir sample) are shown in Table 4. The outcomes revealed that AChE inhibitory activity was low in the extracts, whereas the highest activity was found in EtOH extract of the plant collected from Hatay (NHE) with moderate inhibitory activity (44.60 \pm 4.41 %). The inhibitory activity was nearly half that of galantamine, the reference (97.57 \pm 2.59 %). It was determined that the most effective extract against BChE was the aqueous extract of the plant collected from Izmir (NIW, IC₅₀: 38.52 \pm 1.41 μ g/mL), and the extract demonstrated more activity than galantamine (IC₅₀: 92.34 \pm 5.05 μ g/mL). In addition, NHE was also found to exhibit a high inhibition (IC₅₀: 157.3 \pm 6.93 μ g/mL) against BChE.

Collagenase and elastase inhibitory activity results of the extracts indicated that only water extract of the plant collected from Hatay (NHW) extract inhibited collagenase moderately. The other extracts possessed low or no inhibition against both of the enzymes (Table 5).

3.2. Antioxidant activity results

Antioxidant activity of the extracts was analyzed *via* determination of metal-chelating capacity, FRAP, and DPPH radical scavenging activity methods (Table 3). The extracts did not exert remarkable activity in metal-chelating capacity and FRAP assays. Only the NIW extract had a moderate level of metal-chelating capacity (22.7 ± 2.35 %). On the other hand, all of the extracts demonstrated high DPPH radical scavenging activity from 64.97 ± 1.81 % to 87.39 ± 0.17 %. Especially, the EtOH extracts exerted high activity nearly as reference quercetin (85.51 ± 0.17 %).


3.3. Total phenol and flavonoid content in the extracts

Total phenol and flavonoid contents of the extracts were analyzed spectrophotometrically and expressed in mg equivalent of gallic acid and quercetin, respectively (Table 2). The results demonstrated that the total phenolic and flavonoid contents in the EtOH extracts were found to be higher than those of the aqueous extracts. The highest total phenolic content was found in the NHE extract (141.55 ± 2.93 mg/g gallic acid equivalent, GAE), while the highest total flavonoid content was found in the EtOH extract of the cultivated plant in Izmir (CE) extract (91.87 ± 0.81 mg/g quercetin equivalent, QE). The results were found to be consistent with FRAP and DPPH activity results. The extract with the highest phenolic content was NHE which displayed the highest FRAP (1.49 ± 0.0) and DPPH (87.39 ± 0.17 %) activity. Also, the extracts demonstrated AChE, elastase, and prominent BChE inhibitory activity.

3.4. Quantification of chlorogenic acid in the extract using RP-HPLC

Chlorogenic acid as one of the major compounds in *H. stoechas* flowers (capitula) was determined in the extracts by using HPLC-DAD (Table 6). As aforementioned, the compound is also used for the standardization of *H. stoechas* subsp. *barrelieri* and *H. plicatum* subsp. *plicatum* flower monographs in Turkish Pharmacopoeia (Pharmacopoeia, 2019). The equation of the chlorogenic acid calibration curve was $y = 124.09x - 9.988$ ($r^2: 0.9999$) and the test range was 1-200 ppm. The results indicated that the highest chlorogenic acid content was also found in NHE extract (1.95 ± 0.000 %, Figure 1). It might also be related to the highest AChE, BChE, and elastase inhibitory activity of the extract.

In a study, AChE inhibitory activity of the flower and stem/leaf water extracts of *H. stoechas* was analyzed, and their chemical profiles were detected by using liquid chromatography-mass spectrometry (LC-MS/MS) and HPLC-DAD (Silva et al., 2017). The extracts inhibited AChE with IC₅₀ values of 260.7 and 654.8 µg/mL, respectively. The phytochemical analysis revealed presence of chlorogenic acid, myricetin-3-*O*-glucoside, cynarin, dicaffeoylquinic acid, dicaffeoylquinic acid, and arzanol in both of the extracts, whereas malonyl-dicaffeoylquinic acid was found only in the stem/leaf water extracts. Molecular docking studies pointed out that arzanol, chlorogenic acid, and cynarin was compatible with the anti-AChE active site channel and prohibited all access to the catalytic triad. In a similar study, enzyme inhibitory, antioxidant activities, total phenolic and flavonoid contents, and phytochemical analysis using UHPLC/MS of five extracts of *H. stoechas* subsp. *barrelieri* obtained by different extraction techniques were analyzed (Zengin et al., 2020).

Figure 1. HPLC-DAD chromatograms of the extracts

The results demonstrated that the extracts were able to inhibit AChE in a range from 3.56 ± 0.04 to 4.23 ± 0.07 as galantamine equivalent (GAE), BChE from 5.42 ± 0.01 to 6.05 ± 0.03 (GAE), α -glucosidase from $1.59 \pm$

0.01 to 1.66 ± 0.01 acarbose equivalent (ACE), α -amylase from 0.46 ± 0.01 to 0.63 ± 0.02 ACE and tyrosinase from 174.50 ± 2.71 to 183.32 ± 0.78 kojic acid equivalent (KAE). Besides, the extracts exhibited antioxidant

activity to some extent *via* DPPH in a range from 90.05 ± 0.92 to 219.92 ± 3.21 mg trolox equivalent (TE)/g, ABTS radical scavenging activities from 138.68 ± 1.20 to 313.12 ± 8.42 mg TE/g, FRAP from 285.14 ± 5.25 to 662.87 ± 20.41 mg TE/g, cupric-reducing antioxidant capacity (CUPRAC) from 335.97 ± 9.89 to 927.39 ± 11.19 mg TE/g, metal-chelating capacity from 2.91 ± 0.43 to 17.11 ± 0.69 mg EDTA equivalent/g, and phosphomolybdenum assay from 1.65 ± 0.07 to 2.27 ± 0.20 mmol TE/g. In ultraperformance liquid chromatography-mass spectrometric (UHPLC/MS) characterization, a total of 107 compounds was identified, 40 of which were found as hydroxycinnamic acid derivatives, while 50 of them were flavonoids. Quercetin, 5-O-caffeoyl-quinic acid, and *p*-hydroxybenzoic acid were reported as the major molecules in highest amount.

Except *H. stoechas*, various *Helichrysum* species also demonstrated ChE inhibitory and antioxidant activities in previous studies. For instance; *H. pallasii* inhibited AChE (IC₅₀: 1.49 mg/mL), BChE (IC₅₀: 1.98 mg/mL), α -amylase (IC₅₀: 2.09 mg/mL), α -glucosidase (IC₅₀: 0.51 mg/mL), tyrosinase (IC₅₀: 0.68 mg/mL), and pancreatic lipase (IC₅₀: 42.5 μ g/mL) (Nejmi et al., 2023). Furthermore, antioxidant activity of *H. pallasii* was shown by FRAP (2205 μ mol Fe²⁺/gE), oxygen radical scavenging (ORAC) capacities (2540 μ mol Trolox Eq./gE), DPPH (IC₅₀: 0.58 mg/mL), CUPRAC (IC₅₀: 0.37 mg/mL), phosphomolybdenum (IC₅₀: 1.34 mg/mL), and metal-chelation (IC₅₀: 1.42 mg/mL) methods. In another study, *H. plicatum* inhibited AChE by 41.15 ± 1.68 % at 500 μ g/mL concentration. At 200 and 100 μ g/mL, it is shown similar results, which was indicative of dose-independent activity (Jovanović et al., 2020). In another study, methanol extract from *H. plicatum* DC. subsp. *plicatum* inhibited carbonic anhydrase I (hCAI), hCAII, AChE (IC₅₀: 115.50 mg/mL), BChE (IC₅₀: 117.46 mg/mL), and α -glycosidase (IC₅₀: 81.53 mg/mL) (Aydin,

2020). The study also described isolation of apigenin, β -sitosterol, β -sitosterol-3-*O*- β -D-glucopyranoside, helichrysin A and B, isosalipurposide, and nonacosanoic acid. All of the compounds inhibited AChE and BChE, ranging between IC₅₀ values of 1.69–2.90 and 1.09–3.89 μ M, respectively. AChE and BChE inhibitory activity of some other species, *e.g.* *H. chionophilum* and *H. plicatum*, was demonstrated in another report (Acet et al., 2020). In particular, EtOH and ethyl acetate extracts of the flower and stem of *H. chionophilum* and *H. plicatum* inhibited AChE and BChE at moderate levels, where their BChE inhibitory activity was found higher than their AChE inhibition, which is consistent with our data. In the study conducted by Taşkın et al. (Taşkın et al., 2020), anti-ChE, anti-inflammatory, antioxidant, antimicrobial, and anti-urease activities of methanol extracts of *H. plicatum* subsp. *plicatum* by Soxhlet extraction and conventional maceration techniques were investigated. Furthermore, phytochemical analysis of the methanol extracts obtained by maceration and Soxhlet using HPLC-DAD and LC-MS/MS presented 42.10 ± 0.79 % and 58.51 ± 0.85 % of AChE inhibitory activity at 500 μ g/mL concentration, which later led to identification of chlorogenic acid, dicaffeoylquinic acid, luteolin, luteolin-7-*O*-glucoside, naringenin-*O*-hexoside, and isoquercitrin. ChE inhibitory activity of chlorogenic acid described as one of the major molecules in genus *Helichrysum* was demonstrated in former studies. Chlorogenic acid inhibited AChE and BChE with IC₅₀ values of 8.01 ± 0.01 and 6.30 ± 0.02 μ g/mL, respectively (Obloh et al., 2013), whereas, in another study, it was able to inhibit AChE only IC₅₀ value of 98.17 μ g/mL (Obloh et al., 2013).

Our literature survey indicated no any previous study relevant to the effect of *H. stoechas* on elastase and collagenase. However, elastase and collagenase inhibitory activity of leaf EtOH extract of *H. petiolare* was weak (Sagbo & Otang-Mbeng, 2020). The

essential oil of aerial parts of *H. italicum* subsp. *italicum* inhibited collagenase and elastase activities with IC₅₀ values of 36.99 ± 1.52 and 135.43 ± 6.32 µg/mL, respectively (Fraternale et al., 2019).

4. Conclusion

Our present study revealed water and EtOH (80%) extracts prepared from *H. stoechas* subsp. *barrelieri* capitula growing naturally in two localities (Hatay and Izmir), and water and EtOH (80%) extracts prepared from the capitula of cultivated *H. stoechas* sample inhibited AChE weak to moderate levels. Aqueous extract of the plant collected from Izmir (NIW) and EtOH extract of the plant collected from Hatay (NHE) extracts inhibited BChE strongly with 38.52 ± 1.41 and 157.3 ± 6.93 µg/mL IC₅₀ values. The activity of NIW was more than galantamine, the reference drug. The extracts exhibited potent DPPH radical scavenging and FRAP activities; but the metal-chelating capacity was weak except NIW extract (22.7 ± 2.35 %). In addition, amount of chlorogenic acid in the extracts was determined and the highest chlorogenic acid was found in NHE and then in NIW. The findings suggested that chlorogenic acid may be one of the substances responsible for the tested activities.

The current study discloses the first outcomes on AChE, BChE, elastase, and collagenase inhibitory activities and antioxidant data of the capitulum extracts from *H. stoechas* and *H. stoechas* subsp. *barrelieri* from Türkiye as well as their chlorogenic acid quantification.

Conflict of interest

The authors declare no conflict of interest.

References

1. Acet, T., Ozcan, K., & Zengin, G., (2020). An assessment of phenolic profiles, fatty acid compositions, and biological activities of two *Helichrysum* species: *H. plicatum* and *H. chionophilum*. *Journal of Food Biochemistry*, 44(2), <https://doi.org/10.1111/jfbc.13128>
2. Aksoy, A., Hamzaoglu, E., & Budak, Ü., (2011). Taxonomic Revision of Turkey *Helichrysum* Mill. Asteraceae Species. Erciyes University, Research Project, Project No: FBA-08-519, Kayseri. 2011.
3. Aslan, M., (1994). Pharmacognostic Researches on *Helichrysum plicatum* ssp. *plicatum*. Department of Pharmacognosy, Institute of Health Sciences, Gazi University, Master's thesis. 76.
4. Aydın, T., (2020). Secondary metabolites of *Helichrysum plicatum* DC. subsp. *plicatum* flowers as strong carbonic anhydrase, cholinesterase and α-glycosidase inhibitors. *Zeitschrift für Naturforschung C*, 75(5-6), 153-159. <https://doi.org/10.1515/znc-2020-0026>
5. Barrantes, E., & Guinea, Ma., (2003). Inhibition of collagenase and metalloproteinases by aloins and aloe gel. *Life Sciences*, 72(7), 843-850. [https://doi.org/10.1016/s0024-3205\(02\)02308-1](https://doi.org/10.1016/s0024-3205(02)02308-1)
6. Barros, L., Baptista, P., & CFR, F. I., (2007). Effect of *Lactarius piperatus* fruiting body maturity stage on antioxidant activity measured by several biochemical assays. *Food and Chemical Toxicology*, 45(9), 1731-1737. <https://doi.org/10.1016/j.fct.2007.03.006>
7. Carter, P., (1971). Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine). *Analytical Biochemistry*, 40(2), 450-458. [https://doi.org/10.1016/0003-2697\(71\)90405-2](https://doi.org/10.1016/0003-2697(71)90405-2)
8. Ellman, G. L., Courtney, K. D., Andres, V., Jr., & Feather-Stone, R. M., (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochemical Pharmacology*, 7(2), 88-95. [https://doi.org/10.1016/0006-2952\(61\)90145-9](https://doi.org/10.1016/0006-2952(61)90145-9)
9. Eroğlu, H. E., (2018). Names of *Helichrysum* taxa of Türkiye in Turkish and other languages. *Avrasya Terim Dergisi*, 6(1), 26-34.
10. Fraternali, D., Flamini, G., & Ascrizzi, R., (2019). *In vitro* anticollagenase and antielastase activities of essential oil of *Helichrysum italicum* subsp. *italicum* (Roth) G. Don. *Journal of Medicinal Food*, 22(10), 1041-1046. <https://doi.org/10.1089/jmf.2019.0054>
11. Gök, H., Pekacar, S., & Deliorman Orhan, D., (2022). Investigation of enzyme inhibitory activities, antioxidant activities, and chemical

- properties of *Pistacia vera* leaves using LC-QTOF-MS and RP-HPLC. *Iranian Journal of Pharmaceutical Research*, 21(1). <https://doi.org/10.5812/ijpr-127033>
12. Gras, A., Garnatje, T., Ibanez, N., Lopez-Pujol, J., Nualart, N., & Valles, J., (2017). Medicinal plant uses and names from the herbarium of Francesc Bolòs (1773-1844). *Journal of Ethnopharmacology*, 204, 142-168. <https://doi.org/10.1016/j.jep.2017.04.002>
 13. Haddouchi, F., Chaouche, T. M., Ksouri, R., Medini, F., Sekkal, F. Z., & Benmansour, A., (2014). Antioxidant activity profiling by spectrophotometric methods of aqueous methanolic extracts of *Helichrysum stoechas* subsp. *rupestre* and *Phagnalon saxatile* subsp. *saxatile*. *Chinese Journal of Natural Medicines*, 12(6), 415-422. [https://doi.org/10.1016/S1875-5364\(14\)60065-0](https://doi.org/10.1016/S1875-5364(14)60065-0)
 14. Hatano, T., Kagawa, H., Yasuhara, T., & Okuda, T., (1988). Two new flavonoids and other constituents in licorice root: their relative astringency and radical scavenging effects. *Chemical and Pharmaceutical Bulletin*, 36(6), 2090-2097. <https://doi.org/10.1248/cpb.36.2090>
 15. Jovanović, M., Drinić, Z., Bigović, D., Alimpić-Aradski, A., Duletić-Laušević, S., & Šavikin, K., (2020). *In vitro* antineurodegenerative activity and *in silico* predictions of blood-brain barrier penetration of *Helichrysum plicatum* flower extract. *Lekovite Sirovine*, (40), 45-51. <https://doi.org/10.5937/leksir2040045J>
 16. Kraunsoe, J. A., Claridge, T. D., & Lowe, G., (1996). Inhibition of human leukocyte and porcine pancreatic elastase by homologues of bovine pancreatic trypsin inhibitor. *Biochemistry*, 35(28), 9090-9096. <https://doi.org/10.1021/bi953013b>
 17. Lee, S., Sandesh, S., Shruti, S., & Seo, S., (2009). Potent antielastase and antityrosinase activities of *Astilbe chinensis*. *American journal of Pharmacology and Toxicology*, 4(4), 127-129. <https://doi.org/10.3844/ajptsp.2009.127.129>
 18. Memariani, Z., Moeini, R., Hamed, S. S., Gorji, N., & Mozaffarpur, S. A., (2018). Medicinal plants with antithrombotic property in Persian medicine: a mechanistic review. *Journal of Thrombosis and Thrombolysis*, 45, 158-179. <https://doi.org/10.1007/s11239-017-1580-3>
 19. Mukherjee, P. K., Maity, N., Nema, N. K., & Sarkar, B. K., (2011). Bioactive compounds from natural resources against skin aging. *Phytomedicine*, 19(1), 64-73. <https://doi.org/10.1016/j.phymed.2011.10.003>
 20. Nejmi, I., Mükemre, M., Türker, R. S., Zengin, G., & Dalar, A., (2023). Analysis of phytochemical composition and biological activities of *Helichrysum pallasii* (Sprengel) ledeb leaves *International Journal of Secondary Metabolite*, 10(1), 71-85. <https://doi.org/10.21448/ijsm.1132698>
 21. Oboh, G., Agunloye, O. M., Akinyemi, A. J., Ademiluyi, A. O., & Adefegha, S. A., (2013). Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer's disease and some pro-oxidant induced oxidative stress in rats' brain-*in vitro*. *Neurochemical Research*, 38, 413-419.
 22. Oyaizu, M., (1986). Studies on products of browning reaction antioxidative activities of products of browning reaction prepared from glucosamine. *The Japanese Journal of Nutrition and Dietetics*, 44(6), 307-315. <https://doi.org/10.5264/eiyogakuzashi.44.307>
 23. Sagbo, I. J., & Otang-Mbeng, W., (2020). Evaluation of the efficacy of ethanol leaf extract of *Helichrysum petiolare* Hilliard and BL Burt against skin aging. *Tropical Journal of Pharmaceutical Research*, 19(12), 2631-2638. <https://doi.org/10.4314/tjpr.v19i12.22>
 24. Silva, L., Rodrigues, A. M., Ciriani, M., Falé, P. L. V., Teixeira, V., Madeira, P., Machuqueiro, M., Pacheco, R., Florêncio, M. H., & Ascensão, L., (2017). Antiacetylcholinesterase activity and docking studies with chlorogenic acid, cynarin and arzanol from *Helichrysum stoechas* (Lamiaceae). *Medicinal Chemistry Research*, 26, 2942-2950. <https://doi.org/10.1007/s00044-017-1994-7>
 25. Singleton, V. L., & Rossi, J. A., (1965). Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. *American Journal of Enology and Viticulture*, 16(3), 144-158.
 26. Taşkın, T., Gezmiş, T., Çam, M. E., Taşkın, D., Çelik, B. Ö., Şenkardeş, İ., & Süzgeç-Selçuk, S., (2020). The *in vitro* and *in vivo* investigation of biological activities and phenolic analysis of *Helichrysum plicatum* subsp. *plicatum*. *Brazilian Journal of Pharmaceutical Sciences*, 56. <https://doi.org/10.1590/s2175-97902019000418345>
 27. Terry, A. V., & Buccafusco, J. J., (2003). T The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. *Journal of Pharmacology and Experimental Therapeutics*, 306(3), 821-827. <https://doi.org/10.1124/jpet.102.041616>
 28. Tsioutsiou, E. E., Amountzias, V., Vontzalidou, A., Dina, E., Stevanović, Z. D., Cheilari, A., & Aligiannis, N., (2022). Medicinal plants used traditionally for skin related problems in the South Balkan and East Mediterranean region-A review. *Frontiers in Pharmacology*, 13. <https://doi.org/10.3389/fphar.2022.936047>
 29. Van Wart, H. E., & Steinbrink, D. R., (1981). A continuous spectrophotometric assay for

- Clostridium histolyticum* collagenase. *Analytical Biochemistry*, 113(2), 356-365.
[https://doi.org/10.1016/0003-2697\(81\)90089-0](https://doi.org/10.1016/0003-2697(81)90089-0)
30. Version 7.2 of the Turkish Pharmacopoeia. Turkish Medicines and Medical Devices Agency, Ankara, Turkey, ISBN:978-975-590-733-8, 2019.
 31. Woisky, R. G., & Salatino, A., (1998). Analysis of propolis: some parameters and procedures for chemical quality control. *Journal of Apicultural Research*, 37(2), 99-105.
<https://doi.org/10.1080/00218839.1998.11100961>
 32. Zengin, G., Cvetanović, A., Gašić, U., Tešić, Ž., Stupar, A., Bulut, G., Sinan, K. I., Uysal, S., Picot-Allain, M. C. N., & Mahomoodally, M. F., (2020). A comparative exploration of the phytochemical profiles and bio-pharmaceutical potential of *Helichrysum stoechas* subsp. *barrelieri* extracts obtained via five extraction techniques. *Process Biochemistry*, 91, 113-125.
<https://doi.org/10.1016/j.procbio.2019.12.002>



Current Perspectives on Medicinal and Aromatic Plants



An International Journal
ISSN: 2619-9645 | e-ISSN: 2667-5722

Echinacea Genus: An Endless Natural Therapeutic Resource? An Overview

Aurel VASIU¹ , Carmen Dana ȘANDRU^{1,2} , Emeline CHANOVE¹ , Diana Ioana OLAH¹ 
Emoke PALL^{1,2} , Gheorghită DUCA² , Marina SPÎNU^{1,2*} 

¹Department of Clinical Sciences, Faculty of Veterinary Medicine, Division of Infectious Diseases, University of Agricultural Sciences and Veterinary Medicine, 400372, Cluj-Napoca, Romania, marina.spinu@gmail.com

²Institute of Research and Development for Montanology, 557085, Cristian-Sibiu, Romania

*Corresponding author : icdmcrstian@gmail.com

Received: 20/06/2023

Accepted: 02/07/2023

<https://doi.org/10.38093/cupmap.1317531>

Abstract

Echinacea spp., Asteraceae family represented one of the important genera of cultivated biologically active plants, well-known in traditional medicine. Its multiple effects were investigated along time, within the research for alternative therapies to synthetic drugs. Due to those effects the *Echinacea* genus represented a valuable resource for medicine in general and for veterinary medicine especially. In the latter, the fight to increase resistance against diseases counter-balances the antimicrobial therapies; further, the potential adjuvant role of *Echinacea* products provide perspectives of an enhanced innate rather than adaptive immunity along with antibacterial effects.

Still, the involvement of plant extracts in therapy and prevention of diseases in general, even by enhancing immunity or increasing the post-vaccination responses needs careful species and age-based tailoring to avoid unwanted or noxious side effects. Could this genus represent more than an alternative? Are its effects more valuable in medicine than thought before? This mini-review is exploring those possibilities.

Key Words: *Echinacea* spp., general biological effects, innate immunity, specific immunity

© CUPMAP. All rights reserved.

1. Botanical Description

Compared to other species with medicinal uses, the history of *Echinacea* is relatively short. *Echinacea* includes several plants of the Asteraceae family: *Echinacea purpurea* (L.) Moench, *Echinacea angustifolia* DC. and *Echinacea pallida* (Nutt.) Nutt. In Methodus Plantas Horti Botanici et Agri Marburgensis, Conrad Moench (1794) accepted that *Echinacea* (*E. purpurea* (L.) Moench) was equivalent to *Rudbeckia purpurea* L. from the family Asteraceae.

The currently accepted taxonomy for *Echinacea* species is based on morphological and anatomical studies by McGregor (McGregor, 1968, American Herbal Pharmacopoeia and Therapeutic Compendium, 2007). According to these data, the genus comprises nine to ten (WFO, 2023) species and two varieties. The ten accepted species are: *Echinacea angustifolia* DC. (Narrow-leaf coneflower), *Echinacea atrorubens* (Nutt.) Nutt. (Topeka purple coneflower), *Echinacea laevigata* (C.L. Boynton & Beadle) S.F. Blake (Smooth

coneflower, smooth purple coneflower), *Echinacea pallida* (Nutt.) Nutt. (Pale purple coneflower), *Echinacea paradoxa* Britton (Yellow coneflower, Bush's purple coneflower), *Echinacea purpurea* (L.) Moench (Purple coneflower, eastern purple coneflower), *Echinacea sanguinea* Nutt. (Sanguine purple coneflower), *Echinacea simulata* McGregor (Wavyleaf purple coneflower) and *Echinacea tennesseensis* (Beadle) Small (Tennessee coneflower) (The International Plant Names Index and World Checklist of Vascular Plants 2023). According to Bauer and Wagner (1990), *Rudbeckia serotina* Sweet (Table 1) represented just a

synonym for *Echinacea purpurea* (L.) Moench.

The *Echinacea* spp. distribution is defined by the natural or introduced status of the plant, broader geographical areas being lately covered by the introduced *Echinacea* (Fig.1).

Corresponding to the Royal Botanic Kew Gardens "Plants of the World Online", native *Echinacea* spp. are found in the North American continent, while introduced species are spread from Western Europe to South Eastern Asia (Fig.1, <https://powo.science.kew.org/>).




Figure 1. The distribution map of *Echinacea* spp. native or introduced species (<http://www.ipni.org> , <https://powo.science.kew.org/>). The green color indicated the native species distribution, while introduced plants are represented by purple color.

Echinacea spp. are perennial herbaceous plants, growing from either tap- or fibrous (*E. purpurea*) roots in relatively dry climate. The stems are erect up to 1.4 m, with no branches in most species and the rough, hairy leaves are arranged alternately. The leaves decrease in size towards the top of the plant, showing a linear, lanceolate, ovate or elliptic shape,

with entire or dentate/serrate margins, showing species specific differences (Belaeva and Butenkova, 2018, WFO 2023). As in all Compositae, the flowers of *Echinacea* spp. are inflorescences, with the outer pink or sometimes yellow florets pointing downward and the middle florets are positioned in a cone-shaped head (cone-flower- WFO 2023).

Table 1. Taxonomy of the genus ECHINACEA, after MCGregor (1968)(Bauer R., Wagner H., 1990)

<p><i>Echinacea angustifolia</i> DC. var. <i>angustifolia</i> Synonyms: <i>Brauneria angustifolia</i>, <i>Echinaceea pallida</i> var. <i>angustifolia</i> (DC) Cronq</p> <p><i>Echinacea angustifolia</i> DC. Var. <i>strigosa</i>, McGregor</p> <p><i>Echinacea alrorubens</i> Nutt Synonyms: <i>Rudbeckia alrorubens</i> Nutt.</p> <p><i>Echinacea levigata</i> (Boynton & Beadle) Blake Synonyms: <i>Brauneria levigata</i> Boynton & Beadle, <i>Echinaceea purpurea</i> (L.) Moench var. <i>levigata</i> Cronq</p> <p><i>Echinacea pallida</i> (Nutt.) Nutt. Synonyms: <i>Echinaceea angustifolia</i> Hooker, <i>Rudbeckia pallida</i> Nutt., <i>Brauneria pallida</i> Britton, <i>Echinaceea pallida</i> (Nutt.) Nutt. <i>F. albida</i> Steyerem.</p> <p><i>Echinacea paradoxa</i> (Norton) Britton var. <i>paradoxa</i> Synonyms: <i>Brauneria paradoxa</i> Norton, <i>Echinaceea atrorubens</i> Nutt. var. <i>paradoxa</i> (Norton) Cronq.</p> <p><i>Echinacea paradoxa</i> (Norton) Britton var. <i>neglecta</i> McGregor</p> <p><i>Echinacea purpurea</i> (L.) Moench Synonyms: <i>Rudbeckia purpurea</i> L., <i>Rudbeckia hispida</i> Hoffm. & G., <i>Rudbeckia serotina</i> Sweet, <i>Echinaceea purpurea</i> (L.) Moench var., <i>arkansana</i> Steyerem., <i>Echinaceea purpurea</i> (L.) Moench f. <i>ligettii</i> Steyerem., <i>Echinaceea speciosa</i> Paxton, <i>Echinaceea intermedia</i> Lindley, <i>Brauneria purpurea</i> (L.) Britton.</p> <p><i>Echinacea simulata</i> McGregor Synonyms: <i>Echinaceea speciosa</i> McGregor.</p> <p><i>Echinacea sanguinea</i> Nutt</p> <p><i>Echinacea serotina</i> (Nutt.) DC.</p> <p><i>Echinacea tennesseensis</i> (Beadle) Small, Synonyms: <i>Brauneria tennesseensis</i> Beadle, <i>Echinaceea angustifolia</i> DC. var. <i>tennesseensis</i> (Beadle) Blake</p>

2. Chemical Composition


Echinacea spp. has a complex composition. The chemical constituents have been more or less defined over the years, and chemical investigations have even identified different species of *Echinacea* that are difficult to differentiate botanically. The various plant preparations belonging to the genus *Echinacea* must be classified according to the

plant species (*Echinacea purpurea*, *E. pallida* or *E. angustifolia*), the processed portion of the plant (root, aerial part or whole plant) and the method of processing. Significant pharmacological effects have been described both *in vivo* and *in vitro* for the extract from the aerial parts of *E. purpurea* and for alcoholic extracts from the roots of *E. pallida*, *E. angustifolia* and *E. purpurea*. This activity is mainly directed towards the non-specific

cellular immune system. The active components of these plants are polysaccharides, glycoproteins, caffeic acid derivatives (cynarin) and alkaloids (Bauer et al., 1999, Nyalambisa et al., 2016).

When chemists and pharmacologists started showing interest in Echinacea, numerous constituents were isolated such as polysaccharides, echinacosides, cyclochoric acid, ketoalkenes and alkyl amides (El-Gengaihi et al., 1998). These extracts have shown immune stimulating capacity and were mainly used in prophylaxis and therapy of colds, influenza and septic disorders, however the identity of the active principles was not well known (Hostettmann, 2003).

The main biologically active constituents are: echinacoside (*E. pallida*), verbascoside (*E. angustifolia*, *E. pallida*) (Fig.2), quinic acid derivatives (cynarin) (*E. angustifolia*, *E. tennesseensis*), chicoric acid (*E. purpurea*) (Fig.3), flavonoids; essential oils, polyacetylenes, alkylamides, alkaloids, polysaccharides and other constituents (resins, acids: oleic, linoleic, cerotic, palmitic, etc.).



b

Figure 2. Echinacoside(a) (*E. pallida*) and verbascoside (b) (*E. angustifolia*, *E. pallida*) – caffeic acid glycosides from the phenylpropanoid class





Figure 3. Chicoric acid (*E. purpurea*) a hydroxycinnamic acid, an organic compound of the phenyl-propanoid class



a




Figure 4. The flavonoid backbone




Figure 5. Cynarin (*E. angustifolia*) hydroxy-cinnamic acid derivative




Figure 6. Alkylamides (*E. angustifolia*, *E. tennesseensis*) hydroxy-cinnamic acid derivative (Raduner et al., 2006)

Chemical evaluation by HPLC showed a differentiated distribution of active compounds in the roots of *E. angustifolia*, *E. purpurea* and *E. pallida*. Cyclic acid and verbascosides predominated in *E. purpurea* extracts while cynarin and dodeca-2E,4E,8Z,10Z/E-tetraenoic acid isobutylamide represented a major component of *E. angustifolia* extract. Echinacoside and 6-O-caffeoyl-echinacoside were dominant in extracts from *E. pallida* roots. Characteristic alkamides were also examined by tandem electrospray mass spectrometry (MS/MS), finding their characteristic fragmentation. All root and leaf extracts of the three plants showed antioxidant properties in the free radical assay and in the lipid peroxidation assay (Sloley et al., 2001; Kahlos et al., 1989). The flowers of *Echinacea* spp. contained monoterpenes and monoterpenoids, sesquiterpenes and sesquiterpenoids, as well as other hydrocarbons, the most prevalent being Sesquiterpenic hydrocarbons identifiable by HS-SPME-GC/MS (Kaya et al., 2018).

3. Biological Effects

The plant is native to North America and has served in the traditional medicine of native Indians. There are records of this plant being used medicinally by the Cheyenne, Dakota,

Fox, Kiowa, Crow, Delaware, Comanche and other North American tribes. It is likely that the *Echinacea* used by them belonged to the species *E. angustifolia*, *E. purpurea* or *E. pallida*. The earliest archaeological evidence of the use of the plant for therapeutic purposes dates from the 18th century. The first *Echinacea* preparation, known as Meyers Blood Purifier, was marketed around 1880 for rheumatism, neuralgia and snakebites. In the early 20th century, *Echinacea* was used as the most popular herbal preparation in the US. Commercial cultivation began in Germany around 1939 and since 1950, Vogel has cultivated the plant in Switzerland (Bauer et al., 1988).

For a long time, *Echinacea* species were regarded as esoteric medicinal plants, their use being restricted to a few areas in Germany and the United States. Due to ignorance of its mechanism(s) of action, no relations were sought between its wound healing activity or anti-snake venom effect and modern pharmacology. Until 1930, *Echinacea* extracts were used in experiments of varying scientific accuracy in the treatment of abscesses, puerperal sepsis, septicemia, uremia, malaria, septic shock, typhus, tuberculosis, tetanus or other bacterial toxemias (Bauer and Wagner, 1990).

After 1940, clinical trials became more circumscribed, based on intravenous

administration of *Echinacea* EchinacinR extract or intramuscular administration of Myo-EchinacinR, more rarely oral, drops or

external ointments. The main clinical indications of these extracts were shown in Table 2.

Table 2. Clinical results of EchinacinR extracts applied externally or injected (Bauer and Wagner, 1990)

External use

Burns, chemical burns, frostbite, radiation ulcers

Post-operative soft tissue injuries

Atherosclerotic soft tissue and bone wounds, not prone to suppuration, phlegmon, fistulization

Decubital ulcers in elderly, cachectic patients

Ulcus cruris

Eczema (including industrial eczema)

EchinacinR , ampoules

Internal medicine and paediatrics: Septic conditions, rheumatoid arthritis, antibiotic resistance. Whooping cough, flu, catarrhal infections. Chronic upper respiratory tract infections.

Gynaecology: endodermatitis, parametritis, post-infectious abortion treatment, pelviperitonitis, chronic adnexitis.

Surgery: chronic osteomyelitis.

Urology: non-specific prostatitis, non-specific urethritis, epididymitis.

Dermatology: Psoriasis arthropathica, psoriasis vulgaris, erythroderma of various origins, pemphigus vulgaris, endogenous eczema, atonic skin ulcers (ulcus cruris, irradiation ulcers, decubital ulcers).

Extensive studies carried out in the last decades highlighted that the plant's active substances have beneficial effects on the non-specific immune system. Establishing, without doubt, the botanical identity of the plant and identifying the effects of isolated components, which was possible both *in vivo* and *in vitro* experiments, allowed a more precise definition of immune modulating activity (Schraner and Losch, 1986, Schraner et al., 1989). Phylloxanthobilins (PBs) which result from degrading of chlorophyll while the plant is aging contained

in *Echinacea purpurea* extracts could be ensuring part of the plant's biological activity (Karg et al., 2019).

Traditionally, *Echinacea* has been prescribed externally for various conditions such as wounds, burns, skin or lymph node swellings, insect bites. The roots have been used to combat dental and neck pain. Internally, it has given results in headaches, digestive cramps, coughs, colds, measles, gonorrhoea or various intoxications (including snakebite). The roots are the most widely used part of the

plant. The fresh plant has been used as a paste or macerate, less often as an infusion.

4. Biological Activities other than on the Immune System

4.1. Local Tissular Activity: Originally, *Echinacea* extracts were used for their healing properties. Using EchinaceaR, its anti-hyaluronidase action was observed, probably associated with other effects, due to indirect intervention on the hyaluronic acid-hyaluronidase system, expressed by changes in fibroblasts (Koch, cited by Bauer R., Wagner H., 1990). EchinacinR appears to induce synthesis of mesenchymal mucopolysaccharides, suggesting also the pituitary-adrenal axis as a target of influence (Koch cited by Bauer and Wagner, 1990).

Echinacea extract, used in equine feed for 42 days, acts as a haematinic agent, improving blood quality, decreasing haemoglobin concentration and erythrocyte count and thus oxygen transport, thereby increasing physiological parameters of exercise and sports performance (O'Neill et al., 2002).

4.2. The Anti-inflammatory Activity: Factor A, a compound isolated from aqueous extracts of *Echinacea purpurea*, shows cortisol-like activity and a mixture of polysaccharides from *E. angustifolia* show effects in the rat model of edema disease. An alkylamide fraction has also been found to be responsible for anti-inflammatory effects (Bauer, 2002). Anti-inflammatory effects have also been observed for the isolated polysaccharide fraction from *E. angustifolia* (Tubaro et al., 1988).

Echinacea crude extract (Echinacea B) inhibited auricular edema induced in mice by application of 0.015 ml of a 0.25% croton oil emulsion in water, during its peak (6 h) or decline (18 h), by topical application, the effect being dose-dependent. Moreover, this anti-edema effect has been shown to be stronger than that of benzidamine, a non-steroidal topical anti-inflammatory drug.

Intravenous administration one hour prior to inoculation of a 1% carrageenan extract amounting in 0.05 ml, in the posterior plantar perineum of the rat, inhibited edema in the histamine phase as well as the inflammatory process (Tragni et al., 1985, 1988; Tubaro et al., 1988).

Components such as phyllobilins (PBs)(phylloleucobilin, dioxobilin-type phylloleucobilin, phylloxanthobilin, etc.) were also found in *E. purpurea*. Pharmacological activities such as anti-inflammatory and anti-oxidative have been described for PBs of *Echinacea purpurea*, including those present in infusions of the plant (Gorfer et al., 2023).

4.3. Antiviral, Antibacterial, Antifungal, Oncolytic and Insecticidal Activities:

Echinacosides isolated from *E. angustifolia* strains have anti-staphylococcal activity, at the lower limit of antibiotic activity. Polyacetylenic compounds from the roots of *E. angustifolia* and *E. purpurea* have been shown to inhibit the growth of bacteria (*E.coli*, *Pseudomonas aeruginosa*) and fungi. High dilutions (1:1000) of an *E. angustifolia* extract completely inhibited the growth of *Epidermophyton interdigitale*. Antiparasitic effects of these extracts were also mentioned, thus *in vitro*, an alcoholic extract of *E. angustifolia* weakly inhibited the growth of *Trichomonas vaginalis*.

EchinacinR, the already mentioned extract, was shown to be effective against encephalomyocarditis and vesicular stomatitis virus in cell cultures. Extracts of *E. purpurea* reduced the number of plaques in cell cultures treated with influenza virus, herpesvirus and vesicular stomatitis virus respectively (Wacker and Hilbig, 1978). This activity has been described as "interferon-like", but without inducing interferon synthesis.

Peroral treatment for four weeks with *Echinacea* extract in combination with *Eupatorium perfoliatum* and *Thuja*

occidentalis (*Echinacea* complex) in patients undergoing surgery for tumour diseases, did not induce the activation of leukocyte or lymphocyte populations or amplification of the secretion of IL-1- α , IL-1- β , IL-2, IL-6, TNF- α , or IFN- γ in supernatants of stimulated whole blood cultures compared to the untreated group of patients (Elsässer-Beile et al, 1996; Bodinet and Freudenstein, 1999; Block and Mead, 2003).

Phytochemical preparations obtained from *Echinacea* spp., by stimulating non-specific immune effectors (micro- and macrophages), act in the first line of defense against virally infected/transformed cells. Increased levels of these cells in the bone marrow following treatment in rats indicate that at least one of the mechanisms of action of the active compounds is the stimulation of the appearance of new cells in situ (Sun et al., 1999, 2005, Burlou-Nagy et al., 2022).

PBs of *E. purpurea* were proven to bind to actin and inhibit cancer cell migration (Vollmar and Moser, 2023). Further, phylloxanthobilin, induces cell cycle blockage and apoptosis in cancer cells, an increase in anti-proliferative activity being induced by esterification inactive phylloleucobilin and depending on the chain lengths of the alkyl esters (Karg et al., 2020)

4.4.Toxicity: Acute toxicity tests by Lorke (1983) in mice using two of the *Echinacea* polysaccharides resulted in death following intraperitoneal inoculation of over 5000 mg/kg-1, but the nature of the histological lesions (pronounced alveolar and interstitial edema with localized leuko-diapedesis) suggested acute circulatory collapse (decompensated shock) caused by the syrupy nature of the extract and not the plant polysaccharides themselves.

Neutral polysaccharides from *E. purpurea* have been tested for possible genotoxicity in human lymphocyte cultures (Schimmer and Leimeister, 1989). No sister chromatid exchange or chromosomal aberrations

occurred in either long or short term experiments.

Experiments carried out recently (Balciunaite et al., 2020) identified by LC-MS/MS glycoproteins were homologous with the lysine motif (LysM) domain containing lectins, common to several Asteraceae plants. Tested in vivo, these induced toxic effects expressed by statistically significant kidney glomerular vacuolization and tubular necrosis.

5. Immunological Investigations

A review of research conducted over the last 40 years (January 1966-July 1999) to confirm the immune stimulating effects of *Echinacea* extracts or purified *Echinacea* components revealed a lack of agreement between these results obtained by different working groups, with arguments pro and against immunomodulatory activity but not for the safety of using these extracts (Giles et al, 2000).

According to some authors (Văgîi et al., 1996), the immune modulating influence of *Echinacea* extracts is global, with usefulness in immune deficiencies, particularly in combination with extracts from *Epilobii herba*, *Usnea barbata*, *Urticae folium*, *Alchemillae herba*, *Hyperici herba*, *Crataegi folium cum flores*.

By correlating the results obtained with the composition of the different parts of the plant or with that of the different *Echinacea* species, it could be stated that the immune stimulating effects of alcoholic or aqueous extracts depended very much on the combined action of their constituents. Most chemical analyses have been carried out on *Echinacea angustifolia*, particularly the older ones, while immune activity has been tested mainly on *Echinacea purpurea* (Schumacher and Friedberg, 1991).

5.1. Influence on the Complement System:

Due to the extremely important physiological role of the complement system, its modulation (inhibition or stimulation) is a target of interest in the development of various drugs. Some plant polysaccharides are known to have complement-modulating activities. However, the classically used hemolysis assay does not allow differentiation between complement inhibitors or activators due to low hemolysis.

Comparative evaluation of the inhibitory and activating effects, respectively, using heparin (inhibitor) and an arabino-galactan from *Echinacea purpurea* extract demonstrated that the latter was a complement activator, both in the classical and alternative pathways, by altering the complement incubation periods. Removal of the side chains of the tested arabinogalactan significantly reduced complement stimulating activity, proving that the three-dimensional structure was an essential component of the activating potential. The involvement of arabinogalactan in complement activation could represent one of the attributes of the immune stimulating efficacy traits of *Echinacea purpurea* extract (Alban et al., 2002).

5.2. Influence on the Phagocytic System:

The positive effects of *Echinacea* extracts on phagocytosis have been followed on isolated rat liver (Bauer, 1996). In order to determine any differences between extracts from plants belonging to different species, the carbon particle inclusion test was performed and extracts of *E. purpurea*, *E. angustifolia* and *E.*

pallida were tested. Phagocytosis was amplified in the presence of alcohol extracts by 20-30% at doses of 10⁻² to 10⁻⁴.

The *E. purpurea* extract was found to be the most active, and the chloroform-extracted fractions of the ethanolic extract were more effective than the hydrophilic ones (Fig. 7). The results of this *in vitro* assay correlated with those obtained *in vivo* by oral administration of the alcoholic extract.

Of the isolated compounds, chicoric acid induced a significant increase in phagocytosis, confirmed by the carbon particle inclusion assay.

The polysaccharide fraction favored phagocytosis after intravenous injection (*EchinacinR*), an effect supported by assessing the percentage of lymphocytes and granulocytes labelled with tritiated thymidine in Cohen's experiment (1980) (Table 3).

In vitro investigations using a polysaccharide-rich mixture from the aerial parts of *E. purpurea* demonstrated its predilect influence on the mononuclear cell subsystem. The same mixture stimulates macrophages to release interleukin-1, but does not induce T lymphocyte proliferation (Lowenthal and MacDonald, 1986; Lowenthal et al., 1999, 2000, Barrett, 2003). Macrophage stimulation and induction of cytokine secretion are due not only to the polysaccharide fraction but also to the glycoprotein fraction (Bauer, 2002).




Figure 7. Influence of *Echinacea* extract versus other principles on phagocytic activity in humans (after Bauer R. et al., 1999)

Legend: Echinacea preparations used: 1:5 - Myo Echinacin 5%, 1:20-1:50 - Echinacea angustifolia extract 5:1/30%; Aristolochia - Tardolyt Madaus; Intraglobin F, Ch-B 4111107 Biotest, Human Transferrin - Ch-B 1672 Behringwerke

Echinacea purpurea extracts, stabilised, are well-tolerated, allergic reactions, particularly skin reactions, are reversible and can occur particularly in people with contact hypersensitivity to plants of the Compositae family. Pharmacological data suggested that cold-pressed Echinacea preparations stimulate the non-specific immune system and increase resistance to respiratory infections by stimulating oxidative shunt and modulating monokine secretion (Kligler, 2003, Bauer, 2002; Bauer et al., 1988). These claims are supported by stimulation of natural killer cell activity (Barrett, 2003).

A series of studies in mice using polysaccharides purified from Echinacea cell cultures have shown an immune stimulating effect in cell cultures from mice or in animals injected intraperitoneally. These effects include amplification of phagocytic activity, chemotaxis and respiratory shunting of neutrophils and macrophages respectively. Peritoneal macrophages from treated animals produced increased amounts of tumour necrosis factor (TNF), interleukins (IL-1, IL-6 and IL-10) and were more active in destroying WEHI 164 lineage of tumour cells as well as cells infected with Leishmania

enriettii or *Candida albicans*. Similar effects were observed after administration of Echinacea extracts even in mice suppressed with cyclophosphamide or cyclosporine. These studies highlight the immune stimulating activity of Echinacea polysaccharides in both healthy and immunosuppressed animals (Percival, 2000).

A comparative study carried out to investigate the immune-biological effects of some components of Echinacea extract (cychoric acid, polysaccharides and alkylamides) demonstrated the maximum efficacy of alkylamides at a dose of 12 µg/kg body weight/day in significantly increasing phagocytic activity as well as the phagocytic index of alveolar macrophages. Simultaneously, alveolar macrophages obtained from this group produced significantly more TNF-α and nitric oxide after *in vitro* stimulation with LPS than any other component or the control. None of the concentrations of the investigated components induced TNF-α, IFN-γ and IL-2 release by splenocytes. The immunomodulatory effects of alkylamides appear to be more pronounced on lung

immunocompetent cells than on splenic cells (Goel et al., 2002).

Western blot analysis of the *in vivo* effects of *Echinacea purpurea* (L.) Moench extract showed that it induced, along with changes in lipopolysaccharide (LPS) response, IFN- γ -induced cyclooxygenase-2 (COX-2) and nitric

oxide synthase (iNOS) expression in peritoneal macrophages. Thus, treatment with 100 mg kg⁻¹ of *Echinacea* extract reduced only COX-2 expression, demonstrating that the anti-inflammatory effect of the extract may be due to this mechanism (Raso et al., 2002).

Table 3. Percentages of labelled lymphocytes and granulocytes in the total population (after Bauer and Wagner, 1990)

Time for thymidine inoculation (h)	Lymphocytes	Granulocytes
24	11	0
48	15	6
72 (Echinacin application)	7	34
78	40	89
97	7	59

5.3. Influence on Specific Humoral-Mediated Immunity:

Numerous immunomodulatory effects have been attributed to *Echinacea angustifolia* extracts, however little is known about the stimulation of antigen-specific immunity. Studies in rats shed some light on these issues, indicating increased synthesis of immunoglobulins by enhancing the primary and secondary IgG immune response to antigen (Rehman et al., 1999). Contrary to these results, administration of *Echinacea* preparations of different origin (standard or officinal products) to male and female rats decreased the concentration of antigen-specific immunoglobulins (standard products) or had no effect (officinal products) in females, but was neutral in efficacy in males (South and Exon, 2001).

5.4. Influence On Specific Cell-Mediated Immunity:

Although *Echinacea* extract acted immune stimulating, not all cell categories were encouraged. Thus, B lymphocytes were not activated nor did they produce antibodies in increased concentrations against a thymus-dependent antigen, sheep red blood cells (Barett, 2003). In some papers, a weak stimulation of T lymphocytes was reported, but those cells did not synthesize increased amounts of IL-2, IFN- β 2, or IFN- γ . Delayed

hypersensitivity, a T lymphocyte-mediated reaction, was not affected by treatment with *Echinacea* extract. These data strongly indicate the action of purified polysaccharides from *E. purpurea* on the non-specific side of the immune response, i.e. phagocytes, rather than on the specific side of immunity (Percival, 2000). Other works (Wagner et al., 1984, 1985; Wagner, 1991; Wagner and Jurcic, 2002) suggest that *Echinacea purpurea* extract in mixture with extracts from other plants (*Glycyrrhiza glabra*), in tablet form (Revitonil), exerted a remarkable stimulating effect both on phagocytic activity, measured by the carbon particle engulfment test and chemiluminescence, and on T lymphocytes (30-50%) in the CD69 bioassay at a concentration of 100 microg-1/ml.

6. Is There More?

Several researchers mention that their results open gates for further investigations on the biological effects of *Echinacea* genus, given the sometimes substantial composition differences, which were found among the species. Similarly, some of the biological effects of these plants supported by traditional medicine uses still remain unexplained. Therefore, several

areas/directions to be tackled by further research and several unanswered questions could be identified.

There is an obvious need for identifying new compounds, whose biological effects remained insufficiently unveiled, i.e., further research on phyllobilins and all the compounds included in this group, where investigations are at their beginnings.

Similarly, not all the effects connected with single components have been revealed, therefore new research techniques, mainly *in vivo* studies with respect to the three R (replacement, reduction, refinement) could be applied to increase the database on the biological efficacy result of these plants.

One of the difficulties in preparing plant products for medicinal use consist of standardization, therefore the use of single purified components seems to be a solution to the problem. But will the overall effects be those expected under these circumstances? Will the patients' reactions be the same? Broadening the variety of subjects, will the "species" factor become a more influential one? Other questions yet to be answered in the future.

Finally, all the available data suggest that the "pharmacy of nature" withholds numerous secrets and to avoid the Pandora box effect only depends on those involved in its research.

7. Conclusion

Due to multiple biological effects, the *Echinacea* genus represents a valuable resource for medicine in general and especially for veterinary medicine, where the fight of increasing resistance against diseases counter-balances the antimicrobial therapies; further, the potential adjuvant role of *Echinacea* products provide perspectives of an enhanced innate rather than adaptive immunity along with antibacterial effects.

Still, the involvement of plant extracts in therapy and prevention of diseases in general, even by enhancing immunity or increasing the post-vaccination responses needs careful species and age-based tailoring to avoid unwanted or noxious side effects.

Acknowledgements

We would like to thank you for the all contributed authors.

Author Contribution

All the authors gave the same effort and contribution to this review and they approved the final version for the submission.

Conflicts of Interest

There is no conflict of interest for any of the authors of this article.

References

1. Alban S, Classen B, Brunner G, Blaschek W. -2002 - Differentiation between the complement modulating effects of an arabinogalactan-protein from *Echinacea purpurea* and heparin. *Planta Med.*;68(12):1118-24.
2. Balciunaite, G.; Haimi, P.-J.; Mikniene, Z.; Savickas, G.; Ragazinskiene, O.; Juodziukyniene, N.; Baniulis, D.; Pangonyte, D. Identification of *Echinacea Purpurea* (L.) Moench Root LysM Lectin with Nephrotoxic Properties. *Toxins* 2020, 12, 88.
3. Barrett B. -2003- Medicinal properties of *Echinacea*: a critical review. *Phytomedicine*. Jan;10(1):66-86.
4. Bauer R. - 2002 - New knowledge regarding the effect and effectiveness of *Echinacea purpurea* extracts] *Wien Med Wochenschr.*;152(15-16):407-11.
5. Bauer R. -1996-*Echinacea* drugs effects and active ingredients, *Z Arztl Fortbild (Jena)*; 90(2):111-5.
6. Bauer R, Hoheisel O, Stuhlfauth I, Wolf H. - 1999 - Extract of the *Echinacea purpurea* herb: an allopathic phytoimmunostimulant, *Wien Med Wochenschr.*; 149 (8-10): 185-9.
7. Bauer R, Jurcic K, Puhlmann J, Wagner H.- 1988 - Immunologic *in vivo* and *in vitro* studies on

- Echinacea extracts *Arzneimittelforschung*. Feb;38(2):276-81.
8. Bauer R., Wagner H. – 1990 – Echinacea – Handbuch für Ärzte, Apotheker und andere Naturwissenschaftler, Wissenschaftliche Verlagsgesellschaft, Stuttgart.
 9. Belaeva T.N., Butenkova, A.N. - 2018 - Comparative analysis of the leaf anatomy of *Echinacea purpurea* and *E. pallida*. *Biosyst. Divers.* 26, 77–84
 10. Block K.I., Mead MN. – 2003 - Immune system effects of Echinacea, ginseng, and astragalus: a review. *Integr Cancer Ther.*;2(3):247-67
 11. Bodinet, C., Freudenstein, J. - 1999 - Effects of an orally applied aqueous-ethanolic extract of a mixture of *Thuja occidentalis* herba, *Baptisia tinctoriae* radix, *Echinacea purpurea* radix and *Echinacea pallida* radix on antibody response against sheep red blood cells in mice, *Planta Med.*, Dec 65:8 695-9.
 12. Burlou-Nagy C., Bănică F., Jurca T., Vicaș L.G., Marian E., Muresan M.E., Bácskay I., Kiss R., Fehér P., Pallag A. – 2022- *Echinacea purpurea* (L.) Moench: Biological and Pharmacological Properties. A Review. *Plants (Basel)*. 11(9):1244.
 13. Cohen, A., Lee, J. W., Dosch, H. M., Gelfand, E. W. - 1980- The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation. *Journal of immunology (Baltimore, Md. : 1950)*, 125(4), 1578–1582.
 14. *Echinacea purpurea* Aerial Parts, *Echinacea purpurea* (L.) Moench- Standards of Analysis, Quality Control, and Therapeutics - 2007- American Herbal Pharmacopoeia and Therapeutic Compendium Ed. Roy Upton
 15. El-Gengaihi S.E., Shalaby A.S., Agina E.A., Hendawy S.F. -1998 - Alkylamides of *Echinacea* sp. *purpurea* L. as influenced by plant ontogeny and fertilization. *J Herb Spices Med Plant* 5: 35–41
 16. Giles JT, Palat CT 3rd, Chien SH, Chang ZG, Kennedy DT. – 2000 - Evaluation of echinacea for treatment of the common cold. *Pharmacotherapy*.;20(6):690-7.
 17. Goel V., Chang C., Slama J.V., Barton R., Bauer R., Gahler R., Basu T.K.-2002 - Alkylamides of *Echinacea purpurea* stimulate alveolar macrophage function in normal rats. *Int Immunopharmacol.*;2(2-3):381-7.
 18. Gorfer, L.M., Grigoletto, V., Pramsohler, M., Robatscher, P. and Oberhuber, M. - 2023- Mass-spectrometric determination of two phyllobilins in leaves of three medicinal plants and their application forms. *Acta Hort.* 1358, 195-202
 19. Hostettmann K. – 2003 - History of a plant: the example of Echinacea, *Forsch Komplementarmed Klass Naturheilkd.*;10 Suppl 1:9-12.
 20. Kahlos K, Kangas L, Hiltunen R. – 1989 – Ergosterol peroxide, an active compound from *Inonotus radiatus* *Planta Med.*;55(4):389-90.
 21. Karg C. A., Wang P., Vollmar A. M., Moser S. -2019- Re-opening the stage for Echinacea research - Characterization of phylloxanthobilins as a novel anti-oxidative compound class in *Echinacea purpurea*. *Phytomedicine*, 60:152969
 22. Karg C.A. Wang P., Kluibenschedl F., Müller A.P.D.T., Allmendinger L., Vollmar A.M. Moser S. - 2020 - Phylloxanthobilins are Abundant Linear Tetrapyrroles from Chlorophyll Breakdown with Activities Against Cancer Cells. *Eur. J. Org. Chem.* , 4499–4509
 23. Kaya, M.; Merdivan, M.; Tashakkori, P.; Erdem, P.; Anderson, J.L. Analysis of Echinacea flower volatile constituents by HS-SPMEGC/MS using laboratory-prepared and commercial SPME fibers. *J. Essent. Oil Res.* 2018, 31, 91–98.
 24. Kligler B. – 2003 – Echinacea, *Am Fam Physician*.;67(1):77-80
 25. Lorke D. -1983- A new approach to practical acute toxicity, *Arch. Toxicol* 54(4), 275-287
 26. Lowenthal J.W., Lambrecht B., van den Berg T.P., Andrew M.E., Strom A.D., Bean A.G. – 2000 - Avian cytokines - the natural approach to therapeutics. *Dev Comp Immunol.*;24(2-3):355-65
 27. Lowenthal J.W., MacDonald H.R. – 1986 - Binding and internalization of interleukin 1 by T cells. Direct evidence for high- and low-affinity classes of interleukin 1 receptor, *J Exp Med.*;164(4):1060-74.
 28. Lowenthal J.W., O'Neil T.E., Broadway M., Strom A.D., Digby M.R., Andrew M. York J.J. – 1998 - Coadministration of IFN-gamma enhances antibody responses in chickens. *J Interferon Cytokine Res.*;18(8):617-22.
 29. Lowenthal J.W., O'Neil T.E., David A., Strom G., Andrew M.E. – 1999 - Cytokine therapy: a natural alternative for disease control, *Vet. Immunol Immunopathol.* ;72(1-2):183-8
 30. McGregor, R.L. (1968) *The Taxonomy of the Genus Echinacea (Compositae)*. University of Kansas.

31. Moench C. -1794 - Echinacea Moench, Methodus (Moench) 591. immunity in the mouse, *Arzneimittelforschung*;41(2):141-7.
32. Nyalambisa, M., Oyemitan, I., Matewu, R., Oyedeji, O., Oluwafemi, O., Songca, S. Nkeh-Chungag, B., Oyedeji, A. -2016- Volatile constituents and biological activities of the leaf and root of Echinacea species from South Africa. *Saudi Pharmaceutical Journal*. 25. 10.1016/j.jsps.2016.09.010.
33. O'Neill W., McKee S., Clarke A.F.-2002- Immunological and haematonic consequences of feeding a standardised Echinacea (*Echinacea angustifolia*) extract to healthy horses. *Equine Vet J*;34(3):222-7.
34. Percival, S.S. - 2000 - Use of Echinacea in medicine, *Biochem Pharmacol.*, 60:2 155-8.
35. Raduner S., Majewska A., Chen J.-Z., X-Q., Hamon J., Faller B., Altmann K.H., Gertsch J. -2006- Alkylamides from Echinacea Area New Class of Cannabinomimetics, *The Journal Of Biological Chemistry*, 281(20):14192-14206
36. Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. -2002 -In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and *Hypericum perforatum*. *J Pharm Pharmacol.*;54(10):1379-83.
37. Rehman J., Dillow J.M., Carter S.M., Chou J., Le B., Maisel A.S. - 1999 - Increased production of antigen-specific immunoglobulins G and M following *in vivo* treatment with the medicinal plants *Echinacea angustifolia* and *Hydrastis canadensis*. *Immunol Lett.*;68(2-3):391-5.
38. Schimmer O., Leimeister U., The SCE-inducing potency of the furoquinoline alkaloid, γ -fagarine, and a γ -fagarine-containing tincture from *Rutae Herba*, in cultured human lymphocytes, *Mutagenesis*, Volume 4, Issue 6, November 1989, Pages 467-470,
39. Schraner I., Losch V. - 1986 - Immunological identification of avian monomeric and polymeric immunoglobulin M and immunoglobulin A after fractionation on sodium dodecylsulfate pore gradient polyacrylamide gels, *Poultry Sci.*, 65(2):360-8
40. Schraner I., Wurdinger, M., Klumpp, N., Loch, U., Okpanzi, S.N. - 1989 - Beeinflussung der aviaren humoralen Immunreaktion durch Influx und *Echinacea angustifolia* Extrakt, *Zentralblt. Veterinar. Med.* - B, 36(5), 353-364.
41. Schumacher A., Friedberg KD.- 1991 - The effect of *Echinacea angustifolia* on non-specific cellular immunity in the mouse, *Arzneimittelforschung*;41(2):141-7.
42. Sloley B.D., Urichuk L.J., Tywin C., Coutts R.T., Pang P.K., Shan J.J. - 2001 -Comparison of chemical components and antioxidants capacity of different Echinacea species. *J Pharm Pharmacol.*;53(6):849-57.
43. South EH, Exon JH. - 2001 - Multiple immune functions in rats fed Echinacea extracts. *Immunopharmacol Immunotoxicol.*;23(3):411-21.
44. Sun J.H., Yan Y.X., Jiang J., Lu P. - 2005 - DNA immunization against very virulent infectious bursal disease virus with VP2-4-3 gene and chicken IL-6 gene. *J Vet Med B Infect Dis Vet Public Health.*;52(1):1-7.
45. Sun L.Z., Currier N.L., Miller S.C.-1999 - The American coneflower: a prophylactic role involving nonspecific immunity. *J Altern Complement Med.*;5(5):437-46.
46. Tragni E., Galli C.L., Tubaro A., Del Negro P., Della Loggia R.-1988- Anti-inflammatory activity of *Echinacea angustifolia* fractions separated on the basis of molecular weight., *Pharmacol Res Commun.*;20 Suppl 5:87-90.
47. Tragni E., Tubaro A., Melis S., Galli C.L.- 1985 - Evidence from two classic irritation tests for an anti-inflammatory action of a natural extract, *Echinacina B. Food Chem Toxicol.*; 23(2):317-9.
48. Tubaro A., Tragni E., Del Negro P., Galli C.L., Della Loggia R. - 1988 - Anti-inflammatory activity of a polysaccharidic fraction of *Echinacea angustifolia*. *Pharmacol Res Commun*;20 Suppl 5:87-90
49. Văgîi, F., Ionescu, E., Cojocaru, C. - 1996 - Cercetări în vederea obținerii fitocomplexului VOIMUN util în deficiențe imunitare, The First Symposium "Drug research between information and life sciences", Bucharest, 3-4 October, 137.
50. Vollmar, A., Moser, S. -2023- The advent of phyllobilins as bioactive phytochemicals - natural compounds derived from chlorophyll in medicinal plants and food with immunomodulatory activities. *Pteridines*, 34(1), 20220047
51. Wacker, A., Hilbig, W. -1978- Virushemmung mit *Echinacea purpurea* [Virus-inhibition by *Echinacea purpurea* (author's transl)]. *Planta medica*, 33(1), 89-102.
52. Wagner H., Jurcic K. -2002 - Immunological studies of Revitonil, a phytopharmaceutical containing *Echinacea purpurea* and *Glycyrrhiza glabra* root extract. *Phytomedicine.*;9 (5):390-7.

53. Wagner H., Proksch A., Riess-Maurer I., Vollmar A., Odenthal S., Stuppner H., Jurcic K., Le Turdu M., Fang J.N. - 1985 - Immunostimulating action of polysaccharides (heteroglycans) from higher plants, *Arzneimittelforschung*;35(7):1069-75.
54. Wagner H., Proksch A., Riess-Maurer I., Vollmar A., Odenthal S., Stuppner H., Jurcic K., Le Turdu M., Heur Y.H.- 1984 - Immunostimulant action of polysaccharides (heteroglycans) from higher plants. Preliminary communication *Arzneimittelforschung*;34(6):659-61
55. Wagner, H. - 1991 - Echinacea Species as Potential Immunostimulatory Drugs, *Economic and medicinal Plant Res.*, vol.5, Academic Press, London.
56. WFO (2023) *Echinacea simulata* McGregor. Published on the Internet; <http://www.worldfloraonline.org/taxon/wfo-000042098> Accessed on: 30 Jun 2023
57. <http://www.ipni.org>, <https://powo.science.kew.org/>- 2023- The International Plant Names Index and World Checklist of Vascular Plants